Investigation of DNA repair gene expression and protein function in human oocytes and preimplantation embryos by Tulay, P
 1 
 
 
 
Investigation of DNA repair gene expression 
and protein function in human oocytes and 
preimplantation embryos 
 
by 
 
 
Pinar Tulay 
 
 
 
Thesis submitted for the degree of Doctor of Philosophy at 
University College London 
 
 
 
June 2013 
 
Supervisors: Dr. Sioban SenGupta 
     Dr. Joyce Harper 
 
 
 
 
UCL Centre for PGD  
Institute for Women’s Health 
University College London
 2 
 
 
 
 
 
 
 
 
 
 
 
 
I, Pinar Tulay, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
Acknowledgements 
 
 
3 
 
ACKNOWLEDGEMENTS 
It is my pleasure to thank to those who made this project possible and helped 
through my PhD. First of all, I would like to thank my dear supervisor, Sioban 
SenGupta. Sioban, you have helped and guided me throughout my PhD and 
PGD training. You have patiently listened to me several times to talk about how 
things with the experimental work are not progressing as I wanted. You always 
supported me. It was a great pleasure to be your PhD student. Without your 
help, guidance and continuous support, I wouldn’t have been at this stage now. 
I have already missed our 3-hour PGD and PhD meetings. Thank you very 
much for making me a better scientist. 
I would like to thank to my secondary supervisor, Dr. Joyce Harper. Joyce, you 
were the first person who introduced me to preimplantation genetics during my 
Master’s degree. Your passion in this field made me grow a great interest in 
preimplantation genetics and embryology. I would like to thank you for your 
warm welcoming to this field and all your support and guidance throughout my 
PhD. I would also like to thank to Professor Joy Delhanty for her expert advice 
and guidance through my PhD and PGD training. I would like to thank to the 
whole PGD team; Seema Dhanjal, Thalia Mamas, Leoni Xanthopoulou and 
Harita Gheveria. Seema, you have helped me though my PGD training. I have 
learned so much from you. Thank you for being patient with me and being there 
to support both the experimental side of things and personal things. Thank you 
very much for reading this thesis- your comments were very much appreciated. 
I miss our tube rides to Waterloo. Thalia, you were the first person at the UCL 
(starting from my Master’s) to help me. You were extremely patient with me. I 
have learned what I know about aCGH from you. It was very nice to know that I 
could turn to you when I felt down. Leoni, thank you very much for helping me 
with the FISH work-ups. I am very glad that you were there with me at CM 
during long hours at the weekends- it was very nice to come to the office in 
between running around in the lab to have lunch with you and take short 
breaks. Harita, thank you for your help in FISH work-ups and being a friend. I 
Acknowledgements 
 
4 
 
will miss going to conferences with you. Roy, thank you for all your guidance 
and statistical advice for my expression study. You have been always a good 
friend and supported me when I felt down- thank you very much. I also would 
like to thank to the rest of the group members; Aisha, Razan and Amanthi- it 
was nice working with you all. Razan, thank you for helping me sort out lab 
things after I left London. 
I also would like to thank to my friends outside the lab for all their support and 
motivation- Didem, Melek and Acelya. Didem, you are one of my best friends. 
You were always there to support me and calm me when I felt much stressed. It 
was very comforting to know that I could turn to you when I needed. 
I also would like to acknowledge all the patients who made this project possible 
by giving consent to use their samples. 
Finally and most importantly, I would like to thank to my family. My dear sister, 
Bahar, I am extremely lucky to have you as a sister. You always supported me. 
No matter what time I needed you, you were there to keep me motivated and 
cheer me up. My brother in law, Necati, thank you for cheering me up when I 
thought the end would never come. My little niece, Melisa, even though you are 
very little to know that you were a great courage to me, you have motivated me 
and kept me going by saying: “auntie finish school and come home”. My 
grandmother, Fikriye, and my aunt, Semral, thank you very much to you both. 
You have called me and checked on me constantly to keep me company while I 
was far away from home.  
And finally, my parents, Muyesser and Erdal, there are not enough words to 
explain how grateful I am to you. You have supported me until this age without 
thinking twice. You stood by all my decisions. You encouraged me to start my 
PhD and complete it. You have motivated me all the time. I hope in return I had 
made you proud. I could not have accomplished any of this without you. Thank 
you for loving me and supporting me.  
 
Acknowledgements 
 
5 
 
I am dedicating this PhD to my parents, Muyesser and Erdal. 
Abstract 
 
 
6 
 
Abstract 
This study investigated microRNA and mRNA expression and protein function 
associated with DNA repair in human oocytes and embryos. 
MicroRNAs have been shown to down-regulate and in some cases to stabilise 
the expression of several genes including repair genes. The first aim of this 
study was to analyse the differences in the expression of microRNAs and their 
target mRNAs involved in repair. This study showed that the levels of 
expression of most of the repair gene mRNAs were higher in oocytes than 
blastocysts and this was also the case for many of the miRNAs. The correlation 
analysis of the miRNA and their target expression levels in the oocyte and 
blastocyst samples were restricted by the limited size and number of available 
samples, but indicated no clear cut pattern of differences in relative expression. 
Differential methylation of parental genomes that may lead to differential 
parental gene expression had been observed previously in mouse embryos. 
The second aim of this study was to investigate differential parental expression 
of BRCA1 in human embryos. This study showed that differential 
paternal BRCA1 expression exists in the early developing embryos. Moreover, 
embryos with paternally inherited BRCA mutations were shown to develop more 
slowly compared to embryos with maternally inherited BRCA1 mutations. Both 
differential expression and the developmental delay may be associated 
with differential methylation of parental genomes. 
Expression analyses are crucial to investigate the potential function of genes. 
However these analyses do not provide information on the functionality 
of biological processes. Therefore, the final part of this study aimed to develop a 
sensitive functional assay detecting mismatch repair efficiency in 
preimplantation embryos. In this study a unique assay was developed to detect 
mismatch repair efficiency using small amounts of nuclear/whole cell extracts 
and experiments demonstrated that mismatch repair is active in mouse and 
human blastocysts. 
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1.1. DNA repair in human oocytes and preimplantation 
embryos 
Normal development of preimplantation embryos involves complex 
mechanisms. Determining the expression of repair genes and their possible 
regulatory factors provide a better understanding of the embryo’s capacity to 
perform repair and therefore verify the survival ability of the embryo. This thesis 
focuses on the expression of DNA repair genes and the functional activity of 
these genes in preimplantation human embryos. Possible correlation between 
expression of miRNAs and mRNAs involved in DNA repair was investigated. It 
was hypothesised that an inverse correlation between miRNAs and their target 
mRNAs would be observed. Differential expression of parental genes may be 
observed in embryos due to differential demethylation of parental genomes at 
the early stages of preimplantation embryos in mouse. Therefore, further 
analysis focused on investigation of possible differential expression of four 
genes (ACTB, SNRPN, H19 and BRCA1) in human embryos. It was 
hypothesised that differential gene expression was present at the early stages 
of cleavage stage human embryos. Although expression studies provide 
information on genes present in the embryos, these analyses cannot establish 
the functional activity of these genes. Therefore, a functional assay was 
developed to evaluate the mismatch repair efficiency in mouse and human 
oocytes and blastocysts, respectively. It was hypothesised that since the 
expression of mismatch repair genes are detected, mismatch repair is 
functionally active in human oocytes and blastocysts.  
Introduction 
 
 
26 
 
1.2. Gametogenesis and preimplantation embryo development 
Mammalian preimplantation embryo development follows a series of critical 
events. These events start at gametogenesis and last until parturition. Male and 
female gametes are derived from primordial germ cells (PGCs) by the 
processes of spermatogenesis and oogenesis, respectively. In mice once the 
primordial germ cells undergo mitosis, spermatogenesis and oogenesis 
progress differently. In spermatogenesis, spermatogonia undergo mitosis 
starting at puberty until death and each primary spermatocyte produces four 
spermatids at the end of meiosis. In mouse oogenesis, primordial germ cells 
differentiate into oogenia and they enter meiosis. Unlike meiosis in 
spermatogenesis, primary oocyte arrests at prophase I until puberty. At puberty 
a single oocyte completes meiosis I forming the secondary oocyte. Oocytes 
arrest in metaphase II and at this stage transcription stops and translation of 
mRNAs reduces (Bachvarova, 1992). After fertilisation, meiosis II is completed 
and each oocyte produces a single viable oocyte forming the maternal 
pronucleus (Figure 1.1) (Dean et al., 2003, Jaroudi and SenGupta, 2007).  
After fertilisation oocyte and sperm nuclei fuse resulting in syngamy (Figure 
1.2). The one-cell mammalian embryo contains one haploid paternal and one 
haploid maternal pronucleus from the sperm and oocyte, respectively (Zheng et 
al., 2005). DNA from each pronucleus is replicated prior to mitosis. The two-cell 
embryo is produced in the first cleavage division consisting of two diploid nuclei 
with one set of maternal and one set of paternal chromosomes (Figure 1.2). In 
mammals, during the cleavage stage divisions programming of maternal and 
paternal chromosomes takes place to create the embryonic genome (embryonic 
genome activation, EGA) and to start the preimplantation embryo development. 
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Figure 1-1 Schematic diagram of spermatogenesis and 
oogenesis.
 
Spermatogenesis and oogenesis follow the same initial steps. During spermatogenesis, 
spermatogonia undergo mitosis starting at puberty until death and each primary spermatocyte 
produces four spermatids at the end of meiosis. During oogenesis DNA replication occurs and 
primary oocyte arrests at birth. Each oogonium produces a single viable oocyte following 
fertilisation. N represent the amount of DNA in a haploid chromosome set (Jaroudi and 
SenGupta, 2007). Copyright (2009), Oxford University Press.  
 
The embryonic genome is suggested to be activated at the 2-cell and 4- to 8-
cell stages in mouse and human embryos, respectively (Wang et al., 2004, 
Flach et al., 1982, Telford et al., 1990). This activation is initiated by 
degradation of maternal nucleic acids, specific RNAs stored in human oocytes, 
proteins and other macromolecules (Moore, 1998, Tesarik et al., 1988, Braude 
et al., 1988). Upon embryonic genome activation, remarkable reprogramming of 
expression occurs in the preimplantation embryo. In mammals, these 
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reprogramming events are controlled by DNA methylation, histone acetylation, 
transcription, translation and microRNA (miRNA) regulation (Bell et al., 2008).   
DNA replication and cell proliferation is fast in rat preimplantation embryo 
development. However as the cell cycle is short, this increases the risk of 
genetic errors, in replication or segregation (Mac Auley et al., 1993). These 
errors may damage the DNA and to preserve the genomic integrity detection of 
DNA damage is crucial in preimplantation embryos. Once the DNA damage is 
detected, cells may undergo apoptosis, or different DNA repair mechanisms; 
base excision repair (BER), nucleotide excision repair (NER), double strand 
break repair (DSBR) and mismatch repair (MMR) (Haber, 2000, Johnson and 
Jasin, 2000, Cromie et al., 2001); may be activated (Vinson and Hales, 2002). 
 
Figure 1-2 Schematic diagram outlining the main stages of preimplantation embryo 
development. 
 
Zygote is formed following fertilisation. Fusion of male and female pronuclei takes place. DNA 
replication occurs and the 2-cell stage embryo forms. Cleavage divisions result in 2, 3, 4 etc. 
cell embryos which eventually form the morula and the blastocyst.  
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1.3. Origin of DNA damage and DNA repair in gametes and 
preimplantation embryos 
In mammals DNA damage can rise from exogenous genotoxic chemical 
modifications, such as ultraviolet (UV) light and chemicals, and from 
endogenous chemical modifications, such as reactive oxygen species (Jackson 
and Bartek, 2009). Different types of lesions may be observed in the genome, 
such as mismatches, crosslinks and insertion/deletion of loops due to DNA 
replication and recombination errors. In mammals, the cell may naturally 
experience DNA depurination by non-enzymatic hydrolytic cleavage of glycosyl 
bonds and lose between 9000 to 10000 nucleotides per day (Nakamura et al., 
1998, Lindahl and Nyberg, 1972, Lindahl and Barnes, 2000).  
In oocytes, damage can occur because of the long duration of meiosis. 
Although mouse oocytes have been shown to express genes and enzymes 
involved in DNA repair, many oocytes at the germinal vesicle stage have been 
shown to enter the meiotic divisions even in the presence of DNA damage 
(Marangos and Carroll, 2012). In human sperm, damage is more common than 
in oocytes and this can be due to mutagenic events during spermatogenesis 
(Drost and Lee, 1995, Huttley et al., 2000). One of the main reasons for this 
greater damage could be the high number of pre-meiotic divisions in 
mammalian sperm at spermatogenesis that can be more than 1000, whereas 
there are only about twenty mitotic divisions in oogenesis (Hurst and Ellegren, 
1998, Baarends et al., 2001). Although the mouse sperm have a higher 
occurrence of mutation compared to oocytes, male germ cells have lower risk of 
spontaneous mutation rate compared to the somatic tissues (Walter et al., 
1998). Studies in mice show that the mutation frequency is reduced in younger 
males and as the mice grow older this frequency is increased in post-replicative 
meiotic cells (Walter et al., 1998).  
In mammalian preimplantation embryo development, DNA damage detection 
and coordination of the cell cycle is crucial. Cell cycle arrest occurs during 
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replication and at G1/S (first gap phase/ DNA synthesis phase) or G2/M 
(second gap phase/ mitosis) checkpoints to activate the correct repair pathway 
(Lukas et al., 2004). If the repair mechanisms are unable to repair the damage, 
which can be due to inactive DNA repair mechanisms, apoptosis of an 
embryonic cell may be detrimental to the early developing embryo. Therefore 
correct activation of genes and proteins is critical for fully functioning DNA repair 
pathways.  
1.3.1. Current knowledge on the techniques used for 
investigating the activity of repair pathways in oocytes 
and preimplantation embryos 
1.3.1.1. Functional studies 
Functional studies are the most informative analysis of DNA repair activity. 
Transfection of cells with plasmid/bacteriophage circular DNA substrates is 
widely used to assess the efficiency of repair in vivo or in vitro by exposure to 
nuclear or whole cell extracts. These techniques have been applied to repair 
deficient Escherichia coli (E. coli) (Waters and Akman, 2001, Zhang and 
Dianov, 2005, Fang and Modrich, 1993, Matheson and Hall, 2003, Feldmann et 
al., 2000, Riis et al., 2002, Dyrkheeva et al., 2008, Kadyrov et al., 2009, Littman 
et al., 1999, McCulloch et al., 2003, Wang and Hays, 2002), mouse embryonic 
stem cells (Dronkert et al., 2000) and primate cells (Susse et al., 2004). 
Mismatch repair in live cells has also been assessed using a plasmid enhanced 
green fluorescent protein (EGFP) reporter system (Folger et al., 1985, Lei et al., 
2004).  
A large amount of protein is required for these assays and they can be 
expensive (Tsai-Wu et al., 1999, Lei et al., 2004). One of the main difficulties in 
assessing the repair in human oocytes and embryos is the small amount of 
protein present in these samples, such as 122ng to 0.1µg in cattle oocytes and 
162ng to 50µg in cattle preimplantation embryos (Grealy et al., 1996, Thompson 
et al., 1998). There have been a few studies assessing mismatch repair 
efficiency in Xenopus oocytes using two different methods; egg extracts were 
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used to measure the mismatch repair activity in cell free assays or mismatched 
DNA constructs were microinjected into the oocytes to detect the mismatch 
repair functionality (Maryon and Carroll, 1989, Oda et al., 1996, Petranovic et 
al., 2000, Varlet et al., 1996, Labhart, 1999). All these techniques require 
construction of plasmids which is technically demanding and also time 
consuming. The basis of an aspect of this study was built on the importance of 
functional assay development and therefore one of the projects aimed to 
develop a sensitive in vitro functional assay for mismatch repair that could be 
applied to nuclear and whole cell extracts from human oocytes and embryos. 
1.3.1.2.  Proteomic studies 
Several techniques have been used to detect proteins present in oocytes and 
embryos. Human, rat and mouse proteins involved in DNA repair have been 
localised by immunofluorescence analysis in oocytes and embryos (Barton et 
al., 2007, Adiga et al., 2007, Fernandez-Gonzalez et al., 2008, Roig et al., 2004, 
Wirthner et al., 2008). The presence of proteins in pooled mouse embryos has 
also been studied by two-dimensional gel electrophoresis (Latham et al., 1992, 
Shi et al., 1994). Surface-enhanced laser desorption/ionisation coupled to time-
of-flight mass spectrometry (SELDI-TOF-MS) in addition to western blotting and 
bioinformatics analyses have been used for the detection levels of particular 
proteins in human embryos (Katz-Jaffe et al., 2009, Dominguez et al., 2008, 
Brison et al., 2007). Genome wide proteomic analysis has been performed 
using capillary liquid chromatography-tandem mass spectrometry (CapLC–
MS/MS) in zebrafish embryos (Lin et al., 2009). 
1.3.1.3. Gene expression studies 
Genome wide gene expression in bovine, mouse and human studies are 
generally performed by microarray analysis when the starting material is large 
(Fair et al., 2007, Jaroudi et al., 2009, Xie et al., 2010). However the main 
difficulty of the genome wide expression studies in oocytes and preimplantation 
embryos is the small amount of material obtained from these samples. This has 
been overcome by pooling and/or amplifying rhesus monkey, mouse and 
human embryonic samples prior to the analysis (Mamo et al., 2007, May et al., 
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2009, Wells et al., 2005, Zheng et al., 2005, Xu et al., 2011). However, both 
pooling and amplification has disadvantages; such that analysis of gene 
expression in individual samples is not possible and amplification bias may be 
introduced, respectively (Duftner et al., 2008, Patel et al., 2005). Although 
microarray analysis provides a large expression profile of genes from a single 
experiment, it is still not as sensitive as real time polymerase chain reaction 
(PCR) (Wong and Medrano, 2005). Gene expression in a single human oocyte 
and human embryo has been examined using real time PCR without any 
requirement of a pre-amplification step (McCallie et al., 2009, Kakourou et al., 
2012).  
Many cell cycle checkpoint and DNA repair genes have been shown to be 
expressed in rhesus monkey, mouse and human oocytes and blastocysts by 
both real time PCR and microarray analyses (Zheng et al., 2005, Jaroudi et al., 
2009, Menezo et al., 2007, Wells et al., 2005, Tominaga et al., 2006). 
1.3.1.3.1. Expression of DNA damage sensor genes 
and cell cycle checkpoint genes in oocytes and 
preimplantation embryos 
Several DNA damage sensor genes with different expression levels (ATR, BLM, 
RFC, CHEK1, CHEK2 and TOPBP1, PCNA proliferating cell nuclear antigen, 
ATM ataxia-telangiectasia-mutated) have been detected in rhesus monkey 
oocytes and blastocysts (Zheng et al., 2005). ATR, CHEK2 and BUB1 were 
detected in human oocytes (Menezo et al., 2007, Wells et al., 2005). Expression 
of multiple genes, such as BUB1, APC, MAD2, TP53 and RB1, were detected in 
human blastocysts (Wells et al., 2005). Some of these genes, such as Chek1 
(Takai et al., 2000) and Wee1 were detected in mouse preimplantation embryos 
(Tominaga et al., 2006). 
Cell cycle checkpoint genes and polo-like kinases functioning at the G2/M 
phase (CDKN1B, MDM2, MTBP, PLK1, PLK3 and TP53) were shown to be 
expressed only at low levels in rhesus monkey oocytes and blastocysts. Since 
these genes are expressed at low levels in oocytes, this may indicate reduced 
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repair efficiency at G2/M check point in rhesus monkey (Zheng et al., 2005, 
Jurisicova et al., 1998).  
1.3.1.3.2. Expression of base excision repair genes in 
gametes and preimplantation embryos 
Base excision repair is involved in repairing damaged bases occurring due to 
inflammatory responses and exposure to reactive oxygen species and 
exogenous agents including radiation. Base excision repair pathway repairs the 
damaged DNA in two pathways, short-patch and long-patch (Figure 1.3). In 
mammalian cell extracts, it was shown that the long-patch base excision repair 
constitutes 25% of all base excision repair events and the repair frequency via 
long-patch base excision repair may be higher upon DNA damage (Sung et al., 
2005, Dianov et al., 1998).  
In mammalian cells, the initial steps of the short-patch and long-patch base 
excision repair pathways are common; the detection of the damaged DNA, 
incision at the abasic site by apurinic/apyrimidinic (AP)-endonuclease or by 
lyase activity of glycosylase and end processing. With the short-patch base 
excision repair, DNA polymerase β (pol β) is involved in the insertion of the 
incised single nucleotide, whereas in the long-patch base excision repair two to 
twelve nucleotides are incised by FEN1, DNA pol β, DNA polymerase δ and/ or 
DNA polymerase ε. The gap is repaired and ligated by DNA ligase 3, pol  β and 
XRCC1 in the short-patch base excision repair and DNA ligase 1, pol β, pol δ/ε, 
PCNA, FEN1, XRCC1 and APRATAXIN (APTX) in the long patch base excision 
repair, respectively (Robertson et al., 2009, Caldecott, 2008, Fortini et al., 
2003). PARP1 was shown to interact with base excision repair genes, ligases 
and polymerases in mammalian cells, OGG1, XRCC1, DNA pol β, DNA ligase 
3, PCNA and APTX, and therefore was suggested to have a role in the initial 
steps of base excision repair and single stranded DNA repair (De Vos et al., 
2012, Dantzer et al., 2000, Noren Hooten et al., 2011, Frouin et al., 2003, Harris 
et al., 2009, Heale et al., 2006).  
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Base excision repair genes, such as UNG, APEX1, POLB and OGG1, have 
been shown to be expressed in rhesus monkey oocytes (Zheng et al., 2005) 
and in human oocytes and blastocysts (Menezo et al., 2007, Jaroudi et al., 
2009). Studies suggest that base excision repair may play an important role 
during mouse spermatogenesis, in that high expression levels of base excision 
repair genes were detected in spermatogenic germ cell nuclear extracts and in 
the testis (Walter et al., 1996, Mackey et al., 1997). 
Studies have shown that correct functioning of base excision repair is crucial in 
embryonic development since studies in knock-out mouse have shown that in 
the absence of base excision repair proteins, such as Fen1, Apex, DNA ligase 1 
and DNA pol β, embryos are not viable (Park and Gerson, 2005). FEN1, APEX, 
MPG, UNG and HAP1 were detected in germ cells of rat and human (Olsen et 
al., 2001).  
Somatic mutations in DNA pol β have been associated with human cancers. 
Biallelic mutations of Mut Y homologue (MYH) gene, which is involved in base 
excision repair to prevent 8-oxo-dG induced mutagenesis, are shown to be 
associated with increased susceptibility to colorectal cancer (Jones et al., 2002, 
Lipton et al., 2003, Sampson et al., 2005, Makridakis et al., 2009). 
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Figure 1-3 Schematic diagram of base excision repair pathway. 
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Detection, end processing, gap filling and ligation steps involve multiple genes, proteins and 
polymerases. These steps were summarised with the genes and proteins involved in the repair. 
Base excision repair involves two pathways; short patch, which repairs one nucleotide, and long 
patch, which repairs 2-12 nucleotides. These two pathways follow the same initial steps where a 
lyase removes the damaged base and end processing takes place with multiple proteins, 
polymerases, and ligases. The gap formed is processed with different proteins and ligation 
involves XRCC1 and LIG 3 in short patch and PCNA and LIG 1 in long-patch base excision 
repair.  
 
1.3.1.3.3. Expression of nucleotide excision repair 
genes in gametes and preimplantation embryos 
Nucleotide excision repair is a multi-protein repair system that is involved in 
repairing the majority of DNA damage caused by photoproducts from UV 
radiation, environmental carcinogens, endogenous free radicals and bulky 
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lesions in mouse and Xenopus laevis embryos (Lund et al., 2009, Friedberg et 
al., 2000). This repair pathway is suggested to be the most versatile repair 
system (Lund et al., 2009). Nucleotide excision repair differs from base excision 
repair in that instead of searching for damage due to a particular base change, 
this mechanism checks any distortions in the double helix. Nucleotide excision 
repair is mainly active at the G1 (gap 1) stage of cell cycle (Branzei and Foiani, 
2008).  
This repair pathway is divided into two subgroups, global genomic repair (GGR) 
and transcription-coupled repair (TCR), and the difference between these two 
pathways is the proteins involved in the initial recognition step. In humans, 
global genomic repair, which removes DNA damage from non-transcribed DNA, 
involves initiation with UV-DDB (DDB1 and DDB2) and XPC-HR23B; whereas 
transcription-coupled repair, which repairs transcriptionally active DNA, involves 
initiation with RNA polymerase II (Christmann et al., 2003, Shuck et al., 2008, Li 
et al., 2011). A detailed review on DNA damage response via transcription-
coupled repair was published previously (Lagerwerf et al., 2011). In humans 
multiple proteins, TFIIH (ERCC3, ERCC2), XPA, RPA, RNA polymerase II and 
XPG, bind to the damaged lesion and nucleotide excision repair multi-protein 
complex with ERCC1-XPF. ERCC3 (XPB) and ERCC2 (XPD) remove the lesion 
by DNA helicase activity (Barnes et al., 1993, van Brabant et al., 2000). DNA 
polymerases δ or ε and other replication proteins, PCNA, RPA and RFC, 
resynthesise the gap formed after the lesion is removed and DNA ligase 1 
ligates the nick on the repaired DNA strand (Figure 1.4) (Riedl et al., 2003). 
The activity of nucleotide excision repair has been shown to be lower in murine 
sperm germ cells compared to somatic cells (Xu et al., 2005) and low levels of 
nucleotide excision repair genes were found to be expressed in rhesus monkey 
oocytes (Zheng et al., 2005). In contrast many nucleotide excision repair genes 
were shown to be highly expressed in human oocytes and blastocysts; TFIIH 
CDK7, CCNH, MNAT1, RPA1, ERCC6 (CSB) and LIG1; (Jaroudi et al., 2009, 
Menezo et al., 2007). Expression of ERCC6 (CSB), GTF2H1, GTF2H2, 
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GTF2H5, RAD23B and MMS19L, which are involved in transcription-coupled 
repair pathway, was also detected in human oocytes (Menezo et al., 2007).  
Deficiency in Ercc1, which functions in double strand break repair as well, leads 
to infertility in female and male mice and the correct functioning of this gene 
was shown to be crucial in gametogenesis (Hsia et al., 2003). In the absence of 
Ercc1, the oocytes were shown to degenerate lacking primary follicles. Low 
levels of Ercc1 and Xpf were observed in mouse spermatogonia and high levels 
in spermatocytes and round spermatids (Shannon et al., 1999). Mouse studies 
have shown that particular nucleotide excision repair gene mutations, such as 
Xpd, can be embryonic lethal or cause reduced life span (Friedberg and Meira, 
2000). Homozygous germline mutations of nucleotide excision repair genes 
have been associated with DNA repair disorders, such as Xeroderma 
pigmentosum (XP genes mutations), Cockayne syndrome (CSA and CSB 
mutations) and Trichothiodystrophy (XPB or XPD mutations) (Lehmann, 2003).  
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Figure 1-4 Schematic diagram of nucleotide excision repair pathway; global genomic 
repair, transcription-coupled repair. 
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Nucleotide excision repair involves multiple proteins. The repair involves two pathways, global 
genomic repair and transcription coupled repair. Only the initial steps of these pathways are 
different. UV-DDB (DDB1 and DDB2) and XPC-HR23B are used to remove the damaged bases 
in global genomic repair, whereas TFIIH (ERCC3, ERCC2), XPA, RPA, RNA polymerase II and 
XPG are used in transcription-coupled repair. Damage recognition, DNA opening, incision, 
excision and resynthesis steps were summarised with the genes and proteins involved in the 
repair. 
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1.3.1.3.4. Expression of double strand break repair 
genes in gametes and preimplantation embryos 
Double strand break repair is involved in repairing double strand breaks (DSBs) 
that are formed upon broken sugar backbones disturbing Watson-Crick pairings 
and breaking DNA double strands (Bassing and Alt, 2004). Unrepaired double 
strand breaks are involved in genotoxic damage and cell death via apoptosis 
(Rich et al., 2000, Pfeiffer et al., 2000). Furthermore, if DNA repair mechanisms 
do not function properly, unrepaired double strand breaks can lead to loss of 
chromosome segments and rearrangements, such as tumourgenic 
chromosome translocations in mammalian cells and yeast (Dikomey et al., 
1998, Pfeiffer et al., 2000, Aten et al., 2004). 
It has been shown that in mammalian cells double strand breaks are repaired 
by non-homologous end joining (NHEJ) and homologous recombination (HR) 
repair (Figure 1.5) (Haber, 2000; Johnson and Jasin, 2000; Cromie et al., 2001). 
A detailed review of the two double strand break repair pathways has been 
published (Kasparek and Humphrey, 2011). It has been suggested that these 
two pathways compete with each other. A possible suppression of the KU 
proteins by RAD18, RAD52 and PARP1 is suggested to direct the repair 
towards an homologous recombination repair pathway in mammalian cells 
(Saberi et al., 2007, Van Dyck et al., 2001, Bassing and Alt, 2004, Hochegger et 
al., 2006). 
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Figure 1-5 Schematic diagram of double strand break repair pathway; non-homologous 
end joining and homologous recombination. 
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Damage recognition, DNA processing, gap filling and ligation steps were summarised with the 
genes and proteins involved in the repair. Non-homologous end joining repairs double strand 
breaks by joining the two ends of broken DNA strands, whereas homologous recombination 
repairs double strand breaks by using the homologous chromosome of the broken DNA strand 
where sufficient sequence identity can be established.  
 
1.3.1.3.5. Homologous recombination repair  
Homologous recombination repair is suggested to be an error-free repair 
pathway that is active in the late S (synthesis) and G2/M (gap2/mitosis) phase 
of the cell cycle. A detailed review of the homologous recombination pathway 
and its regulation was published by Krejci et al. (2012). Homologous 
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recombination repairs the damaged chromosome by using its homologous 
sequence as a template since it requires a template with sufficient sequence 
identity to the damaged molecule (Sonoda et al., 2001). Histone variant H2AX is 
one of the first initial sensor proteins in DSB response that regulates DNA 
repair, replication, recombination and cell cycle (Wang et al., 2012). 
Homologous recombination repair starts when MRN complex (MRE11-RAD50-
NBS1) binds to exonuclease I (Exo I) and to the damaged part of the 
chromosome activating ATM. In mammalian cells single stranded DNA is 
released and subsequently RAD51 and the single-strand binding replication 
protein A (RPA) bind to RAD52 (Kagawa et al., 2001, Park et al., 1996). BRCA1 
and BRCA2 facilitate DNA binding to RAD51 (Valerie and Povirk, 2003). When 
BRCA2 is associated with RAD51, the cyclin-dependent kinase (CDK) 
regulatory pathway through homologous recombination repair is activated 
(Hashimoto et al., 2010, Lomonosov et al., 2003, Schlacher et al., 2011). 
Interaction of RAD51 with the DNA template initiates the repair using 
complementary strand by displacing one strand as a D-loop (Baumann and 
West, 1997). Homologous recombination repair via ATR (Ataxia telangiectasia 
and Rad3 related) can also be activated upon the interaction of FANCD2 or 
FANCI with BRCA1. Exonucleolytic digestion of the single stranded DNA is 
protected by RAD52 binding (Singleton et al., 2002, Stasiak et al., 2000, 
Christmann et al., 2003). Repaired strands are elongated by polymerase and 
sealed by DNA ligase 1 and they are released following the resolution of the 
Holliday junctions (Bassing and Alt, 2004, Schlissel et al., 1993). 
Several homologous recombination repair genes were shown to be expressed 
in human oocytes and blastocysts, such as FANCD2, BRCA1, BRCA2, RAD51 
and RAD52 (Jaroudi et al., 2009, Menezo et al., 2007, Wells et al., 2005). 
Several other important genes, NBS1, RAD50, ATM and 53BP1, involved in the 
activation and control of the homologous recombination repair pathway was 
shown to be expressed in human and bovine oocytes and blastocysts (Jaroudi 
et al., 2009, Henrique Barreta et al., 2012, Wells et al., 2005). Of these genes 
53BP1 and RAD52 were shown to be up-regulated before bovine embryonic 
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genome activation which may indicate a role in the transition of maternal to 
embryonic genome (Henrique Barreta et al., 2012). 
Inhibition or deletion of Parp1 in mouse was associated with increased 
exchange rates of spontaneous sister chromatids and homologous 
recombination (Oikawa et al., 1980, Wang et al., 1997). Deficiency of PARP1 
leads to aberrant recruiting of MRN complex with stalled or collapsed replication 
forks (Bryant et al., 2009). Moreover, defective ATM activity was observed in 
the deficiency of PARP1 suggesting a possible role of PARP1 in homologous 
recombination repair pathway (Heitz et al., 2010).  
In HeLa cells inhibition of some of the RAD51 paralogs (RAD51B, RAD51C, 
RAD51D and XRCC3) have been associated with cell cycle defects. The 
absence of XRCC3 caused checkpoint abnormalities with incorrect centrosome 
defects, chromosome alignments, anaphase bridges and aneuploidy (Rodrigue 
et al., 2012). Inhibition of RAD51B and RAD51C caused cell cycle arrest at the 
G2/M phase in HeLa cells (Rodrigue et al., 2012).  
Inaccurate functioning of homologous recombination repair, such as mutations 
in human homologous recombination genes, RAD51, RAD51C/D, BRCA1/2 and 
XRCC2/3, has been correlated with high incidence of leukaemia, breast-ovarian 
cancers and premature aging (Valerie and Povirk, 2003, Krejci et al., 2012).  
1.3.1.3.6. Non-homologous end-joining repair 
Non-homologous end joining repair is the main pathway in mammals which is 
error-prone (Haber, 2000, Johnson and Jasin, 2000, Cromie et al., 2001, 
Jaroudi et al., 2009). Non-homologous end joining is active throughout the cell 
cycle, especially at the G1 phase. Non-homologous end joining is suggested to 
have two pathways, the predominant pathway C-non-homologous end joining 
(classical non-homologous end joining) and PARP1-dependent B- non-
homologous end joining (back up non-homologous end joining) (Wang et al., 
2012).  
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In cell lines non-homologous end joining involves binding of heterodimeric KU 
complex (KU70-KU80) to the damaged DNA to protect digestion of DNA ends 
by exonuclease activity (Jeggo et al., 1999, Reeves et al., 1989). In cell 
extracts, cell lines and humans DNA-dependent protein kinase (DNA-PK) 
holoenzyme is formed upon the interaction of the KU complex with the catalytic 
subunit of DNA-PK (DNA-PKcs) (Hartley et al., 1995, Sipley et al., 1995, 
Gottlieb and Jackson, 1993, Smith and Jackson, 1999). DNA-PKcs targets 
XRCC4 which forms a stable complex with DNA ligase 4 (LIG4) and link the 
duplex DNA molecules with complementary but non-ligatable ends (Leber et al., 
1998, Hammarsten et al., 2000, Martensson and Hammarsten, 2002, Bassing 
and Alt, 2004). DNA-PKcs activates the protein Artemis where it forms a single 
strand specific endonuclease that is essential in the processing of overhanging 
5’ and 3’ ends (Stracker et al., 2009). Complementary DNA molecules are then 
ligated mainly by the MRN complex by removing excess DNA at the 3’ end or 
by FEN1 via removing 5’ end (Maser et al., 1997, Nelms et al., 1998).  
Similar to homologous recombination repair pathway, PARP1 is suggested to 
take a part in non-homologous end joining repair pathway. When KU proteins 
and the classical non-homologous end joining pathway are inactive, PARP1-
dependent back-up- non-homologous end joining is suggested to take over the 
repair process. When PARP1 dependent non-homologous end joining is active, 
PARP1 binds to the double strand breaks and directs the MRN complex to the 
double strand break in hamster cell lines. Resection of the double strand breaks 
is followed by XRCC1 and DNA ligase 3 activities to ligase the gap (Mansour et 
al., 2010).  
Several non-homologous end joining genes, such as XRCC4, KU70 (XRCC5) 
and KU80 (XRCC6), have been shown to be expressed in human oocytes and 
blastocysts (Zheng et al., 2005, Ronen and Glickman, 2001, Jaroudi et al., 
2009). DCLRE1C (ARTEMIS) was only detected in human blastocysts and 
LIG4 was neither present in human oocytes nor in human blastocysts (Jaroudi 
et al., 2009). 
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Deficiency of ATM and DNA-PKcs was shown to be synthetic lethal in 
developing mouse embryos. DNA-PKcs were shown to play an important role in 
the initiation of the cell cycle checkpoint response and to sustain the 
chromosome stability at the S/G2 cell cycle phase (Stracker et al., 2009). 
Defects in the non-homologous end joining repair pathway has been associated 
with human diseases, such as severe combined immunodeficiency (SCID) 
(Park and Gerson, 2005).  
1.3.1.3.7. Expression of mismatch repair genes in 
gametes and preimplantation embryos 
Mismatch repair plays an important role in mammalian gametogenesis 
(Baarends et al., 2001). Mismatch repair protects the genetic code integrity by 
repairing DNA synthesis and replication errors (Aquilina et al., 1999) and it is 
known to be effective in repairing base-base mismatches in addition to insertion 
and deletion of loops (Marquez et al., 2003, Carethers et al., 1996, Hawn et al., 
1995, Aquilina et al., 1999). Mismatch repair is primarily active in the G2 cell 
cycle checkpoint (Marquez et al., 2003, Carethers et al., 1996, Hawn et al., 
1995, Baarends et al., 2001).  
Mismatch repair involves three main stages; recognition, excision and DNA 
synthesis (Modrich and Lahue, 1996, Kunkel and Erie, 2005) (Figure 1.6). The 
mechanism of the initial recognition step is not very well understood but there 
are multiple proposals. Studies in humans suggest that MSH proteins (MutSα: 
MSH2/MSH6 and MutSβ: MSH2/MSH3) bind to the DNA with a mismatch or a 
loop, respectively (Buermeyer et al., 1999, Jiricny and Nystrom-Lahti, 2000, 
Harfe and Jinks-Robertson, 2000). In yeast and human cell extracts studies 
suggest that recognition takes place through the replication fork structure 
(Modrich, 1987, Kunkel and Erie, 2005, Umar et al., 1996). The mechanism of 
excision is also not well established. The excision may be initiated by ATP 
hydrolysis-dependent translocation in Escherichia Coli (E. Coli) (Allen et al., 
1997) or by ATP binding-dependent diffusional sliding in humans (Gradia et al., 
1997). Exonucleases are suggested to digest one strand of DNA from 5’-3’ and 
some studies suggest that the digestion can also take place from 3’-5’ ends of 
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Okazaki fragments in mouse and humans (Genschel et al., 2002, Wei et al., 
2003). Some studies suggest that in human cell extracts the excision from 5’-3’ 
and 3’-5’ is initiated by a pre-existing nick or a gap (Wang and Hays, 2007) and 
mismatch repair directs excision along shorter nick-mismatch path (Wang and 
Hays, 2003, Fang and Modrich, 1993). 
Many mismatch repair genes have been shown to be expressed in rhesus 
monkey (Zheng et al., 2005), mouse and human oocytes, such as MLH1, 
MSH2, MSH3, MSH6 and PMS2 (Richardson et al., 2000, Jurisicova et al., 
1998, Ronen and Glickman, 2001) and also PMS1 in human oocytes and 
blastocysts (Jaroudi et al., 2009, Menezo et al., 2007).  
Aberrant expression of mismatch repair genes have been associated with 
abnormal spermatid phenotypes. The expression of Msh2, Msh3 and Pms2 
were found to be reduced and lost in elongated murine spermatids after meiosis 
is completed (Richardson et al., 2000). Knock-out studies of Pms2 and Mlh1 
showed infertility in both male and female mice and the meiotic recombination is 
affected, respectively (Baker et al., 1996, Baker et al., 1995, Wang et al., 1999). 
In additional to these genes, in mammals MSH4 was suggested to be involved 
in meiotic recombination (Santucci-Darmanin and Paquis-Flucklinger, 2003). 
Absence of Pms2 in mouse oocytes were still able to complete meiotic 
chromosome pairing (Baarends et al., 2001), however knocking-out Mlh3 in 
mouse oocytes caused failure of meiosis I completion (Lipkin et al., 2002). 
Similarly, when Msh4 and Msh5 are inactivated, meiosis in mouse is stopped 
both in males and females and homologous chromosome pairing is reduced 
greatly (Edelmann et al., 1999, de Vries et al., 1999, Kneitz et al., 2000). A 
double-mutation of Fancd2 and Mlh1 in mouse model showed that these 
embryos have growth retardation leading to embryo death (van de Vrugt et al., 
2009). Mutations in MLH1, MSH2 and MSH6 cause hereditary non-polyposis 
colorectal cancers (HNPCC) in humans (de Vos et al., 2005).  
Mutations of mismatch repair proteins may cause microsatellite instability (MSI) 
that is observed in many human cancers. Microsatellite instability is short 
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tandem repetitive DNA sequences (Laghi et al., 2008) that are highly unstable 
(Martorell et al., 1997, White et al., 1999). Different forms of microsatellites are 
present in the human genome with the most common being the mononucleotide 
repeats and less common dinucleotide, tetranucleotide and trinucleotide repeats 
(Eckert and Hile, 2009, Subramanian et al., 2003). Mlh3 and Pms2 deficient 
mice were shown to have microsatellite instability, as a result of a defective 
response to DNA damage and increased risk of gastrointestinal tumours 
(Flores-Rozas and Kolodner, 1998, Lipkin et al., 2000, Gurtu et al., 2002). 
 
 
Figure 1-6 Schematic diagram of mismatch repair. 
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Damage is recognised by MutSα or MutSβ proteins in the presence of PCNA. DNA processing 
involves excision of the mismatched base or removing the inserted loop with a combination of 
proteins with MutLα, PMS2 and EXO1. Gap filling and ligation steps involve DNA polymerases.  
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1.3.1.3.8. Interstrand crosslink repair 
Exposure to environmental mutagens and toxins cause DNA interstrand 
crosslinks (ICL) that are highly toxic lesions. These interstrand crosslinks inhibit 
DNA strand separation and stop transcription and replication. A detailed review 
of the formation and repair of interstrand crosslinks at different cell cycle stages 
was published by Dean and West (2011).  
Interstrand crosslinks were shown to be repaired by a combination of repair 
pathways including nucleotide excision repair, homologous recombination 
repair, translesion synthesis (TLS) polymerases and Fanconi anemia pathway 
(Figure 1.7). Fanconi anemia is a rare autosomal recessive or X-linked genetic 
disease and one of the most known cellular characteristics of Fanconi anemia is 
the hypersensitivity to interstrand crosslinks (Sasaki, 1975).  
In humans, the initial recognition of interstrand crosslink repair was shown to be 
through Fanconi anemia (FA) pathway for the replication-coupled repair of 
interstrand crosslinks or by RAD18, PCNA and DCLRE1A (Bouwman and 
Jonkers, 2012). Fanconi anemia complementation group M (FANCM) is one of 
the initial sensor proteins that recognise interstrand crosslink and recruits the 
Fanconi anemia core complex, Bloom’s syndrome complex (BTR) and ATR-
CHK1 signalling cascade. It was shown that in chicken cells Fanconi anemia 
pathway directs the repair towards homologous recombination by counteracting 
KU70 (Pace et al., 2010). Nucleotide excision repair genes were suggested to 
be involved in the excision step, whereas during S (synthesis) phase of the cell 
cycle double strand breaks were suggested to be repaired by a combination of 
homologous recombination repair and translesion synthesis proteins (Figure 
1.7). Several Fanconi anemia proteins, such as FANCJ (Suhasini et al., 2013), 
MRE11, BRCA1 (Bogliolo and Surralles, 2010), BRCA2/FANCD1 and FANCD2, 
were suggested to protect stalled replication forks from degradation in 
homologous recombination repair pathway (Schlacher et al., 2012). 
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Figure 1-7 Schematic diagram of interstrand crosslink repair pathway at different stages of 
cell cycle. 
 
 
 
Interstrand crosslink involves repair by a combination of different repair genes and pathways 
including Fanconi anemia, homologous recombination and nucleotide excision repair. These 
different pathways are involved in interstrand crosslink repair at different stages of cell cycle 
(Deans and West, 2011). Copyright (2011), Rights Managed by Nature Publishing Group.  
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To sum up, DNA repair involves complex systems. Although correct expression 
of repair genes from different pathways may be crucial, if one is not expressed 
this may not impair the repair due to the existence of alternative pathways, such 
as PARP1 directed non-homologous end joining and base excision repair, and 
CDK or ATR directed homologous recombination repair. Therefore it is 
important to examine DNA repair pathways individually as well as together with 
the other pathways.  
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1.4. Control of gene expression 
For a normal developing embryo, expression of both maternal and paternal 
genes is required. Several factors are involved in the regulation of parental 
genes in preimplantation embryos. In mammals, an intense epigenetic change 
occurs upon fertilisation to establish pluripotency (McClay and Clarke, 2003). In 
embryonic stem cells, the majority of the genes involved in differentiation are 
regulated at the chromatin level by histone modification and nucleosome 
rearrangements (Li et al., 2012). These chromatin modifications involve many 
proteins in mouse including Polycomb-group (PcG) and Trithorax group (TrxG) 
proteins (Dean et al., 2003). One of the most common forms of epigenetic 
modification at the DNA level is the methylation of cytosines at CpG islands (Li 
et al., 2012). Both methylation and chromatin modifications play crucial roles in 
determining the transcriptional state of genes in mouse fibroblast cells, 
Neurospora crassa and Arabidopsis thaliana (Tamaru and Selker, 2001, 
Jackson et al., 2002, Fuks et al., 2003). More recently miRNAs, which are a 
category of small non coding RNAs, have been shown to play a role in gene 
regulation during mouse, bovine and human preimplantation embryo 
development (Yang et al., 2009, Tang et al., 2007, McCallie et al., 2009, 
Mondou et al., 2012). 
1.4.1. Control of gene expression by methylation  
Methylation of the CpG dinucleotides in the promoter regions of genes may 
cause gene silencing. The mechanism leading to changes in methylation is not 
well established, but it has been suggested that at the early stages of mouse 
preimplantation embryo development reprogramming takes place by passive 
and active demethylation (Dean et al., 2003). Methylation is important at two 
stages; in preimplantation embryo development and primordial germ cell 
development.  
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1.4.1.1. Methylation status of the zygote and the 
preimplantation embryos 
In mammals the zygote undergoes genome-wide demethylation (Oswald et al., 
2000, Mayer et al., 2000, Beaujean et al., 2004a) (Figure 1.8). Imprinted genes 
are the only exception to this genome-wide demethylation where the 
methylation is maintained (Olek and Walter, 1997, Howell et al., 2001, Reik et 
al., 2001).  
Upon fertilisation, the nuclear envelope of the mouse sperm breaks and 
protamines are replaced with histones, the chromatin decondenses and 
pronucleus is formed (Wright, 1999). In the absence of DNA replication 
asymmetric methylation of sister chromatids within the male pronucleus of the 
mouse zygote takes place suggesting that active demethylation of the male 
pronucleus occurs (Rougier et al., 1998, Dean et al., 2001, Oswald et al., 2000, 
Mayer et al., 2000). Following sperm decondensation, selective demethylation 
of the male pronucleus of the zygote takes place in humans and with some 
variations in mouse (Beaujean et al., 2004a, Santos and Dean, 2004, Santos et 
al., 2002). This demethylation process is not well established however multiple 
mechanisms have been proposed. Active demethylation may take place where 
hydroxylation of 5-methylcytosine (5mC) may either be by ten-eleven 
translocation3 enzyme (TET3) (Gu et al., 2011) or by glycosylation or 
alternatively some nucleotides may be removed by nucleotide excision repair 
locally (Dean et al., 2003, Weiss et al., 1996, Razin et al., 1986).   
The female pronucleus of the mouse zygote remains highly methylated 
(Beaujean et al., 2004a, Santos and Dean, 2004, Santos et al., 2002). In 
mouse, demethylation of the maternal genome starts with the first cleavage 
divisions (Rougier et al., 1998, Monk et al., 1987, Howlett and Reik, 1991). 
Unlike sperm, demethylation of the maternal genome is suggested to take place 
by passive demethylation and it is proposed to be replication dependent. In 
mouse, demethylation of the maternal genome could take place due to removal 
of DNA methyltransferase 1 (Dnmt1) from the nucleus (Howlett and Reik, 1991, 
Carlson et al., 1992).  
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The loss of Dnmt1 and semi-conservative replication state establishes a status 
of hemi-methylated and unmethylated regions of the chromosome by the eight-
cell stage of the mouse embryo (Dean et al., 2003). It is possible that at this 
stage where methylation status of the parental genomes is different, the 
maternal and paternal genes are differentially expressed. Therefore one of the 
aims of this project was based on this theory to investigate differential gene 
expression in human embryos at cleavage, morula and blastocyst stages. 
Further analysis was based on investigation of possible effect of parental origin 
of a mutation on the development stage of embryos on day 5/6 post fertilisation 
that could be affected due to the differential gene expression and methylation 
status of the embryos. 
By the morula stage, the mouse preimplantation embryos become 
undermethylated and the remethylation process starts shortly after implantation 
(Santos et al., 2002, Mayer et al., 2000, Davis et al., 2000, Monk et al., 1987). 
 
Figure 1-8 Schematic diagram showing the methylation status of gametes and 
preimplantation embryos based on evidence on mouse 
studies.
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At the zygote stage, demethylation occurs differently in the paternal (blue) and maternal (red) 
genome in mouse, such that the paternal genome starts demethylation earlier than the maternal 
genome. During implantation, de novo methylation takes place leading to differential 
methylation of the ICM (inner cell mass) and TE (trophectoderm). DNA demethylation occurs as 
the primordial germ cells (PGCs) migrate to the gonads that are followed by immediate de novo 
methylation by the zygote stage (Dean et al., 2005). Adopted from (Smallwood and Kelsey, 
2012). Copyright (2012), Elsevier. 
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1.4.1.2. Methylation status of the gametes  
Methylation status of mouse primordial germ cells reduces when they reach to 
the gonads (Figure 1.8). When demethylation is completed, primordial germ 
cells either enter mitosis in males, or arrest at meiosis in females. Studies 
suggest that in female mice, remethylation occurs after birth when the oocytes 
are in the process of development (Seki et al., 2005). 
1.4.2. Control of gene expression by miRNA regulation 
MiRNAs, short non-coding RNAs of 17-25 nucleotides (nt) in length (Tang et al., 
2007), have been shown to be involved in many important biological processes 
that includes regulation of cell cycle, apoptosis, cell differentiation, imprinting, 
and development (Harfe et al., 2005). MiRNAs were discovered two decades 
ago in C. Elegans (Lee et al., 1993). Cloning and bioinformatics studies have 
enabled identification of miRNAs in many more organisms, such as flies, fish, 
frogs, mammals and plants (Lee and Ambros, 2001).  
The majority of the miRNA sequences are conserved among mammals (Niwa 
and Slack, 2007). The nomenclature of miRNAs between different species is 
identified by the first three letters, where homo sapiens is defined as hsa (hsa-
miR-145) and mus musculus as mmu (mmu-miR-145) (Griffiths-Jones et al., 
2006). The majority of miRNA sequences are conserved among different 
species, however some miRNA sequences vary only at a single nucleotide 
(Tesfaye et al., 2009). These miRNAs are defined with suffixes, such as miR-
181a and miR-181b. If the origin of miRNAs belongs to separate genomic loci, 
these miRNAs are assigned numerical suffices, such as miR-6-1 and miR-6-2 
(Griffiths-Jones et al., 2006, Ambros et al., 2003). 
1.4.2.1. MiRNA biogenesis  
Correct miRNA biogenesis is shown to be crucial and any defects in the 
biogenesis may lead to abnormalities in the mouse embryos or may even cause 
embryo death at the early stages of preimplantation embryo development (Tang 
et al., 2007, Bernstein et al., 2003, Alvarez-Garcia and Miska, 2005).  
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Biogenesis of a small group of miRNAs was shown to be induced by ATM-
dependent manner and these miRNAs were shown to be associated with KH-
type splicing regulatory protein (KSRP), which is an AU-rich binding protein 
involved in Drosha and Dicer processing and in mRNA decay in cytoplasmic 
extracts and mouse embryonic fibroblasts (Liu and Lu, 2012, Zhang et al., 2011, 
Trabucchi et al., 2009).  
Generally in eukaryotes the biogenesis of miRNAs follows two pathways; 
canonical and non-canonical (Figure 1.9). Only the initial steps of these two 
pathways are different. RNA polymerase II transcribes miRNAs into pri-miRNAs 
that have a stem-loop structure in the canonical pathway (Liu et al., 2005). 
Intergenic miRNAs, which contain their own promoters and regulatory units, are 
transcribed into pri-miRNA by RNA polymerase II (Issabekova et al., 2011). On 
the other hand, intronic miRNAs are co-transcribed with host genes from a 
common promoter (Issabekova et al., 2011). Pri-miRNAs are then cleaved by a 
30-160kDa protein, Drosha with one dsRNA-binding and two catalytic domains 
(Filipowicz et al., 2008). Pasha/DiGeorge syndrome critical region gene 8 
(DGCR8) is required at this step of cleavage. DGCR8 cuts both strands of the 
hairpin forming pre-miRNA at approximately 70nt in length (Berezikov et al., 
2007). Both of these genes play crucial roles in the maturation of miRNAs. 
Drosha cleavage is suggested to define the 5’ and 3’ ends of the mature 
miRNAs. If the cleavage of miRNAs by Drosha is disturbed, the seed sequence 
of miRNAs may be altered (Gregory et al., 2004) (Table 1.1). Computational 
analyses and studies in human colon cancer cell lines showed that the 
interaction of p53 with Drosha and DGCR8 complex up-regulated miRNAs upon 
ionising radiation-induced DNA damage (Suzuki et al., 2009, Boominathan, 
2010). Defects in cell proliferation was observed in the absence of DGCR8, 
however these aberrations were eliminated in mouse embryonic stem cells 
once injected with miR-19, miR-20a, miR-20b, miR-294 and miR-295 (Wang et 
al., 2007). 
The non-canonical pathway does not involve the cleavage by Drosha and 
DGCR8. In mouse embryonic stem cells and Drosophila this pathway involves 
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cleavage either by other endoculeases or the short hairpin RNA is directly 
transcribed (Babiarz et al., 2008, Okamura et al., 2007, Ruby et al., 2007).  
Following this cleavage stage, both canonical and non-canonical pathways 
follow the same steps to complete the miRNA biogenesis. A nucleocytoplasmic 
transporter from karyopherin family exportin-5 (Exp5) has binding sites for pre-
miRNAs in the presence of Ras-related nuclear protein (Ran) and Guanosine 
triphosphate (GTP). Pre-miRNAs are transported from the nucleus into the 
cytoplasm by Exp5 (Lund et al., 2004, Yi et al., 2003). Exp5 was shown to play 
an important role in miRNA processing in Drosophila and human. Knock-out 
studies of Exp5 showed a decreased level of miRNA as well as transfer RNA 
(tRNA) in human and Drosophila, respectively (Shibata et al., 2006). 
Additionally, accumulation of pre-miRNA within the nucleus was observed in the 
absence of Exp5 (Yi et al., 2003). Upon over-expression of Exp5, endogenous 
and exogenous miRNA levels were increased (Yi et al., 2005). These findings 
indicate that Exp5 is important in stabilising the level of pre-miRNAs (Yi et al., 
2003). 
Double stranded 21-22nt miRNAs are formed by Dicer processing. Dicer 
processing of miRNAs is suggested to be vital at the transition of G1/S cell 
cycle in stem cells of Drosophila since the absence of Dicer delayed this 
transition in the developing animals (Hatfield et al., 2005). 
The expression of Dicer mRNA was shown to be higher in mouse oocytes 
compared to other cells that may indicate a role of Dicer in female germline 
(Murchison et al., 2007). Complete loss of Dicer in somatic cells of mouse 
reproductive tract caused reduced expression of miRNAs leading to infertility in 
female mice (Tang et al., 2007). Additionally, in mouse and C. Elegans Dicer 
mutant oocytes were compromised with reduced and disorganised spindles with 
incorrect chromosome alignments (Tang et al., 2007, Alvarez-Garcia and Miska, 
2005).  
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Figure 1-9 Schematic diagram of miRNA biogenesis. 
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There are two main pathways for miRNA biogenesis. In the canonical pathway, pri-miRNA is 
formed after transcription. Pri-miRNAs are cleaved by Drosha/DGCR8 complex and they 
produce pre-miRNA. In the non-canonical pathway pre-miRNAs are formed without 
Drosha/DGCR8 complex cleavage. These pre-miRNAs are transported into the cytoplasm by 
Exp5 that are then processed by Dicer and Ago2/RISC complex forming mature miRNA. 
Adapted from (Suh and Blelloch, 2011). Copyright adapted with permission "Development"; via 
DOI:-http://dev.biologists.org/content/138/9/1653.long/. 
 
As in the female germ cells, Dicer aberrations led to defects in male germline. 
Male mice suffered with reduced fertility in the absence of Dicer (homozygote 
Dicer) due to abnormal spermatogenesis (Maatouk et al., 2008). Mutant testis 
with abnormal Sertoli tubes was observed in Dicer deficient mice (Maatouk et 
al., 2008). Moreover, Dicer deficiency in male mice caused poor proliferation of 
spermatogonia. Abnormal spermatid and spermatocyte phenotypes with 
condensed nucleus were observed with lower number of germ cells (Maatouk et 
al., 2008). Sperm motility was also affected in Dicer deficient mice (Maatouk et 
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al., 2008) and sperm loss was observed in the absence of Dicer (Hayashi et al., 
2008, Tang et al., 2007, Yu et al., 2007, Yan et al., 2009).  
MiRNA processing by Dicer was shown to be essential to prevent any 
developmental defects (Giraldez et al., 2005, Zhao et al., 2009). In Dicer mutant 
zebrafish, although the early differentiation of maternal to zygotic transition was 
normal, embryonic death was observed in the absence of Dicer in zebrafish 
(Wienholds et al., 2005) and in mice around embryonic day 7.5 (Tang et al., 
2007, Bernstein et al., 2003, Alvarez-Garcia and Miska, 2005). Abnormal 
somitogenesis and morphogenesis affecting gastrulation and developmental 
defects, such as in heart and limb, were observed in Dicer mutant vertebrates 
(Harfe, 2005, Alvarez-Garcia and Miska, 2005, Giraldez et al., 2006, Mishima et 
al., 2006, Zhao et al., 2005). These aberrations of gastrulation and 
somatogenesis were partially repaired upon injection of miR-430, which 
functions to hasten the deadenylation and degradation of maternal mRNAs, in 
zebrafish and C. Elegans (Alvarez-Garcia and Miska, 2005, Giraldez et al., 
2006).  
Prior to argonaute (Ago)-protein-containing complex and RISC/miRNP (RNA-
induced silencing complex/mi-ribonucleoprotein) processing, one strand of the 
double stranded-miRNA is generally degraded; however both strands may be 
associated with Ago-RISC/miRNP complex. Degradation of one of these 
strands is random, however the strand known as the regulator and is involved in 
loading of the other strand onto Ago2, miR*, is the one that is usually degraded 
in mammals and if it remains active, it may cause silencing of wrong genes 
(Czech and Hannon, 2011). Ago2 deficiency was shown to reduce mature 
miRNA levels in knock-out mouse embryonic fibroblasts and hematopoietic cells 
(Diederichs and Haber, 2007, O'Carroll et al., 2007, Hayashi et al., 2008). 
Aberrant spindles and chromosome alignment were observed in Ago2 deficient 
mouse oocytes with reduced expression levels of miRNAs. Loss of Ago2 
function was shown to be embryonic lethal around embryonic day 9.5 in mouse 
(Liu et al., 2004).  
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To sum up, the importance of correct miRNA biogenesis has been shown in C. 
Elegans, embryonic stem cells, zebrafish and mouse oocytes and blastocysts. 
When miRNA biogenesis is disturbed due to the defects in miRNA processing 
genes, abnormal miRNA maturation and therefore defects in gametes and 
developing embryos were observed. These results indicate that miRNAs are 
functionally active in gametes and embryos. Although these studies are limited 
to mouse and zebrafish, miRNAs are suspected to be functionally active in 
human gametes and developing embryos. 
Table 1-1 Summary table showing the functions of miRNA processing genes and defects 
caused by abnormal functioning of these genes. 
Genes Functions Defects caused by abnormal functioning of genes 
Drosha  Vital for the formation of mature 
miRNA 
 MiRNA processing by cutting both 
strands of miRNA forming pre-
miRNA product in the presence of 
DGCR8 (Wang et al., 2007, 
Filipowicz et al., 2008) 
 5’ and 3’ nucleotides of the mature miRNA are 
determined by Drosha cleavage and any defects in the 
Drosha cleavage may lead to changes in the seed 
sequence of miRNAs (Gregory et al., 2004) 
Exp5  Stabilisation of pre-miRNAs (Yi et 
al., 2005) 
 Transport of pre-miRNAs from the 
nucleus into the cytoplasm in the 
presence of Ran and GTP (Lund et 
al., 2004, Wang et al., 2007, Yi et 
al., 2003) 
 Knock-down of Exp5 was shown to reduce the miRNA 
expression (Shibata et al., 2006) 
 
Dicer   Maturation of miRNA (Schwarz and 
Zamore, 2002, Filipowicz et al., 
2008, Bernstein et al., 2003) 
 Cell proliferation defects 
 Lack of Dicer in Drosophila germ line stem cells 
postponed the G1/S phase transition 
 Dicer deletion in hippocampal, mouse  and zebrafish 
initiated problems in nervous system and led to 
inability of forming mature miRNAs that resulted in 
variations of brain morphogenesis and differentiation 
of neurons  (Barbato et al., 2008, Davis et al., 2008) 
 Complete loss of Dicer1 caused reduced expression of 
miRNAs and infertile female mice (McCallie et al., 
2009, Tang et al., 2007) 
 Homozygote Dicer1 germ-line mutant male mice 
caused decreased male fertility 
 Dicer deficiency led to embryo death in mouse around 
embryonic day 7.5 (Tang et al., 2007, Bernstein et al., 
2003, Alvarez-Garcia and Miska, 2005) and in 
zebrafish (Wienholds et al., 2005) 
 
Ago2  Component of miRISC (Schwarz and 
Zamore, 2002, Filipowicz et al., 
2008) 
 MiRNAs associated with Ago2/RISC 
complex target mRNAs 
 In the absence of Ago2, oocytes were developed to 
the mature oocytes but reduced miRNA expression 
levels, abnormal spindles and chromosomes were not 
able to unite properly with (Liu et al., 2004) 
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1.4.2.2. Regulation of mRNA expression by miRNAs 
Mouse, bovine, metazoan and human studies showed that miRNAs are 
involved in transcriptional and post-transcriptional regulation of many mRNAs 
and a single miRNA may target multiple mRNAs (Moskwa et al., 2010, Bagga et 
al., 2005, Hayashi et al., 2008, Tesfaye et al., 2009, Bartel, 2004, Bartel and 
Chen, 2004, Miranda et al., 2006). MiRNAs regulate mRNAs that encode up to 
30% human protein-coding genes (Malumbres, 2012). Mouse embryonic stem 
cell studies showed that miRNAs recognises their target mRNAs by base 
complementation of the seed sequence that is the 7-mer sequence present at 
positions of  two to eight nucleotides within the open reading frame and 3’ 
untranslated region of the mRNA sequence (Babiarz and Blelloch, 2009).  
The mRNA regulation by miRNAs involves complex mechanisms. It is well 
established that in C. Elegans, metazoans, mouse and humans miRNAs target 
mRNAs for translational inhibition, cleavage, degradation or destabilisation 
(Bagga et al., 2005, Hayashi et al., 2008, Tesfaye et al., 2009, Bartel, 2004, 
Bartel and Chen, 2004, Miranda et al., 2006). However, more recently it has 
been suggested that these non-coding RNAs also play a role in stabilising their 
targets (Salmena et al., 2011, Seitz, 2009, Arvey et al., 2010, Lee et al., 2009, 
Poliseno et al., 2010, Franco-Zorrilla et al., 2007, Cazalla et al., 2010). This 
direct relationship between miRNA and mRNAs is not well understood, however 
several possible mechanisms have been proposed. The first proposal suggests 
mRNA stabilisation through binding of miRNA to AU rich elements of proteins 
and activation of cell-dependent regulation of mRNAs (Wilusz et al., 2001, 
Carroll et al., 2012). Another study also proposed a cell cycle-dependent 
miRNA regulation by repression and activation of mRNAs (Vasudevan et al., 
2007). Pseudogenes were suggested to be endogenous decoys for miRNAs by 
competing with the legitimate genes and reducing the repression activity of 
miRNAs on their target genes (Cazalla et al., 2010, Lee et al., 2009, Poliseno et 
al., 2010, Franco-Zorrilla et al., 2007). Circular RNAs, which have covalently 
linked ends and are generated by seemingly RNA splicing errors, have been 
recently suggested to act as miRNA decoys in HEK (human embryonic kidney) 
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and HeLa cells (Wilusz and Sharp, 2013, Hansen et al., 2011, Memczak et al., 
2013). These circular RNAs were shown to bind to miR-7 and reduce the 
binding efficiency of miR-7 to other RNAs. Similarly, mouse Sry was shown to 
generate a circular RNA that has multiple miRNA binding sites for miR-138 
(Hansen et al., 2013). From a similar point of view, when a single miRNA has 
multiple mRNA targets the down-regulatory role of the miRNA is reduced in 
HeLa cells (Arvey et al., 2010). Based on these observations, competitive 
endogenous RNA (ceRNA) hypothesis was proposed where coding and non-
coding RNAs can regulate mRNA/miRNA association by competing for the 
miRNA binding sites in humans (miRNA response elements, MRE) (Salmena et 
al., 2011). Interactions among different miRNAs were suggested to have a 
positive regulatory role for their targets since one miRNA may down-regulate 
the other leading to an increased expression of its target gene in HeLa, HEK-
293 and SH-SY5Y cell lines (Carroll et al., 2012).  
1.4.2.3. MiRNA expression in gametes and preimplantation 
embryos 
Expression of miRNAs has been observed in mouse, bovine and human 
gametes (Appendix 7.1.1). MiRNAs are suggested to regulate more than one 
third of the maternal genes in mouse oocytes (Tang et al., 2007). The study of 
immature and mature human oocytes have revealed different expression 
patterns of miRNAs; such as for hsa-miR-602, hsa-miR-193a-5p, hsa-miR-297, 
hsa-miR-625, hsa-miR-888, hsa-miR-212, hsa-miR-662, hsa-miR-299-5p, hsa-
miR-339-5p, hsa-miR-20a, hsa-miR-486-5p, hsa-miR-141, hsa-miR-768-5p, 
hsa-miR-376a and hsa-miR-15a; that suggests a developmental stage 
dependent expression of miRNAs (Xu et al., 2011).  
Expression of miRNAs has been observed in sperm and about 20% of these 
miRNAs are present within the nuclear or perinuclear part of the sperm. This 
may imply that at fertilisation, these sperm-borne miRNAs are transferred to the 
zygote (Liu et al., 2005). Initially it was proposed that these miRNAs were 
involved in the degradation of maternal transcripts. However, it was shown that 
these miRNAs do not play a significant role in mouse (Amanai et al., 2006).   
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Many miRNAs have also been shown to be expressed in mouse, bovine and 
human preimplantation embryos (Appendix 7.1.1) (Rosenbluth et al., 2012, 
McCallie et al., 2009, Tang et al., 2007, Tesfaye et al., 2009, Yang et al., 2008, 
Xu et al., 2011). Similar expression profiles of miRNAs in mature mouse 
oocytes and in the early developing embryos were observed that may be due to 
the maternally inherited miRNAs in the early embryo (Tang et al., 2007). 
Expression levels of these miRNAs vary during cleavage stage divisions, such 
that in murine embryos when the maternally inherited miRNAs are being 
degraded, a 60% decrease in the miRNA expression was observed. However, 
the overall expression of miRNAs was shown to be increased towards the 
blastocyst stage (Tang et al., 2007, Yang et al., 2008).  
1.4.2.4. Regulation of DNA repair genes by microRNAs 
expressed in gametes and preimplantation embryos 
Many miRNAs were shown to be induced after DNA damage and regulate DNA 
repair genes in C. Elegans, human cell lines and tissues (Aqeilan et al., 2009, 
Krichevsky and Gabriely, 2009, Navarro et al., 2008). This formed the basis of 
one of the aims in this project: "Potential correlation analysis between miRNA 
and their target repair transcripts in human oocytes and preimplantation 
embryos”. Since several miRNAs were shown to be expressed in mouse, 
bovine and human oocytes and embryos and that some of these miRNAs were 
shown or suspected to regulate repair genes in cell lines or tissues, it is 
possible that these miRNAs also regulate repair genes in human gametes and 
preimplantation embryos.  
The expression levels of miRNAs were shown to vary depending on the level of 
damage, such that some were shown to be down-regulated upon DNA damage; 
let-7 in C. Elegans and human glioma cells (Weidhaas et al., 2007, Chaudhry et 
al., 2010); and some were up-regulated; miR-15a, miR-16, miR-143, miR-155, 
miR-21 in human glioma cells (Chaudhry et al., 2010) and miR-99 in human 
prostate cancer cell lines (Mueller et al., 2012). This section focuses only on the 
miRNAs that have been shown to be expressed in mouse or bovine or human 
gametes and preimplantation embryos and that were shown or predicted to 
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have a role in regulating or being regulated by DNA damage, DNA repair or cell 
cycle checkpoint genes. 
Cell cycle checkpoint genes and miRNAs expressed in 
preimplantation embryos 
Cell cycle checkpoints play a crucial role in response to DNA damage. Studies 
in C. Elegans and human cell lines and tissues showed that many miRNAs are 
involved in regulating the cell cycle checkpoint genes as well as being regulated 
by these genes (Noto and Peek, 2012, Aqeilan et al., 2009, Krichevsky and 
Gabriely, 2009, Jurado et al., 2012, Massirer et al., 2012).  
Computational studies showed that DNA damage-induced transcription factors 
p53/p63/p73 regulate and are regulated by many miRNAs, such as miR-15/16a, 
miR-145, miR-26, miR-29, miR-146a, let-7 and miR-34 families, that are 
expressed during preimplantation embryo development (Tang et al., 2007, Yang 
et al., 2008, Boominathan, 2010). In human colon cancer cell lines miR-16-1, 
miR-143 and miR-145 were shown to be up-regulated by p53 and p68/p72 
dependent pathway upon DNA damage (Suzuki et al., 2009). The expression of 
p53 and its related family member p63 was shown to be inhibited by several 
miRNAs in hepatocellular carcinoma tissues, neuroblastoma and embryonic 
cells (Jiang et al., 2008, Eggert and Schulte, 2010). These miRNAs, such as 
miR-125b, miRNA-380-5p, miR-34 and miR-200 families, are also shown to be 
expressed in preimplantation embryos (Tang et al., 2007, Yang et al., 2008). 
Additional miRNAs that are expressed in preimplantation embryos are also 
shown to be involved in the regulation of p53 transcription, such as miR-192, 
miR-194, miR-215, miR-17-92 clusters in SJSA (osteosarcoma cell line), HCT 
(human colon carcinoma) DICERex5 cell lines, multiple myeloma cells and 
tumour and normal tissues (Georges et al., 2008, Braun et al., 2008, Yan et al., 
2008, Pichiorri et al., 2010) and miR-34 family in tumour-derived cell line A549 
(He et al., 2007). These miRNAs were also shown to regulate G1/S and G2/M 
checkpoint genes and ectopic expression of these miRNAs caused cell cycle 
arrest in adenocarcinoma, squamous cell carcinomas, normal epithelium and 
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dysplasia specimens (Jiang et al., 2008, Feber et al., 2008, Adare et al., 2010, 
Cannell et al., 2010, Braun et al., 2008, Georges et al., 2008). In addition to 
these miRNAs, miR-21 (Pauli et al., 2011, Wang et al., 2009), miR-17-92 in 
colon cancer cells (Gunaratne, 2009), miR-371 in mouse embryonic stem cells, 
miR-302 in human embryonic stem cells (Kim, 2008) and miR-34c in mouse 
embryonic fibroblasts and HeLa cells (Cannell et al., 2010) were shown to be 
involved in G1/S cell cycle regulation upon DNA damage. Inhibition of miR-34c 
prevents the cell cycle arrest at the S phase caused by DNA damage (Cannell 
et al., 2010). The efficiency of the S cell cycle checkpoint was shown to be 
influenced by the ectopic expression of miR-421, where ATM kinase is down-
regulated and the sensitivity for the ionising radiation was shown to be 
increased. Once the interaction of miR-421 and ATM 3’UTR was hindered, this 
affect was reversed in neuroblastoma cell lines (Hu et al., 2010). ATM and 
DNA-PKcs protein levels were also shown to be reduced by up-regulation of 
miR-421 and miR-101 in human osteosarcoma and colorectal cancer cell lines 
U2OS, MG63, RKO and HT-29 (Mishra et al., 2009). Wip1 phosphates, a key 
inhibitor of ATM-p53 signalling pathway, were shown to be suppressed by miR-
16. This miRNA was also shown to target Cyclin D1 and BCL2 in cancer cells of 
prostate tumours in mouse (Bonci et al., 2008). G2 checkpoint arrest due to 
DNA damage-induced death was shown to be prevented by over-expression of 
miR-143 in lung cancer cells 293T and A549 (Lin et al., 2011).  
Figure 1.10 shows the relationship of genes and proteins involved in the cell 
cycle and miRNAs expressed in mouse, bovine and/or human preimplantation 
embryos. 
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Figure 1-10 Main regulators of the cell cycle and their association with miRNAs. 
 
a) MiRNAs involved in the regulation of cell cycle checkpoint genes at G0, S, G2 and 
M phases. 
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b) MiRNAs involved in the regulation of cell cycle checkpoint genes at the G1/S transition. 
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c) MiRNAs involved in the regulation of cell cycle checkpoint genes at G0/G1 and 
S/G2 transitions. 
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d) MiRNAs involved in the regulation of cell cycle checkpoint genes at G2/M and 
M/G1 transitions. 
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Main cycles of checkpoint; G1 (first gap phase), S (synthesis phase), G2 (second gap phase), M 
(mitosis) and G0; are shown. Cell cycle regulators and effectors (purple labelled), which 
regulate and/or are regulated by miRNAs (blue labelled) expressed in preimplantation embryo 
development, are grouped according to the cell cycle phase. Positive (green labelled) and 
negative (red labelled) relationship between miRNAs and mRNAs are shown according to the 
cell cycle: a) MiRNAs involved in the regulation of cell cycle checkpoint genes at G0, S, G2 and 
M phases. b) MiRNAs involved in the regulation of cell cycle checkpoint genes at the G1/S 
transition c) MiRNAs involved in the regulation of cell cycle checkpoint genes at G0/G1 and 
S/G2 transitions and d) MiRNAs involved in the regulation of cell cycle checkpoint genes at 
G2/M and M/G1 transitions (Hermeking, 2012, Biggar and Storey, 2010, Eggert and Schulte, 
2010, Kim, 2008, Noto and Peek, 2012, Bueno and Malumbres, 2011, Song and Meltzer, 2012, 
Zhang et al., 2010a, Ryazansky and Gvozdev, 2008, Liang and He, 2011, Hu and Gatti, 2010, 
Hu et al., 2010, Yan et al., 2010, Zhang et al., 2010b). 
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Base excision repair genes and miRNAs expressed in 
preimplantation embryos 
Several genes, proteins and polymerases are involved in base excision repair. 
Although expression of several genes was shown to be regulated by miRNAs, 
the possible association of the expression of miRNAs and base excision repair 
genes remains to be analysed. However bioinformatics studies identified 
several miRNAs with putative base excision repair gene targets. PARP1 is 
mainly involved in double strand break repair in mammalian cells and this gene 
was shown to interact with many base excision repair genes (Dantzer et al., 
1999, Dantzer et al., 2000). In the absence of PARP1base excision repair was 
shown to be impaired. The association of PARP1 with base excision repair 
genes and miRNAs are shown in figure 1.11. In addition to this gene, 
bioinformatics studies showed that miRNAs are also involved in the regulation 
of PCNA (Figure 1.11, Appendix 7.1.1, http://www.targetscan.org/, 
http://www.microrna.org/microrna/home.do and http://mirdb.org/miRDB/). 
Therefore, it is likely that some or all of these base excision repair genes 
identified by bioinformatics analyses are regulated by miRNAs in human 
oocytes and embryos. 
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Figure 1-11 Schematic diagram of base excision repair pathway with genes and miRNAs 
regulating these genes. 
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Genes involved in base excision repair and miRNAs that are predicted to regulate these genes 
are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, 
http://mirdb.org/miRDB/). Several miRNAs were shown to target PARP1, which was shown to 
interact with several genes involved in base excision repair and genes functioning at later 
stages of base excision repair pathway. Bioinformatics studies also showed that PCNA is 
regulated by two miRNAs. Although a direct relationship among miRNAs and base excision 
repair genes, proteins and polymerases has not been established, there may be an indirect 
regulation of base excision repair components through miRNA regulated PARP1. 
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Nucleotide excision repair genes and miRNAs expressed in 
preimplantation embryos 
Nucleotide excision repair is a multi-protein repair system. MiRNAs were shown 
or are suggested to regulate expression of several nucleotide excision repair 
genes, such as forced expression of miR-192, which is expressed in bovine 
oocytes, was shown to impair nucleotide excision repair. MiR-192 was shown to 
regulate ERCC3 (XPB) and ERCC4 (XPF), i.e. increased expression of this 
miRNA down-regulated ERCC3 expression in hepatoma cell line HepG2.2.15 
cells (Xie et al., 2011). It is possible that miR-192 also down-regulates these 
genes in gametes and preimplantation embryos. 
Bioinformatics analyses also suggested that several other nucleotide excision 
repair genes are regulated by miRNAs (Figure 1.12), such as hsa-miR-23, hsa-
miR-101, hsa-miR-128, hsa-miR-181c and hsa-miR-212 are suggested to target 
GTF2H2 (http://www.microrna.org/microrna/home.do,http://www.targetscan.org/ 
and http://mirdb.org/miRDB/). Although the association of these miRNAs and 
GTF2H2 have not been analysed previously, it is possible that these miRNAs 
have a regulatory role on GTF2H2 in gametes and embryos. 
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Figure 1-12 Schematic diagram of nucleotide excision repair pathway with genes and 
miRNAs regulating these genes. 
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Genes involved in nucleotide excision repair and miRNAs that are predicted to regulate these 
genes are shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, 
http://mirdb.org/miRDB/). Several miRNAs were shown or suggested to target the initial sensor 
genes and genes functioning at later stages of nucleotide excision repair pathway. 
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Double strand break repair and miRNAs expressed in 
preimplantation embryos 
Several double strand break repair genes, such as H2AX, BRCA1, PARP1, 
RAD23B, RAD51, RAD52 and MRE11, were shown to be targeted by miRNAs 
that are expressed during preimplantation embryo development (Figure 1.13). 
In U2OS human osteosarcoma cell lines and humans, H2AX, a sensor protein 
in double strand break repair response, was shown to be targeted by miR-138 
(Wang et al., 2011), miR-24 (Adare et al., 2010), miR-23b and miR-145 (Revel 
et al., 2011). Ectopic expression of miR-138 in U2OS human osteosarcoma cell 
line was shown to lower -H2AX formation, hindered homologous recombination 
and increased sensitivity to DNA damaging agents (Wang et al., 2011). Over-
expression of miR-24 caused reduced H2AX expression and increased 
sensitivity to ionising radiation with reduced repair capacity (Adare et al., 2010).  
Expression of homologous recombination repair proteins were shown to be 
changed by forced expression of miR-210 and miR-373. The forced expression 
of these miRNAs was shown to reduce RAD52 expression and over-expression 
of miR-373 reduced the expression of RAD23B and RAD52 in HeLa cells 
(Crosby et al., 2009). Unlike this negative regulation, MRE11 was unaffected by 
the over-expression of these miRNAs (Crosby et al., 2009).  
MiR-99 was shown to reduce the repair efficiency by disturbing the localisation 
of RAD51 and BRCA1 to DNA damaged site in human prostate and breast 
cancer cell lines (Tanic et al., 2011, Mueller et al., 2012). BRCA1 was shown to 
be down-regulated by over-expression of miR-146 and miR-182 in sporadic 
breast tumours (Moskwa et al., 2010). Over-expression of miR-182 also caused 
an increased sensitivity to PARP1 inhibition in cultured cells (Moskwa et al., 
2010, Tanic et al., 2011). It is possible that presence of these miRNAs or 
abnormal expression, such as over-expression of these miRNAs, would have 
similar regulatory effects in human gametes and embryos. 
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Figure 1-13 Schematic diagram of the double strand break repair pathways with genes 
and miRNAs regulating these genes. 
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Genes involved in a) Non-homologous end joining and b) Homologous recombination pathways 
and miRNAs that are predicted to regulate these genes are shown 
(http://www.microrna.org/microrna/home.do,http://www.targetscan.org/,http://mirdb.org/miRDB/). 
Several miRNAs were shown to target the initial sensor genes of non-homologous end joining 
and homologous recombination repair pathways. Several more miRNAs were shown to regulate 
the expression of genes functioning at later stages of both non-homologous end joining and 
homologous recombination repair pathways. 
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Mismatch repair and miRNAs expressed in preimplantation 
embryos 
Jaroudi et al. (2009) showed that mismatch repair genes were expressed in 
human oocytes and blastocysts. These genes were shown to be regulated by 
several miRNAs (Figure 1.14). MiR-155, expressed in mouse preimplantation 
embryos, was shown to down-regulate mismatch repair heterodimer proteins 
MSH2-MSH6, MLH1 and PMS2 in human hepatoma cell lines (Valeri et al., 
2010, McPhee et al., 2012). Similarly, high expression of miR-21 was shown to 
down-regulate MSH2 and MSH6 in colorectal tumours (Valeri et al., 2010).  
MiRNA expression was also associated with microsatellite instability, such that 
differential expression of miRNAs, miR-31, miR-552, miR-592, miR-625, miR-
196b and miR-181c, was observed in tumours with microsatellite instability 
and/or absence of protein expression hMLH1 relative to the tumours with no 
microsatellite instability and normal protein expression of hMLH1. Thirty nine 
more miRNAs were differentially expressed between normal colon tissue and 
tumour specimens (Medina and Slack, 2008). Moreover, increased expression 
of miR-101, miR-192 and miR-212 was associated with microsatellite instability 
compared to miRNAs associated with microsatellite stable samples (Schepeler 
et al., 2008). Increased expression of let-7a, miR-31 and miR-145 was shown to 
be linked with low levels of microsatellite instability compared to miRNAs 
associated with both stable and high levels of microsatellite instability indicating 
that the presence of these miRNAs lowers the risk of microsatellite instability 
(Earle et al., 2010). Two miRNAs, miR-181c and miR-196b were shown to be 
down-regulated in tumours with microsatellite instability and/or in the absence of 
protein expression hMLH1 (Sarver et al., 2009, Medina and Slack, 2008). Since 
these miRNAs were shown to be expressed in mouse embryos (Tang et al., 
2007, Yang et al., 2008), they may play a role in stabilising microsatellites or 
hMLH1 in human embryos. 
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Figure 1-14 Schematic diagram of mismatch repair pathway with genes and miRNAs 
regulating these genes. 
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Genes involved in mismatch repair and miRNAs that are predicted to regulate these genes are 
shown (http://www.microrna.org/microrna/home.do, http://www.targetscan.org/, 
http://mirdb.org/miRDB/). Multiple miRNAs are suggested to regulate the expression of 
mismatch repair sensor genes (MSH2, MSH3, MSH6, PCNA) and genes functioning at later 
stages of mismatch repair (MLH1 and PMS2). 
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1.5. Aims and hypothesis 
1) The expression level of miRNAs and their target repair 
transcripts in human oocytes and preimplantation embryos 
Expression of DNA repair genes in human oocytes and embryos was 
investigated by Jaroudi et al. (2009). Similarly, the expression of miRNAs in 
mouse and bovine oocytes and preimplantation embryos at different stages of 
development has been studied (Yang et al., 2009, Tang et al., 2007, Mondou et 
al., 2012, Ro et al., 2007, Xu et al., 2011). To date only three studies have 
investigated the miRNA expression in human oocytes (Xu et al., 2011) and 
blastocysts (McCallie et al., 2009, Rosenbluth et al., 2012). As described in 
section 1.4.2.4 several miRNAs were shown to be involved in the regulation of 
numerous DNA repair genes in human cell lines, (Aqeilan et al., 2009, 
Krichevsky and Gabriely, 2009, Navarro et al., 2008, Wang et al., 2011, Tanic et 
al., 2011, Mueller et al., 2012, Valeri et al., 2010, McPhee et al., 2012). 
However, there have not been any studies focusing on the relationship between 
miRNAs and the expression of genes involved in DNA repair in gametes and 
preimplantation embryos. 
It was hypothesised that miRNAs have regulatory roles on their target mRNAs. 
Since the majority of the previously published studies showed that miRNAs 
down-regulate their targets, it was hypothesised that in these cases an inverse 
correlation would be observed between miRNAs and their target mRNAs. 
However, it was also hypothesised that some miRNAs may have a direct 
relationship with their target mRNAs since recent studies have shown a 
stabilisation effect of miRNAs on their targets. 
The first aim of this project was to investigate the possible correlations of 
miRNAs and their target mRNAs involved in different repair pathways.  
In order to identify target miRNAs and mRNAs, a literature review was 
performed. The expression level of the selected miRNA and mRNA was 
investigated by quantitative real time PCR (using TaqMan assays). Since it was 
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difficult to obtain cleavage stage human embryos, this analysis was performed 
in individual human oocytes and individual human blastocysts. A student’s T-
test was applied to investigate if there was significant association in the 
expression of the mean mRNA and miRNA levels in oocyte relative to the 
blastocyst. Pearson correlation with Dunnett’s post testing was used to identify 
significant association between the levels of miRNAs and their target mRNAs. 
2) Differential gene expression in preimplantation embryos 
and potential relation with differential methylation 
Investigation of epigenetic modifications and differential methylation of parental 
genomes in mouse preimplantation embryos are established (Dean et al., 2003, 
Tamaru and Selker, 2001, Jackson et al., 2002, Fuks et al., 2003). Studies in 
mouse, bovine and human suggest that there is rapid demethylation of the 
paternal genome post fertilisation whereas demethylation of the maternal 
genome is gradual (Fulka et al., 2004, Beaujean et al., 2004b, Santos et al., 
2003). At this stage of development it is possible that parental genes are 
differentially expressed. 
The hypothesis of this study was that up to blastocyst stage global differential 
demethylation of parental genomes may result in preferential parental gene 
expression. When a repair gene carries a mutation, preferential parental gene 
expression may affect preimplantation embryo development. Therefore, it was 
hypothesised that the development of preimplantation embryos may be 
impaired when the embryo carries a paternally inherited mutation compared to 
the embryo with maternally inherited mutation. 
The second aim of this project was to investigate the differential parental 
expression of ACTB, SNRPN, H19 and BRCA1 in human preimplantation 
embryos obtained from patients undergoing preimplantation genetic diagnosis 
(PGD). A further analysis was conducted to investigate if the differential 
parental expression of BRCA1 affects the developmental progression of the 
embryos depending on the parental inheritance. 
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In order to investigate differential parental gene expression in embryos, 
informative single nucleotide polymorphisms (SNPs) between couples were 
required. SNPs with high heterozygosity were identified using Ensembl genome 
browser within the coding region of preselected genes. The alleles at the SNP 
sites were identified by sequencing analysis for each couple. Embryos from 
couples with informative SNPs were used to investigate differential expression 
of parental transcripts. cDNA from these embryos were semi-quantitatively 
analysed by mini-sequencing (SNaPshot) analysis. Differential parental 
expression was examined by calculating the peak height ratios of the alleles for 
the SNPs analysed. Statistical analysis was performed by applying student’s T-
test to investigate if there was significant difference in the expression levels of 
parental transcripts (ACTB, SNRPN, H19 and BRCA1) in embryos. Methylation 
status of the embryos was analysed by bisulfite conversion followed by 
methylation specific PCR to investigate if the differential gene expression profile 
was due to methylation.   
The final part of this study investigated if there was any difference in the 
developmental stage of embryos with paternally inherited BRCA1 and BRCA2 
mutations compared to the maternally inherited BRCA1 and BRCA2 mutations 
on day 5/6 post fertilisation. A chi-squared test was applied to investigate if this 
difference was significant.  
3) Functional assay development for mismatch repair  
Expression and proteomic analyses provide an indication of which DNA repair 
pathways are functionally active in preimplantation embryos. However these 
analyses still do not provide the actual capacity of a cell to perform DNA repair. 
There are no studies analysing mismatch repair efficiency in human 
preimplantation embryos and current techniques analysing mismatch repair 
efficiency require construction of plasmids that are time consuming and 
expensive. It is important to develop an assay sensitive enough to detect the 
mismatch repair efficiency in embryos.  
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It was hypothesised that oocytes and blastocysts have mismatch repair 
activities since previous studies showed that mismatch repair genes are 
expressed both in oocytes and blastocysts. 
The last aim of this project was to develop a simple and sensitive functional 
assay to detect the efficiency of mismatch repair in oocytes and preimplantation 
embryos. Mismatch repair activity was optimised in vitro by exposing 
heteroduplex constructs to commercially available nuclear and whole cell 
extracts. Mismatch repair efficiency was detected by mini-sequencing 
(SNaPshot) analysis. The optimised functional assay was then applied to whole 
cell extracts obtained from pooled mouse and human oocytes and blastocysts, 
respectively. 
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2.1. General laboratory methods and standards 
A general code of laboratory practice and workflow is described. The 
methodology to achieve all three aims is presented in two main sections; 1. 
sample collection, 2. sample processing and analysis. The sample collection 
section describes the sample types, selection of the samples used for each aim, 
how they were collected and processed immediately for the subsequent 
experimental work. The sample processing section explains all the methodology 
and analysis used to accomplish each aim, such as DNA/RNA extraction, DNA 
amplification, sequencing and microarrays and statistical analysis. The workflow 
outlining each methodology used for this study is presented in table 2.1. 
All solutions were prepared with deionised water and they were autoclaved. The 
pH of all the buffers was measured at room temperature (RT). Unless otherwise 
stated all reagents were from VWR (International) and were of Analar Quality 
including ethanol 99.7-100% v/v and salts used for the preparation of buffers, 
such as sodium chloride (NaCl), orthoboric acid and Tris (hydroxymethyl) 
methylamine (TRIS). Molecular grade reagents were supplied by Sigma (UK) 
including ethylenediaminetetra-acetic acid anhydrous 99% (EDTA), adenosine 
5’-triphosphate disodium salt hydrate (ATP), beta-mercaptoethanol (β-Me), 
bovine serum albumin (BSA), ethidium bromide, ethylene diamine tetraacetic 
acid, glutathione, phosphate buffered saline (PBS), polyvinyl alcohol (PVA), 
sodium acetate (3M solution), sodium dodecyl sulfate (SDS) and agarose type I. 
Of these reagents ATP and glutathione were stored at 4ºC, BSA at -20ºC and 
the rest at RT. Proteinase K was supplied by Roche (UK) and Exo I and shrimp 
alkaline phosphate (SAP) were obtained from New England Biolabs (UK). All 
these enzymes were stored at -20ºC.  
For each experiment, dedicated areas were used. All preparations, such as 
single cell isolation, blastomere tubing, PCR, whole genome amplification 
(WGA) and cDNA synthesis preparations were carried out in a dedicated single 
cell room. In the single cell room the air was filtered and replaced 20 times per 
hour under positive pressure. All the equipment and consumables, such as 
boxes containing filter tips, tubes, gloves, pipettes and ice trays entering the 
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room for the first time, were wiped with ethanol. These boxes were then 
exposed to ultraviolet light (Template Tamer, Qbiogene, UK) for at least 10 
minutes to remove DNA contaminants. A microflow advanced Bio-safety cabinet 
class II was used to set up all the PCRs, WGA and cDNA synthesis reactions 
and all the preparations for these reactions were carried out on ice trays. These 
reactions were set up using DNase- and RNase-free water (Promega, UK) in 
DNA-, DNase-, RNase- and pyrogen-free tubes (Molecular BioProducts, Inc, 
UK).  
Extra caution was taken for all the expression experiments, such as RNA 
isolation, cDNA synthesis and real time PCR. RNA isolations were carried out in 
a designated area outside the single cell room. Pipettes, filtered pipette tips and 
tube racks designated for RNA isolation only were used through the expression 
studies. In order to reduce RNase contamination, all the equipment and the 
designated laboratory area were cleaned with 70% ethanol and RNase ZAP 
(Ambion Inc, UK), rinsed with distilled water and dried with clean tissue before 
each experiment. Gloves were frequently changed to reduce any risk of 
contamination. 
All the centrifugation was carried out in a bench top microfuge (MSE 
Microcentaur, Sanyo, UK and Labofuge 400, Heraeus Instruments, UK). All the 
PCRs, WGA and cDNA synthesis reactions were carried out in either of two 
PCR thermocyclers; Mastercycler Gradient® thermal cycler (Eppendorf, UK) 
and GeneAmp PCR System 9700 (Applied Biosystem, UK). All the PCR 
products (PCR analyses including mini-sequencing following PCR) were 
handled in a separate laboratory using pipettes and pipette tips dedicated for 
post-PCR products. A PCR workstation (Template Tamer, Qbiogene, UK) was 
used to carry out all the post-PCR analysis and all the consumables, including 
pipettes and pipette tips, were exposed to UV for at least 10 minutes after each 
use to decontaminate them prior to next use. 
All the samples were collected from patients undergoing in vitro fertilisation 
(IVF)/ intracytoplasmic sperm injection (ICSI)/ PGD at the Centre for 
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Reproductive and Genetic Health (CRGH) and the UCL Centre for PGD who 
had given an informed consent to donate samples for this project. This work 
was licensed by the Human Fertilisation and Embryology Authority (HFEA 
project reference: RO113) and ethical approval was granted by the National 
Research Ethics Service (NRES), Research Ethics Committee (REC reference 
number: 10/H0709/26). 
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2.2. Potential correlation analysis between miRNA and their 
target repair transcripts in human oocytes and 
preimplantation embryos 
The workflow for correlation analysis of miRNAs and mRNAs in human oocytes 
and preimplantation embryos is summarised in figure 2.1. 
Figure 2-1 Workflow of correlation analysis between miRNAs and mRNAs in human 
oocytes and blastocysts. 
RNA
Cell lysis
miRNA specific
cDNA synthesis
cDNA 
synthesis
Real time PCR for 
miRNA detection
Real time PCR for 
mRNA detection
Statistical analysis
RNA
Literature search to identify miRNA and 
their target genes 
Tubing of oocytes and embryos from IVF unit
and and
 
Literature search was performed to identify target miRNAs and mRNAs to be analysed in this 
study. After initial cell lysis, samples were reverse transcribed for specific miRNAs and analysed 
by quantitative real time PCR for miRNA expression. Similarly for mRNA expression, samples 
were reverse transcribed into cDNA and real time PCR was performed to quantitatively analyse 
the expression of mRNA targets. 
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2.2.1. Sample collection 
A total of 31 immature oocytes and 33 surplus embryos from patients 
undergoing IVF were collected for this project. Oocytes and embryos were 
transported in culture dishes from the Centre for Reproductive and Genetic 
Health in a closed thermally insulated carrier (IsoTherm-System®, Eppendorf, 
UK). These samples were processed immediately, especially for the RNA 
expression studies to minimise degradation of RNA. Oocyte and embryo 
morphology grading was performed by the embryologists at the Centre for 
Reproductive and Genetic Health on the day of sample collection. Oocytes were 
grouped in meiosis I (MI) and meiosis II (MII) stages. The blastocysts were 
scored according to Cornell grading (Veeck et al., 2004) (Table 2.1).  
Table 2-1 Cornell grading scheme for the blastocysts. 
Grade Expansion Grade
Inner Cell Mass 
(ICM)
Grade Trophectoderm
1 Early blastocyst A Compact cells A Good cells with a 
cohesive 
epithelium2 Blastocyst
3 Full blastocyst B Large, loose cells B Few large 
healthy cells
4 Hatching blastocyst C ICM is not 
distinguishable
C Poor very large/ 
unevenly 
distributed cells5 Fully hatched 
blastocyst
6 Hatching or hatched 
blastocyst with PGD
D ICM is 
degenerative
D Cells are 
degenerative
 
This figure shows blastocyst grading according to Cornell grading scheme depending on the 
stage of expansion, inner cell mass and trophectoderm. The first number scored the expansion, 
second character scored the quality of ICM and the last character scored the quality of the 
trophectoderm, respectively. Images were adopted from (Veeck et al., 2004). Copyright (2004) 
Elsevier. 
 
All the donated oocytes and embryos were collected and tubed in 0.3U/µl 
RNasin plus RNAse inhibitor (Promega, UK) using an inverted microscope 
(Olympus, Optech microscope services, UK). A hand pipette (Cook, UK) using a 
0.3mm polycarbonate microcapillary (Biohit, Finland) was used for tubing all the 
oocytes and embryos and the samples were stored at -80ºC. This process 
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involved removing the zona pellucida prior to tubing any blastomeres. Oocytes 
and embryos were exposed briefly to acidified Tyrode’s solution (MediCult Ltd, 
UK) to remove the zona pellucida. The cells freed from zona pellucida were 
washed three times in fresh drops of RNasin buffer. The washed cells from the 
individual embryos were transferred into a thin walled 0.2ml microfuge tubes. 
The nomenclature for the embryos collected were presented with the patient 
number followed by embryo number, such that the first digit represents the 
couple number and the second digit represents their embryo numbers; i.e. 1.1 
represent couple one’s first embryo, 1.2 represent couple one’s second embryo. 
2.2.2. Target selection  
In order to identify the target mRNAs and miRNAs, a Medline literature search 
was performed using the keywords “DNA repair genes”, “miRNA”, “expression”, 
“embryo”, “oocyte”, “sperm”, “human” and “preimplantation development”. An 
expression profile of DNA repair genes in human oocytes and blastocysts was 
previously investigated by Jaroudi et al. (2009). A group of DNA repair genes 
showing differential expression between oocytes and blastocysts was identified 
using these data. A further Medline search was carried out to identify miRNAs 
expressed in mouse, bovine and human oocytes. From this profile, miRNAs 
associated with DNA repair genes, especially with the previously identified 
differentially expressed repair genes, were investigated using the keywords 
“miRNA”, “DNA repair”, “nucleotide excision repair”, “base excision repair”, 
“mismatch repair”, “double strand break repair” and “DNA damage”. In addition 
to these published articles, databases were searched to investigate if miRNAs 
expressed in bovine, mouse and human gametes and embryos have any 
putative targets that are involved in DNA repair (http://www.targetscan.org/, 
http://www.microrna.org/microrna/home.do and http://mirdb.org/miRDB/).  
These two profiles of differentially expressed mRNAs between human oocytes 
and blastocysts and miRNAs expressed in bovine, mouse and human and were 
also shown to be involved in different repair pathways, were used to select the 
targets. It was aimed to select one sensor gene or a gene functioning at the 
earlier stages of the particular repair pathway and one gene functioning at later 
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stage of the repair pathway to identify which repair pathway may be functionally 
active. The expression of one miRNA processing gene, DICER, was also 
selected to be examined in order to show that miRNA processing genes are 
present at these stages. MiRNAs, which were shown to be expressed in mouse 
and bovine gametes and preimplantation embryos and target multiple selected 
mRNAs, were selected for this analysis. TaqMan assays were used to target 
both miRNAs and mRNAs in human oocytes and blastocysts. Following cell 
lysis, cDNA synthesis was performed to investigate mRNA expression. 
Customised TaqMan primer assays specific for each mRNA and miRNA were 
used. Neither of the primer assays (mRNA and miRNA) required further 
optimisation prior to analysis. 
For each target, expression analyses were performed in repeat samples to 
eliminate the sample variation. Each mRNA or miRNA had a total of six repeats 
(six individual oocytes and six individual blastocysts) and between two to three 
replicates. Replicates involved analysis of the miRNA expression in the same 
oocyte and blastocyst sample in duplicate to have an internal check of the 
fidelity of the experiment. The samples were grouped together according to the 
oocyte and blastocyst morphologies for each target to avoid inter-individual 
variation. Only meiosis I (MI) and meiosis II (MII) oocytes were used for the 
analysis. Similar developmental stage blastocysts were grouped together to 
investigate the expression of each target. Due to the scarcity of human oocytes 
and blastocysts, the maternal age could not be used as criteria to group the 
samples. Overall, each embryo was tested for between four to nine mRNAs 
and/or miRNAs. 
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2.2.3. Sample processing and analysis 
The expression of nine mRNA and one miRNA processing gene was analysed 
using the TaqMan® gene expression cells-to-Ct™ (cycle threshold) kit (Ambion, 
Life Technologies, UK) in nine single human oocytes and ten single human 
blastocysts. The expression of 20 miRNAs that target these mRNAs in 22 
human oocytes and 23 blastocysts were analysed using the TaqMan® 
microRNA cells-to-Ct™ kit (Ambion, Life Technologies, UK). Both analyses 
involved three main steps; lysis, reverse transcription and real time PCR. Lysis 
of oocytes and blastocysts was performed by addition of 25µl lysis solution with 
0.25µl DNase I to each sample and incubation at RT for 8 minutes. The lysis 
was stopped by addition of the 2.5µl stop solution and incubation at RT for 2 
minutes.  
2.2.3.1. Reverse transcription for mRNA and miRNA 
expression 
A master mix consisting of 25µl of 2xRT buffer, 2.5µl of 20xRT enzyme mix and 
12.5µl of nuclease-free water was added to 10µl of the lysate for the analysis of 
mRNA expression. Reverse transcription was carried out in a thermal cycler at 
37ºC for 1 hour and the reaction was inactivated at 95ºC for 5 minutes.  
Reverse transcription was carried out for each miRNA specifically. Three µl of 
miRNA specific RT primer was added to a master mix of 1.5µl of 10xRT buffer, 
0.15µl of dNTP mix, 0.19µl of RNase inhibitor, 1µl of MultiScribe™ RT and 
4.16µl of nuclease-free water. Five µl of lysate was added for each reaction. 
The annealing was carried out in a thermal cycler at 16ºC for 30 minutes 
followed by reverse transcription at 42ºC for 30 minutes. The reverse 
transcription was stopped at 85ºC for 5 minutes.  
Reverse transcription was carried for each reaction in the absence of embryo 
lysate as a negative control. 
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2.2.3.2. Real time PCR for mRNA and miRNA  
Real time PCR for each sample in duplicates was carried out to analyse the 
relative expression of mRNAs and miRNAs between oocytes and blastocysts 
using the Light cycler Nano (Roche, UK). A negative control for each real time 
PCR was analysed in the absence of cDNA. 
For mRNA analysis, a master mix of 5µl of 2xTaqMan® gene expression mix, 
0.5µl of 20xTaqMan® gene expression assay and 2.5µl of nuclease-free water 
was added to 2µl of reverse transcription product. The real time PCR conditions 
involved an enzyme activation step at 95ºC for 10 minutes followed by 
denaturation at 95ºC for 15 seconds and annealing and extension at 60ºC for 1 
minute for 50 cycles.  
For miRNA analysis, a master mix of 5µl of 2xTaqMan® mix, 0.5µl of TaqMan® 
microRNA assay and 2.5µl of nuclease-free water was added to 2µl of reverse 
transcription product. Real time PCR was carried out by an initial enzyme 
activation step at 95ºC for 10 minutes and denaturation at 95ºC for 15 seconds 
and annealing and elongation at 60ºC for 1 minute for 50 cycles.   
Cq values were assigned automatically by the Light cycler Nano software 
(Roche, UK) and they represent the number of cycles required for the 
fluorescent signal entering the exponential phase. Lower Cq values indicate 
greater expression in the sample.  
For comparative Cq analysis, ΔCq values for mRNA and miRNA were 
investigated by normalisation to the reference gene ACTB for mRNA and 
RNU48 for miRNA, respectively: 
ΔCq = Cq_ target oocyte/blastocyst - Cq_ACTB oocyte/blastocyst  
ΔCq=Cq_ target oocyte/blastocyst - Cq_RNU48 oocyte/blastocyst 
Fold change was analysed by the relative quantification method, 2^-ΔΔCq: 
ΔΔCq = (Cq_target-Cq_ACTB)blastocyst - (Cq_ target-Cq_ACTB)oocyte  
Materials and Methods 
 
90 
 
ΔΔCq=(Cq_target-Cq_RNU48)blastocyst-(Cq_ target-Cq_RNU48)oocyte 
2.2.3.3. Statistical analysis 
GraphPad prism v6 software was used for the statistical analyses. The 
expression level of each mRNA expression was examined by one-way ANOVA 
with Dunnett’s multiple comparison post test. Similarly, each miRNA expression 
was examined by one-way ANOVA with Dunnett’s multiple comparison post 
test. 
Each mRNA and miRNA expression in oocytes relative to blastocysts was 
examined by applying an unpaired two-tailed student’s T-test with the Welch 
correction. Pearson correlation test was used to correlate expression of each 
miRNA with its target mRNA. An inverse correlation was defined as r=-1 and a 
direct correlation as r=+1 following Pearson correlation test. The closer the r 
value was to +1 or -1, the stronger was the correlation. Similarly, a perfect 
correlation was defined as Pearson’s r2 coefficient equal to 1. For all the 
statistical analysis, p<0.05 indicated a statistical significance. 
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2.3. Differential gene expression in preimplantation embryos 
and potential relation with differential methylation 
The workflow for differential gene expression in preimplantation embryo 
analysis is summarised in figure 2.2. 
 
Figure 2-2 Workflow of correlation analysis between miRNAs and mRNAs in human 
oocytes and blastocysts. 
Determine informative SNPs between the partners by sequencing the paternal 
and maternal genome
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Informative SNPs between the male and female partners were identified by sequencing. RNA 
from the couple’s embryos was extracted and cDNA was synthesised. Differential parental gene 
expression was analysed in the embryos by mini-sequencing. DNA from the embryos was also 
extracted to test the aneuploidy status of the embryos and to analyse the methylation status by 
bisulfite conversion followed by methylation specific PCR. 
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2.3.1. Sample collection 
This project involved blood samples from the patients undergoing PGD. Bloods 
were collected in sodium ethylenediaminotetra acetic acid (EDTA) tubes for 
DNA extraction or Lithium heparin tubes for lymphocyte separation. If the DNA 
extraction (2.3.2.1) was not carried out on the same day as it was collected, the 
sample was stored at -80ºC until the day of the extraction. Lymphocyte 
separation (2.3.2.2) and single cell isolations were carried out on the same day 
that the samples were received. In the first part of this study, differential 
expression analysis, embryos diagnosed as affected following PGD for a range 
of monogenic disorders or were unsuitable for transfer were collected on days 
5/6 post fertilisation and tubed in RNAsin solution as described in section 2.2.1. 
A total of 95 embryos at cleavage and blastocyst stages were collected for this 
study. The cleavage stage embryos were graded according to Bolton et al. 
(1989) and the number of cells and the presence of fragments were recorded. 
Grade 1 represent the ideal symmetrical and even-sized blastomeres with no 
fragmentation, 1- is symmetrical and even blastomeres with less than 10% 
fragmentation, grade 2+ is uneven blastomeres with less than 20% 
fragmentation, grade 2 is compromised development with uneven blastomeres 
with 25-50% fragmentation and grade 3 is the compromised development with 
uneven blastomeres with more than 50% fragmentation. The blastocysts were 
graded as described in section 2.1.1. In the second part of the study, the 
developmental progression of 16 embryos with maternally inherited BRCA 
mutations were compared to 15 embryos with paternally inherited BRCA 
mutations. 
2.3.1.1. Sample selection 
To investigate the parental origin of genes expressed in preimplantation 
embryos, SNP rich regions were amplified and sequenced using the DNA 
obtained from couples undergoing PGD. Complete updated DNA sequences of 
ACTB, GAPDH, SNRPN, IGF2, H19, UBE3A and BRCA1 including the 
locations of SNPs with heterozygosity information were obtained using Ensembl 
genome browser, http://www.ensembl.org/index.html. Primers were designed to 
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amplify SNP rich areas within the coding regions of these genes as described in 
2.3.2.3. All the primer sequences and the amplified regions for these genes are 
shown in Appendix 7.2.1.1 (a). Sequencing panels obtained from GeneScan 
analysisTM on ABI PrismTM 3100 of each partner were compared to the gene 
sequences of ACTB (ENSG00000075624, Ensembl release 60), GAPDH 
(ENSG00000111640, Ensembl release 60), SNRPN (ENSG00000128739, 
Ensembl release 60), UBE3A (ENSG00000114062, Ensembl release 60), IGF2 
(ENSG00000167244, Ensembl release 60), H19 (ENSG00000130600, Ensembl 
release 60) and BRCA1 (ENSG00000012048, Ensembl release 60) on the 
Ensembl genome browser (Appendix 7.2.1.1.b).  
A couple was defined as fully-informative for an SNP if each partner was 
homozygous or heterozygous for different alleles. Similarly, they were 
considered to be semi-informative for an SNP when one partner was 
homozygous and one heterozygous sharing one allele. The embryos from these 
couples where the origin of parental transcripts could be distinguished were 
selected for this study. 
2.3.2. Sample processing and analysis 
2.3.2.1. DNA extraction from whole blood samples 
DNA extraction from whole blood was carried out using Qiagen QIAamp maxi 
kit edition 3 (Qiagen, UK) according to the manufacturer’s protocol. Briefly, 
500μl protease was mixed with 5ml of blood. Six ml of buffer AL was added to 
the mixture and the sample was incubated at 70°C for 10 minutes in a 
waterbath. Five ml of 100% ethanol was added to the sample and mixed. The 
sample was transferred onto the QIAamp Maxi column and centrifuged at 
3000rpm for 3 minutes in a microfuge. Five ml of Buffer AW1 was added to the 
column and the sample was centrifuged at 4000rpm for 1 minute in a microfuge. 
Five ml of buffer AW2 was added to the column and it was centrifuged at 
4000rpm for 15 minutes in a microfuge. The column was incubated for 10 
minutes at 70°C in an incubator to evaporate residual ethanol. DNA was 
collected by applying 600μl buffer AE directly onto the membrane of the column. 
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The sample was incubated at RT for 5 minutes and DNA was eluted by 
centrifugation at 5000rpm for 2 minutes in a microfuge. This step was repeated 
one more time to achieve higher DNA concentration. 
2.3.2.2. Lymphocyte separation using the ficoll-paque plus 
method 
Five ml of blood was diluted 1:1 with 0.9% sodium chloride (NaCl). Six ml of 
ficoll-paque was added to a 15ml centrifuge tube and 8ml of diluted blood was 
layered. The samples were centrifuged at 1300rpm for 30 minutes at RT in a 
bench top centrifuge (the brake of the centrifuge was removed). The 
lymphocyte layer was removed and placed in a new tube. The layer was 
washed with 0.9% NaCl by centrifugation at 1300rpm for 15 minutes in a 
centrifuge. Supernatant was discarded and the pellet was washed two more 
times. The pellet was resuspended in a fresh 2ml 0.9% NaCl. The cell 
suspension was stored at 4°C until single cell isolation for no longer than two 
days. 
Cell clumps consisting of 50, 100 and 150 cells were isolated similar to embryo 
tubing as described in section 2.1.1 excluding the exposure of the cells to 
acidified Tyrode’s solution step. These clumps of cells were used to optimise 
RNA extraction prior to processing the embryos. 
2.3.2.3. Primer design 
For sequencing analysis primers were designed using the Primer3 tool in a 
product size range of 120- 600bp (http://primer3.sourceforge.net/) within the 
exonic region of ACTB, GAPDH, SNRPN, IGF2, H19, UBE3A and BRCA1. The 
best primer pairs had lengths of 18-30bp, a maximum guanine-cytosine (GC) 
base of 50%, similar melting temperature (Tm) values between the forward and 
the reverse primers and did not have any SNPs within the primer sequence. 
The selected primers were then analysed on Basic Local Alignment Search 
Tool (BLAST) program in order to confirm that the primer did not bind non-
specifically anywhere else in the genome.  
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All the primers were ordered in lyophilised form (Eurogentec, UK) and 
resuspended in Tris-EDTA buffer (Promega, USA). Each primer was aliquoted 
in 20µl volumes at 50µM upon arrival to prevent multiple freeze-thawing. These 
aliquots were kept at -20ºC whereas the original stocks were stored at -80ºC.  
Primers amplifying short tandem repeat sequences were found using 
www.genloc.com. These primers were labelled with a fluorochrome at the 5’- 
end for fluorescent PCR analysis and were designed for aneuploidy screening 
(Appendix 7.2.1.1.d).  
2.3.2.4. Polymerase chain reaction (PCR) 
PCR was performed prior to sequencing analysis. DNA obtained from five 
couples were amplified by PCR for one exonic region within GAPDH, three 
within ACTB, five within UBE3A, six within SNRPN, two within IGF2, two within 
H19 and eleven within BRCA1, respectively (Appendix 7.2.1.1.a and b). PCR 
was carried out using 1x Qiagen Taq PCR master mix consisting of final 
concentrations of 2.5 units Taq DNA Polymerase, 1.5mM MgCl2 and 200µM 
dNTPs (Qiagen, UK). PCR amplification was performed in a final volume of 
24µL containing 12.5µL QiaTaq buffer and final concentrations of 0.2-0.3μM 
forward and reverse primers (Eurogentec, UK) (Appendix 7.2.1.1.a and b) in 
nuclease-free water. One µL of genomic DNA extracted from blood from 
couples who donated embryos to this project was added to each reaction 
mixture making the final volume of 25µL. For each PCR one negative control 
sample was used in the absence of DNA. Thermal cycling conditions involved 
denaturation, annealing and extension steps (Table 2.2).  
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Table 2-2 PCR cycling conditions. 
Number of cycles Temperature (ºC) Time of incubation 
1 94 3 minutes 
10-30 
96 15 seconds 
54-60 45 seconds- 1 minute 
72 1 minute 
30-50 
94 15 seconds 
54-60 45 seconds 
72 1 minute 
1 72 10 minutes 
1 4 Hold 
 
 
PCR conditions were carried out as suggested by the manufacturer (Qiagen, UK) with slight 
modifications. Briefly, one cycle of initial denaturation step at 94ºC was carried, followed by a 
total of 40-80 cycles of denaturation at 96ºC, annealing at 54-60ºC and extension at 72ºC. A 
final annealing was performed at 72ºC.  
 
Successful amplification was examined by observing the intensity of the band 
with appropriate product size on ethidium bromide stained (2%/1xTBE, tris-
borate-EDTA) agarose gel electrophoresis as described in section 2.3.2.5. 
Failed amplifications and no DNA control samples were detected by the lack of 
a band. 
2.3.2.5. Agarose gel electrophoresis 
Non-fluorescent PCR products were analysed by agarose gel electrophoresis. 
DNA molecules were separated by size using 1-2% agarose gel (agarose 
powder type 1, Sigma, USA) in 50µL of 1xTris/Borate/EDTA (TBE) buffer. Ten 
times concentrated TBE buffer was prepared from 108g 
Tris(hydroxyl)methylamine, 55g orthoboric acid and 40ml of 0.5M EDTA 
(Sigma, USA) in 900ml deionised water at pH 8. Agarose and TBE mixture was 
heated in a microwave at medium-high for 2 minutes. One and a half µL of 
10mg/ml ethidium bromide was added to the melted agarose (Sigma, USA) to 
make DNA bands visible on the agarose gels. The warm melted agarose was 
poured into a gel mould and allowed to set. To have a molecular weight 
comparison, 1.5µL of GeneRuler™ 100bp-1kb plus DNA ladder (Fermentas, 
UK) was used. Five μL of product was mixed with 6xloading dye (10mM Tris-
HCl at pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol 
and 60mM EDTA) and the mixture was pipetted into the wells of the gel. The 
samples were run on the gel in 1xTBE buffer at 150V for 15-20 minutes. The 
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analysis of DNA bands on agarose gel was carried out with an ultraviolet lamp 
transilluminator at 360nm (Alpha Innotech Corporation, MultiImage Light 
Cabinet, Flowgen Staffordshire). The gel was photographed with a camera and 
the image was analysed on the computer. 
2.3.2.6. Sequencing     
Successfully amplified samples were sequenced following an initial purification 
of the samples.  
Purification of amplified samples 
The amplified products were purified using Microcon Centrifugal Filter Device 
version PR02725 Rev.B, 07/09 (Millipore, UK) following manufacturer’s 
protocol. Briefly, the amplified products were transferred into a Microcon 
Centrifugal Filter Device. The sample was centrifuged at 14000rcf for 5 minutes 
in a microfuge. Four hundred µl DNase- and RNase-free water was added to 
the sample and they were centrifuged at 14000rcf for 5 minutes in a microfuge. 
The purified product was then collected by centrifugation at 1000rcf for 2 
minutes in a microfuge.  
Cycle sequencing reaction 
Cycle sequencing was carried out using the BigDye® Terminator v1.1 Cycle 
Sequencing kit (ABI, UK). The amount of amplified product used for sequencing 
was estimated from the intensity of the PCR product on agarose gel. If a good 
amplification (a band with a strong signal on agarose) was observed, 2µl of 
product was used. If the amplification was moderate (poorer signal on agarose), 
4µl of the product and if the amplification was poor (faint signal on agarose), 8µl 
of the product was used for cycle sequencing. Two to eight µl of amplified 
sample was mixed with 1µl cycle sequencing primer (2.5µM final concentration), 
2µl Big Dye Terminator v1.1 cycle sequencing mix, 3µl BigDye terminator v1.1 
5xsequencing buffer and 6-12µl DNase- and RNase-free water. The reaction 
mixture was mixed and incubated at 96ºC for 10 seconds, 50ºC for 5 seconds 
and 60ºC for 4 minutes in a thermal cycler. This cycle was repeated 25 times.  
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Purifying the extension product 
The amplified products were purified using DyeEx 2.0 clean up kit (Qiagen, UK) 
following manufacturer’s protocol. Briefly, resin columns were vortexed and 
centrifuged for 3 minutes at 760g in a microfuge. The sample was applied on 
the resin and the purified product was collected by 3 minute centrifugation in a 
microfuge. The purified products were pipetted into 96-well PCR prism plates 
for sequencing analysis.  
Analysis of sequencing products 
The sequencing analysis was carried out by the automated laser DNA analyser 
(ABI Prism™ 3100, UK) using POP-4™ polymer with the dye/primer set of 
DT3100POP4(BDv3)v1.mob. The data was analysed by GeneScan analysis 
software (Applied Biosystems, UK). The informativity of the SNPs was 
investigated by comparing these sequences to the sequence from Ensembl 
genome browser (Appendix 7.2.1.1.b). If any semi/fully- informative SNPs were 
identified, RNA from the couple’s embryos were extracted as described in 
section 2.3.2.7 and cDNA was obtained for differential expression analysis 
(2.3.2.9). 
2.3.2.7.  DNA and RNA extraction from embryos 
Initial practices for RNA extraction were carried out on isolated clumps of 
lymphocytes (~150, 100 and 50 cells) using the AllPrep DNA/RNA Micro kit 
version 07/2007 (Qiagen, UK) and Absolutely RNA® Nanoprep kit (Agilent, 
USA) according to the manufacturer’s instructions. DNA and RNA extraction 
from embryos for differential expression study was carried out using the AllPrep 
DNA/RNA Micro kit version 07/2007 (Qiagen, UK) with brief modifications to the 
manufacturer’s instructions. Briefly, cells were disrupted by addition of 75µl 
Buffer RLT containing 0.1% beta-mercaptoethanol (β-Me). Due to the small 
number of cells, 200ng carrier RNA (Sigma, USA) was added to the Buffer RLT 
(5µl of 4ng/µl). DNA was retrieved on the AllPrep DNA spin column after 
centrifugation for 30 seconds at 13000rpm in a microfuge. Five hundred µl of 
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70% ethanol was added to the flow-through and transferred to the RNeasy 
MinElute spin column. The sample was centrifuged for 15 seconds at 13000rpm 
in a microfuge. The column was washed with 500µl of Buffer RPE followed by 
500µl 80% ethanol, respectively. RNA was collected in 14µl elution buffer by 
centrifuging for 1 minute at 13000rpm in a microfuge.  
DNA was extracted by washing the AllPrep DNA spin column with 500µl AW1 
and AW2, respectively. DNA was eluted by adding 30µl preheated buffer EB 
(70ºC) to the spin column and centrifuging for 1 minute.  
2.3.2.8. Assessment of nucleic acids by Nanodrop and 
Bioanalyzer 
The concentration of DNA was investigated using the Nanodrop technology 
(Nanodrop, UK) according to manufacturer’s protocol. The concentrations of 
nucleic acids were measured in sample volumes of 1μL at 260nm. The machine 
was calibrated with DNase- and RNase-free water. Measurements of DNA 
concentration were presented in ng/μL.  
The Agilent 2100 Bioanalyzer (Agilent, CA, USA) was used to assess the 
quality of RNA and any DNA contamination. Eukaryote Total RNA Pico Series II 
chip (Agilent, UK) was used following manufacturer’s protocol for quantification. 
This analysis revealed the concentration of RNA, rRNA ratio (28S/18S; ratios 
greater than 2 indicated lower RNA degradation) and the RNA Integrity Number 
(RIN) measured RNA quality by assignment of a number from 1 to 10 by the 
Agilent Bioanalyzer software where 10 indicated the most intact sample 
(Schroeder et al., 2006). 
GraphPad prism v6 software was used for the statistical analyses. RIN values 
and RNA and DNA concentrations examined by the Bioanalyzer and NanoDrop 
were analysed by one way ANOVA with Dunnett’s post test to examine if there 
is a trend for RIN values and RNA and DNA concentrations among embryos at 
cleavage, morula and blastocyst stages due to the embryo quality and the 
number of cells present, respectively. Further analysis was performed by 
unpaired two-tailed student’s T-test analysing these values. 
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2.3.2.9. Reverse transcription of RNA obtained from 
embryos 
RNA obtained from embryos were reverse transcribed using the SuperScript™ 
III first-strand synthesis system for RT-PCR (Invitrogen, UK) following 
manufacturer’s protocol. Briefly, a master mix of 1µl of 50ng/µl random 
hexamers and 1µl of 10mM dNTP mix was added to 6µl of extracted RNA and 
incubated at 65ºC for 5 minutes in a thermal cycler. Two µl of 10xRT buffer, 4µl 
of 25mM MgCl2, 2µl of 0.1M DTT, 1µl of 40U/µl RNaseOut™ and 1µl of 200U/µl 
SuperScript™ RT were added to the mixture and the cDNA synthesis was 
carried out by incubation at 25ºC for 10 minutes and 50ºC for 50 minutes in a 
thermal cycler. This reaction was terminated at 85ºC for 5 minutes. Any mRNA 
template remaining in the reaction was digested by RNase H at 37ºC for 20 
minutes. 
cDNA obtained from the embryos was then amplified by PCR (2.3.2.4) and 
mini-sequencing (2.3.2.10) was carried out to establish a semi-quantitative 
analysis of differential parental gene expression. A detailed description on how 
the differential expression was evaluated in cDNA samples from embryos is 
summarised in section 2.3.2.10. 
2.3.2.10. Mini-sequencing (SNaPshot™) 
After an initial round of PCR with outer primers, 15µl of PCR product (40 cycles) 
was treated with 1U SAP (New England BioLabs, UK) and 1U Exo I (New 
England Biolabs, UK). The reaction mixture was incubated at 37ºC for 1 hour, 
followed by an enzyme deactivation step at 75ºC for 15 minutes. 
SNaPshot™ (Applied Biosystems, UK) analysis involved detection of 
fluorescence of a single complementary base adjacent to the 3’end of the 
primer annealing site. Primers were designed to interrogate the base of interest 
(Appendix 7.2.1.1.c). The reaction was carried out following the manufacturer’s 
instructions with slight changes. Briefly, 2µl SNaPshot™ multiplex ready 
reaction mix, containing AmpliTaq® DNA polymerase, fluorescently labelled 
ddNTPs and reaction buffer, 3µl of SAP/Exo I treated PCR product were mixed 
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with 1µl mini-sequencing primer (final concentration of 0.1µM) and deionised 
water to make the final reaction volume of 10µl. For each mini-sequencing 
analysis, genomic DNA from the couple was examined to show the robustness 
of this technique. The reaction mixture was denatured at 96ºC for 10 seconds, 
followed by annealing at 50ºC for 5 seconds and elongation at 60ºC for 30 
seconds for 25 cycles in a thermal cycler. Each ddNTP was labelled with 
different fluorescent dyes yielding different product sizes by the SNaPshot™ 
reaction. ddGTP was labelled with dR110 (blue), ddATP with dR6G (green), 
ddCTP with dTAMRA™ (black) and ddTTP with dROX™ (red), respectively. 
SNaPshot™ products were analysed by ABI Prism™ 310/3100, UK. A mixture 
of 0.5μl SNaPshot product, 9μl formamide and 0.3μl Liz 120 size standard (PE 
Applied Biosystems, UK) were aliquoted into lidless tubes (PE Applied 
Biosystems, UK). All tubes were secured with septa lids (PE Applied 
Biosystems, UK) and they were denatured for 5 minutes at 95ºC in a thermal 
cycler. The denatured SNaPshot products were subjected to capillary 
electrophoresis with the matrix of POP-4™ G5 module 5, 5 seconds of injection 
at 15 KV and run temperature at 60ºC for 15 minutes (Applied Biosystems, UK). 
SNaPshot products were analysed by GeneScan analysis software (Applied 
Biosystems, UK).  
Differential expression of parental genes was analysed at previously selected 
SNP sites. For each SNP analysed paternal to maternal allele peak height 
ratios was calculated. Differential expression was defined as an allele peak 
height ratio greater than 1:2. Therefore if the paternal to maternal peak height 
ratio was equal or more than 2, this was defined as differential expression 
favouring the paternal transcript. Similarly if the maternal to paternal peak 
height ratio was 2 or more, this was defined as differential expression favouring 
the maternal transcript. If the ratio was between 1 and 2, this was defined as 
similar parental expression level. Mono-allelic or preferential allelic gene 
expression was only considered in embryos where both parental alleles could 
be identified at the SNP in the cDNA from the embryo and the only expressed 
allele present in the cDNA could be attributed to a single parent. In the cases 
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where a shared allele was the only allele, the sample was excluded from the 
differential gene expression analysis for that locus (inconclusive result). 
Statistical analysis was performed using GraphPad prism v6 software. 
Significance of differential paternal and maternal expression of the four genes 
was examined in the embryos using the peak heights of the SNaPshot 
products.  
2.3.2.11. SNaPshot assay sensitivity for semi-quantitative 
analysis 
2.3.2.11.1. Real time PCR validation 
cDNA samples obtained from the embryos were amplified by real time PCR to 
confirm that the parental transcripts can still be quantified accurately and that 
the product has not reached to plateau prior to mini-sequencing analysis. The 
same SNP regions analysed in the embryo by SNaPshot assay were 
quantitatively amplified using high resolution melting (HRM) kit (HRM, Roche, 
UK) using LightCycler® 480 High Resolution Melting kit (Roche, UK) following 
manufacturer’s protocol. Briefly, 10µl of the Melting Master mix, 0.1µl of the 
forward and reverse primer (0.25µM), 2µl (2.5mM) MgCl2 in nuclease free water 
were added to 1µl of cDNA sample in a final reaction volume of 20µl. The 
cycling conditions for HRM are shown in table 2.3.  
The Cq values (the cycle number calculated at the start of the exponential 
phase of linear amplification) were analysed. 
 
Table 2-3 High resolution melting cycling conditions. 
Number of 
cycles 
Temperature (°C) Ramp (ºC/s) 
Time of incubation 
(seconds) 
Acquire 
1 95 4 600  
45 
95 5 10  
58 4 25 
 
 
72
 
4 15
  
Yes 
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2.3.2.11.2. Chromosome copy number determination by 
PCR 
Copy number of chromosomes 7, 11, 15 and 17 was examined by haplotyping 
using fluorescently labelled polymorphic short tandem repeat (STR) markers to 
confirm that the quantification detected by SNaPshot assay was not due to a 
loss or gain of a chromosome. PCR was carried out as described in section 
2.3.2.4 using DNA obtained from embryos and polymorphic markers shown in 
appendix 7.2.2.1.d. Polymorphic markers used for the analysis of chromosome 
7 were linked to CF gene, chromosome 11 markers were linked to HBB, 
chromosome 15 to FBN1 and chromosome 17 to BRCA1, respectively. 
Fluorescent PCR products were separated and the fragment analysis was 
performed with an automated laser DNA analyser (ABI Prism™ 310/3100, 
Applied Biosystems, UK). A mixture of 1μL fluorescent PCR product, 12μL 
formamide (Applied Biosystems, UK) and 0.3μL ROX size standard (Applied 
Biosystems, UK) were aliquoted into lidless tubes (Applied Biosystems, UK) and 
the mixture was denatured at 95ºC for 5 minutes. The denatured PCR products 
were subjected to capillary electrophoresis with the matrix of Performance 
Optimised Polymer 4 (POP-4™ G5 module 5, 5 seconds of injection at 15 KV 
and run temperature at 60ºC for 24 minutes) (Applied Biosystems, UK).  
The copy number of the chromosomes was only scored if the embryo was 
heterozygote and the origin of the parental alleles at that locus can be 
distinguished. Loss of a chromosome was verified if only one unshared allele 
was detected. Similarly, gain of a chromosome was detected when three alleles 
were detected at the locus analysed. Gain of a chromosome due to an 
isodisomy of the same chromosome could not be detected by this analysis. If 
only the shared allele was detected, this result was concluded as inconclusive. 
Allele drop out (ADO) was defined as amplification failure of one of the alleles in 
a heterozygote cell for that particular region. 
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2.3.2.11.3. Aneuploidy screening by aCGH 
In order to investigate the aneuploidy status of all the chromosomes in the 
embryos including isodisomies of the same chromosome, aCGH was 
performed. Whole genome amplification, labelling, hybridisation and microarray 
kits were performed according to manufacturer’s protocol (BlueGnome, UK) 
(Figure 2.3). 
Figure 2-3 Schematic diagram of embryo analysis for chromosomal imbalances using 
aCGH. 
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Embryos was analysed for aneuploidy screening by aCGH. The initial step was whole genome 
amplification by extraction of DNA from cells and formation of library by random fragmentation. 
The successful WGA was checked by agarose gel electrophoresis. The amplified sample and 
the reference DNA were labelled with different dyes, respectively and hybridised on arrays. This 
was then analysed by BlueFuse Multi program. 
 
Whole genome amplification  
DNA obtained from embryos was whole genome amplified using SurePlex DNA 
amplification system v3 (BlueGnome, UK). Whole genome amplification was 
carried out as described by the manufacturer. The first step was extraction of 
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DNA from the cells. Three µl extraction buffer was added to each sample. A 
mixture of 4.8µl extraction enzyme dilution buffer and 0.2µl cell extraction 
enzyme was added to the sample. DNA was extracted by incubating the 
reaction mixture at 75ºC for 10 minutes and 95ºC for 4 minutes in a thermal 
cycler.  
A DNA library was created based on random fragmentation using universal 
primers. A mixture of 4.8µl SurePlex pre-amp buffer and 0.2µl SurePlex pre-
amp enzyme was added to the extracted sample. The thermal cycling condition 
for the pre-amplification is shown in table 2.4. 
Table 2-4 Thermal cycling conditions for pre-amplification step of WGA. 
Number of cycles Temperature (ºC) Time of incubation 
1 95 2 minutes 
12 
95 15 seconds 
15 50 seconds 
25 40 seconds 
35 30 seconds 
65 40 seconds 
75 40 seconds 
1 4 Hold 
 
 
The final step of amplification was carried out by adding 25µl SurePlex 
amplification buffer, 0.8µl SurePlex amplification enzyme and 34.2µl nuclease-
free water to the samples. The amplification cycling condition is shown in table 
2.5. 
The successful amplification was analysed by observing the intensity of smear 
and the size range produced on 1%/1xTBE agarose gel as described in 2.3.2.5. 
Failed amplifications were identified when the smear was absent. 
Table 2-5 Thermal cycling conditions for amplification step of whole genome 
amplification. 
Number of cycles Temperature (ºC) Time of incubation 
1 95 2 minutes 
14 
95 15 seconds 
65 1 minute 
75 1 minute 
1 4 Hold 
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Successfully amplified embryonic and reference male genomic DNA 
(BlueGnome, UK) samples were labelled using BlueGnome (UK) fluorescent 
labelling system, pack 1 v1.1 according to manufacturer’s protocol (Figure 2.2). 
Labelled test and reference samples were hybridised on 24Sure and 24Sure+ 
bacterial artificial clone (BAC) microarrays, consisting of 3226 BAC clones 
spaced 1Mb apart for 24Sure and higher resolution of 0.5Mb BACs across 
genome and 0.25Mb in peri/sub-telomeric regions of human genome for 
24Sure+, respectively.  
Labelling of the test and reference samples 
All labelling steps were carried out on ice and in a darkened room with samples 
covered during incubation steps. Briefly, 5μL reaction buffer, 5μL primer 
solution and 5μL dCTP-labelling mixes were added to both test and reference 
sample tubes, respectively. One μL Cy3 and one μL Cy5 fluorophore were 
added to test and reference tubes, respectively. Eight μL of amplified libraries of 
DNA from embryos and reference DNA were added to the sample tubes, 
respectively. The test and reference tubes were denatured in a pre-warmed 
thermal cycler for 5 minutes at 94ºC. One μL of Klenow enzyme was added to 
each tube and the samples were labelled by incubation at 37ºC in a pre-
warmed thermal cycler for 16 hours.  
Combination and ethanol precipitation 
The labelled test (Cy3 fluorophore labelled) and reference samples (Cy5 
fluorophore labelled) were mixed. Twenty five μL of 0.1mg/ml COT-1 Human 
DNA (BlueGnome, UK) was used to suppress the hybridisation of highly 
repetitive sequences and 7.5μL of 3M sodium acetate (Sigma, USA) were 
added to each tube for co-precipitation. Absolute ethanol (VWR, UK) was added 
to each tube and the samples were mixed. The reaction mixture was 
precipitated at -80ºC for 10 minutes. Labelled samples were pelletted by 
centrifugation at 13000rpm in a microfuge for 10 minutes. After the supernatant 
was discarded, the mixture was washed with 500μL of 70% ethanol and air-
dried for 2 minutes.  
Materials and Methods 
 
107 
 
Hybridisation 
The pellets were re-suspended in 21μL of pre-warmed 15% dextran sulphate 
(DS) buffer at 75ºC to ensure that the pellet was completely dissolved. The 
samples were denatured at 75ºC for 10 minutes in a heating block (VWR, USA). 
During this time interval, hybridisation chamber was prepared. A slide box with 
correct dimensions, that enable slides to be laid horizontally across the width of 
the box, was used. A tissue was saturated with 2xsaline sodium citrate 
(SSC)/50% formamide (20xSSC: 175.3g of 3M NaCl and 88.2g of 0.3M tris-
sodium citrate at pH 7.2). The cover-slips were placed on an array template 
provided by BlueGnome (UK). Eighteen μL of labelled sample was placed in the 
centre of each cover-slip and they were transferred to the slide by lowering the 
slide with the barcode-down. The slides were placed in the hybridisation 
chamber box where the wet tissue was not in contact with the slides. The box 
was wrapped with Parafilm (Bemis, USA) and incubated in hybridisation 
chamber for 3 hours at 47ºC water bath.  
Washes 
The cover slips were removed manually by agitating in a coplin jar with 
2xSSC/0.05% Tween20 (100ml 20xSSC, 899.5ml dH2O, 0.5ml Tween20) and 
the slides were washed to remove any un-hybridised DNA as shown in table 
2.6. The slides were dried by centrifugation at 11000rpm for 3 minutes in a 
centrifuge and they were stored in the original blue box until scanning for 
analysis. 
Table 2-6 Washing conditions following aCGH hybridisation. 
Wash Volume Temperature 
Time of 
incubation 
Agitation Buffer 
1 500ml RT 10 minutes Stirrer 1xPBS/0.05% Tween 20 
2 500ml RT 10 minutes Stirrer 1xPBS/0.05% Tween 20 
3 500ml RT 10 minutes Stirrer 1xPBS/0.05% Tween 20 
4 100ml 42°C 30 minutes Rocker 2xSSC/50% formamide 
5 500ml RT 10 minutes Stirrer 1xPBS/0.05% Tween 20 
6 500ml RT 5 minutes Stirrer 1xPBS 
7 500ml RT 5 minutes Stirrer 1xPBS 
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Scanning and analysis of aCGH slides 
aCGH slides were scanned with slide scanner (ScanArray Express, Perkin 
Elmer, USA) and analysed using BlueFuse Multi analysis software v.2.6 
(BlueGnome, UK). The data was evaluated in two stages. The first stage was 
carried out during array scanning procedure by checking the intensity and 
evenness of the fluorescence derived from WGA product and photomultiplier 
(PMT) values of the individual clones on the array. The second part of the 
evaluation was carried out after the BlueFuse Multi analysis of the array. This 
evaluation included checking the number of clones included in the analysis 
(>60%) and the relation of the autosomes observed within the threshold of 
±3xSD (standard deviation). The cut-off for a gain of a segment/whole 
chromosome was considered when the log2 ratio was more than +0.3 following 
the BlueFuse Multi analysis v.2.6 (BlueGnome, UK). When the log2 ratio was 
less than -0.3, this was considered to be loss of that particular segment/whole 
chromosome. 
2.3.2.11.4. Methylation studies 
Bisulfite conversion followed by methylation specific PCR was used to 
investigate the methylation status of ACTB, H19 and BRCA1 in embryos. 
EpiTect Bisulfite conversion kit v09/2009 (Qiagen, UK) was used for DNA 
treatment according to the manufacturer’s protocol. Briefly, 85µl bisulfite mix 
was added to a total volume of 40µl of DNA and water mixture (maximum value 
of DNA being 40µl). Fifteen µl DNA protect buffer was added to the DNA-
bisulfite mixture to prevent fragmentation caused by bisulfite treatment at high 
temperatures and low pH. The bisulfite conversion was carried out by 
denaturation and incubation steps in a thermal cycler (Table 2.7). 
Table 2-7 Thermal cycling conditions for bisulfite conversion. 
Number of cycles Temperature (ºC) Time of incubation 
1 95 5 minutes 
1 60 25 minutes 
1 95 5 minutes 
1 60 85 minutes 
1 95 5 minutes 
1 60 175 minutes 
1 20 Hold 
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Five hundred and sixty µl of buffer BL with 10µg/ml carrier RNA was added to 
each sample. This mixture was transferred into the EpiTect spin columns and 
they were centrifuged at 14000rpm for 1 minute in a top bench centrifuge. The 
flow-through was discarded and the columns were washed with 500µl buffer 
BW by centrifuging at 14000rpm for 1 minute. The columns were incubated at 
RT for 15 minutes with desulfonation buffer and the columns were centrifuged 
for 1 minute at 14000rpm. The columns were then washed twice with 500µl 
buffer BW. The columns were incubated for 5 minutes at 56ºC in a water bath to 
remove any residual liquid. Converted DNA was eluted in 40µl of EB buffer.  
Primer design for methylation-specific PCR 
Promoter regions of three genes, ACTB, H19 and BRCA1, were amplified by 
nested PCR using outer primer sequences directed to the bisulfite converted 
sequence and excluding CpG dinucleotides. Two sets of inner primers directed 
to CpG dinucleotides were designed. One primer was designed to amplify 
converted and fully methylated sequences producing a product only if the 
sequences were fully methylated. If the sequence was not methylated, no 
product was obtained. The second primer was directed to the converted and 
fully unmethylated sequences. Therefore a product was only obtained when the 
sequence was unmethylated and if the sequence was methylated, no product 
was obtained. 
Outer primer pairs with no CpG dinucleotides were designed for amplification of 
bisulfite converted DNA of ACTB, H19 and BRCA1. As a result of bisulfite 
conversion, unmethylated CpG were altered to TpG. Methylated CpG were 
protected from bisulfite conversion and therefore the sequence remained 
unchanged. Two sets of inner primer pairs were designed to amplify the 
converted DNA; one that would bind to the sequence of a fully methylated DNA 
template and another one that was complementary to a fully unmethylated and 
therefore to the bisulfite converted template. The primer sets for ACTB were 
designed using the sequence E01094, AF125183 for H19 and U37574 for 
BRCA1 (Esteller et al., 2000), respectively. Primer sequences and the expected 
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product sizes for these genes are shown in (Appendix 7.2.1.1.e). PCR products 
were analysed by observing a band and size range produced on 1%/1xTBE 
agarose gel as described in 2.3.2.5. The absence of a band indicates a failed 
amplification determining the methylated and unmethylated status. 
2.3.2.12. Analysis of developmental progression in embryos 
carrying BRCA mutations 
Developmental progression of all the embryos with BRCA mutations was 
examined on day 5/6 post fertilisation. Statistical analysis was performed to 
investigate if there is significant difference in the developmental progression of 
embryos with paternally inherited BRCA mutations compared to the maternally 
inherited BRCA mutations by Chi-square test using GraphPad prism software 
v6. The number of embryos with maternally inherited BRCA mutations arrested 
at the cleavage stage was compared to the number of embryos with paternally 
inherited mutations. Similarly, the significant difference was analysed between 
the number of embryos arrested at morula stage and embryos that reached to 
the blastocyst stages depending on the parental inheritance. 
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2.4. Functional assay development for mismatch repair 
2.4.1. Sample collection 
A total of 15 immature oocytes and 12 blastocysts were obtained from mouse 
MF1 strain. Five and ten MF1 oocytes were pooled together, respectively. Four 
and eight MF1 blastocysts were pooled together, respectively. Good quality 11 
surplus human blastocysts were obtained and pooled together from in vitro 
fertilisation (IVF) patients for this project. Embryos were tubed as described in 
section 2.2.1 with slight changes. The oocytes and blastocysts freed from zona 
pellucida were washed with 0.1% PBS/PVA and they were pooled together.  
2.4.2. Sample processing and analysis 
2.4.2.1. Formation of homo/heteroduplex constructs 
Homo/heteroduplex molecules were constructed using commercially available 
oligonucleotides. The oligonucleotides (two complementary strands) with 
different alleles around rs1981929 SNP site were designed on the MSH2 gene 
on chromosome 2 (2p22-p21) by Dr Jaroudi using Ensembl genome browser 
(http://www.ensembl.org/index.html). Two forward sequences with the same 
sequence and one complementary (reverse) strand; A, G and T; were used to 
form homo/heteroduplex constructs, respectively (Table 2.8). The location of the 
oligonucleotides within the MSH2 gene is shown in Appendix 7.2.1.2. The 
original stocks for oligonucleotides at 50/100µM were kept at -20ºC and 5µM 
working aliquots were prepared to avoid multiple freeze-thawing. 
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Table 2-8 Oligonucleotide sequences used to make homo/heteroduplexes. 
Strand Oligonucleotide sequence
Fragment 
size
Forward
Strand A
5’-TAAAATAAATTGAGTACGAAACAATTTGAATTAAAACACCTGA
GTAAATAGTAACTTTGGAGACCTACTGTACTATTTGTACCTTTTG
GATCAAATGATGCTTGTTTATCTCAGTCAAAATTTTATGATTTGTA
TTCTGTAAAATGAGATCTTTTTATTTGTTTGTTTTACTACTTTCTT-3’
180 bases
Forward
Strand G
5’-TAAAATAAATTGAGTACGAAACAATTTGAATTAAAACACCTGA
GTAAATAGTAACTTTGGAGACCTGCTGTACTATTTGTACCTTTTG
GATCAAATGATGCTTGTTTATCTCAGTCAAAATTTTATGATTTGTA
TTCTGTAAAATGAGATCTTTTTATTTGTTTGTTTTACTACTTTCTT-3’
180 bases
Reverse
Strand T
5’- AAGAAAGTAGTAAAACAAACAAATAAAAAGATCTCATTTTACAG
AATACAAATCATAAAATTTTGACTGAGATAAACAAGCATCATTTGA
TCCAAAAGGTACAAATAGTACAGTAGGTCTCCAAAGTTACTATTTA
CTCAGGTGTTTTAATTCAAATTGTTTCGTACTCAATTTATTTTA-3’
180 bases
Reverse
Strand Ta
5’-AAGAAAGTAGTAAAACAAACAAATAAAAAGATCTCATTTTACAG
AATACAAATCA-3’
55 bases
Reverse
Strand Tb
5’-TAAAATTTTGACTGAGATAAACAAGCATCATTTGATCCAAAAGG
TACAAATAGTACAGTAGGTCTCCAAAGTTACTATTTACTCAGGTGT
TTTAATTCAAATTGTTTCGTACTCAATTTATTTTA-3’
125 bases
A
G
T
Ta
Tb
Primer Primer sequence Locus Product size
ForA/G (F) 5’-TAAATAGTAACTTTGGAGACCT-3’ 2p22-p21 23 bases
RevT/C (R) 5’-GGTACAAATAGTACAG-3’ 2p22-p21 17 bases
a)
b)
 
a) The oligonucleotide sequences around the SNP site rs1981929 showing A and G sequences 
and the complementary sequence of T and the nicked T; Ta and Tb. The alleles at the SNP site 
rs1981929 are highlighted in yellow. b) Primer sequences for mini-sequencing analysis. For A/G 
primer was complementary to T and Tb sequences, and Rev T/C primer was complementary to 
A and G sequences, respectively. 
 
The mismatched substrates were constructed using the G and T sequences (G-
T, Eurogentec, UK) at equal molarity by denaturing at 95ºC for 5 minutes and 
incubating at 37ºC for 16 hours (Table 2.8). Similarly, a homoduplex (A and T 
sequences) was constructed by incubation of two complementary strands. 
Nicked homo/heteroduplex constructs were formed (A/G sequence with Ta and 
Tb sequences, A-Tn and G-Tn, Table 2.8.a) to test whether the repair was nick-
directed (Figure 2.4). 
The successful formation of the constructs was confirmed by SNaPshot™ 
analysis as described in 2.3.2.10 with slight changes. Two primers were 
designed to detect the allele at the SNP site rs1981929 with different product 
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sizes (Table 2.8b). The “For A/G” primer binds to the T sequence and “Rev T/C” 
primer binds to the A and G sequences showing the complementary allele at 
the SNP site rs1981929, respectively. Two different SNaPshot reaction 
conditions were applied for each sample. The first condition involved 25 cycles 
of denaturation at 96ºC for 10 seconds, annealing at 30ºC for 5 seconds and 
elongation at 37ºC for 30 seconds. The second condition involved the same 
steps excluding the denaturation step (only annealing at 30ºC for 5 seconds 
and elongation at 37ºC for 30 seconds for 25 cycles) to test whether there was 
excess sequences present in the reaction mixture. In the denatured samples, 
the same fluorescence of each amplified allele as the single sequences should 
be detected; whereas in the non-denatured constructs, unless excess single 
sequences were present in the reaction mixture, no fluorescence should be 
detected (Figure 2.4).  
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Figure 2-4 Schematic diagram of experimental procedures for assessment of mismatch 
repair functional assay. 
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The homoduplex constructs were formed with the two complementary A and T sequences. 
Mismatched heteroduplex constructs were formed with two complementary sequences; G and T 
except at the SNP site rs1981929. Nicked heteroduplex constructs were formed using the G 
sequence and Ta and Tb sequences that are complementary to the G sequence. Successful 
formation of homo/heteroduplex constructs was confirmed by SNaPshot™ assay using two 
different cycling conditions by detecting the allele at the SNP site rs1981929. Each allele 
fluorescences with a different colour; A in green, T in red, C in black and G in blue. Denatured 
SNaPshot reaction showed all the alleles at the SNP site within that reaction, whereas in the 
non-denatured samples the alleles that are present in the mixture belonged to the excess 
sequences following the formation of homo/heteroduplex constructs. Mismatch repair reaction 
was carried out in the presence and absence of mismatch repair proteins. The mismatch repair 
efficiency was evaluated by SNaPshot™ assay by detecting the allele at the SNP site 
rs1981929. 
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2.4.2.2. Mismatch repair using commercially available 
nuclear cell extracts 
DNA repair efficiency was assessed by exposure of homo/heteroduplex 
constructs to commercially available nuclear extracts (HeLa, mismatch repair 
efficient and LoVo, mismatch repair deficient human colorectal cancer cell 
lines). The reaction conditions were adopted from Wang and Hays (2002b). 
Briefly, 5-2.5µl homo/heteroduplex DNA constructs (3.33-1.67µg/µl final) were 
mixed with 13.35-1.33µg nuclear extract in the presence of 3µl of 5x mismatch 
repair buffer (Table 2.9). Each experiment was also carried out in the absence 
of nuclear extract or mismatch repair buffer as negative controls. Mismatch 
repair reaction mixture was incubated at 37ºC for 1-23 hours in a thermal cycler. 
The reaction was stopped by addition of 30µl stop solution (Table 2.9) and 
incubation in a thermal cycler at 37ºC for 30 minutes followed by an enzyme 
deactivation step at 75ºC for 15 minutes. 
DNA constructs were purified immediately using DNA clean and concentrator™ 
(Zymo research corporation, USA) following manufacturer’s protocol. Briefly, 
90µl of binding buffer was added to each sample and transferred to the column. 
The reaction mixture was centrifuged at 13000rpm for 30 seconds in a 
microfuge. The columns were washed twice with 200µl wash buffer and 
centrifuged at 13000rpm for 30 seconds in a microfuge. The purified product 
was eluted in 30µl nuclease free water and the products were stored at 4ºC. 
The purified repaired/non-repaired DNA constructs were analysed by SNaPshot 
assay as described in 2.3.2.10. The alleles at the SNP site was evaluated for 
repair, i.e. on a G-T heteroduplex, allele G could be repaired to allele A, or allele 
T to allele C or partial repair of both sequences could be observed. The peak 
sizes were compared to obtain an estimate of the repair efficiency for each 
allele. 
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2.4.2.3. Mismatch repair using commercially available 
whole cell extracts 
The reaction conditions were optimised to assess mismatch repair in whole cell 
extract. Similar to the nuclear cell extract assay, DNA constructs at final 
concentrations of 0.83-0.33µg/µl were incubated with 5-2.5 µg/µl whole cell 
extract in the presence of 3µl of 5x mismatch repair (MMR) buffer (Table 2.9). 
The products were purified and analysed as described for the nuclear extracts 
(2.4.2.2). 
 
Table 2-9 Summary of mismatch repair buffer and stop solution reagents and the 
preparation of these solutions. 
Reagents used in the MMR reaction (final 
concentrations)
Preparation of each reagent
MMR buffer Step1: Preparation of 10ml of MMR buffer:
7.5 ml nuclease free water + 2ml 1M Tris-HCl at pH 
7.6 (VWR International, UK) + 0.5ml 1M stock MgCl2 
(Sigma-Aldrich, USA) + 0.82g KCl (Sigma-Aldrich, 
USA)
Step 2: Preparation of 10x MMR buffer with ATP 
and Glutathione
1ml of 10xsolution1 + 0.008g ATP (Sigma-Aldrich, 
USA) + 0.003g Glutathione (Sigma-Aldrich, USA)
Step3: Preparation of 0.1ml of 5 x MMR buffer:
45µl of 10 x solution1 (from 1ml to which ATP & 
Glutathione were just added) + 5µl dNTPs (Promega 
Corp., USA) + 1.25µl BSA (20mg/ml stock 
concentration, Sigma-Aldrich, USA) + 40µl nuclease 
free water
Stop Solution
25mM EDTA, 0.67% SDS, 9001µg/ml Proteinase K
MMR Reaction Mix
For 30µl of stop solution (for one reaction):15µl of 
50mM EDTA (Sigma-Aldrich, USA) + 11.94µl 
nuclease free water + 2.01µl 10% SDS + 1.05µl 
Proteinase K (Roche Diagnostics, USA)
20mM Tris-HCl (ph 7.6), 1.5mM ATP, 1mM 
Glutathione, 0.1mM of each of the 4 dNTPs, 5mM 
MgCl2 and 110mM KCl 
 
Mismatch repair buffer was prepared fresh for each experiment. 10x mismatch repair buffer was 
prepared first that was then diluted to 5x mismatch repair buffer as the working solution. Stop 
solution was also prepared fresh for each experiment. 
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2.4.2.4. Mismatch repair using extracted protein from 
mouse blastocysts 
Total protein was extracted from ten and fifteen pooled MF1 strain mouse 
blastocysts using AllPrep RNA/protein kit using manufacturer’s protocol.  
2.4.2.5. Mismatch repair using whole cell extracts from 
mouse oocytes and mouse and human blastocysts 
Whole cell extraction from pooled oocytes and blastocysts was carried out using 
the whole cell extraction kit (Millipore,UK) following manufacturer’s protocol with 
slight changes. Briefly, each pooled oocyte and blastocyst (mouse MF1 strain 
and human, respectively) samples were mixed with 20-30µl of extraction buffer 
mixture and incubated on ice for 15 minutes. This mixture was then centrifuged 
to obtain the whole cell extract at full speed in a bench top centrifuge. The 
concentration of proteins within the whole cell extract was measured using the 
NanoDrop technology (NanoDrop, UK) as described in 2.3.2.8. 
Mismatch repair reaction was carried out as described in 2.4.2.2 by exposing a 
final concentration of 1.67 of heteroduplex to 67% (volume of protein/volume of 
mismatch repair mixture) oocyte or embryo extract to mismatch repair (MMR) 
buffer. Semi-quantitative analysis was performed by SNaPshot™ assay as 
described in 2.3.2.10. 
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3. Results and Discussion: 
 
The expression level of miRNAs and their target repair 
transcripts in human oocytes and preimplantation embryos 
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3.1 Results 
Aims summary: 
Gene expression is regulated by complex mechanisms. Previous studies 
showed that miRNAs are involved in the regulation of mRNA expression, such 
that knocking-down a miRNA led to increased expression of its target mRNA. 
Similarly, over-expression of a certain miRNA caused reduced expression of its 
target mRNA. To date, there has not been any study analysing the possible 
correlation of the expression level of miRNAs with their target repair mRNAs in 
gametes or preimplantation embryos. The first aim of this project was to 
investigate if there was any correlation between the expression of miRNAs and 
their target repair genes in human oocytes and blastocysts. If the expression of 
a target gene is regulated by a miRNA then the level of expression of the target 
gene might be expected to be correlated with the level of expression of the 
corresponding miRNA across samples. A literature search was performed to 
identify miRNAs and their targets that were shown to play roles in DNA repair 
(Figure 3.1). The expression of these miRNAs and mRNAs were analysed by 
real time PCR using TaqMan assays. The possible correlation between the 
level of each miRNA and its target mRNA in human oocyte and blastocyst 
samples available was analysed by Pearson correlation test.  
3.1.1 Identification of target mRNAs and miRNAs 
Differentially expressed DNA repair genes in human oocytes and blastocysts 
were identified previously (Jaroudi et al., 2009). A literature search to identify 
miRNAs expressed in human oocytes and blastocysts was performed. This 
search was narrowed down on the miRNAs that were shown or predicted to 
regulate these differentially expressed DNA repair genes. From these mRNA 
and miRNA profiles, repair genes such as miRNAs targeting an important cell 
cycle checkpoint gene, sensor genes from each pathway and genes involved in 
different repair pathways, were selected to be analysed in this study (Table 3.1). 
MiRNAs were selected to target more than one gene that is involved in different 
repair pathways to be able to have a general idea of the possible regulatory 
roles of miRNAs in DNA repair pathways.  
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Figure 3-1 Schematic diagram of the complex association of miRNAs in DNA repair 
pathways. 
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MiRNAs that were shown or predicted to target genes involved in repair were shown in a target 
map. MiRNAs that were associated with microsatellite instability (indicative of defective 
mismatch repair) were also shown in this diagram. MiRNAs were colour coded according to 
their target mRNAs. Double strand break repair genes (DCLRE1A, PARP1, BRCA1 and 
RAD50) are shown in pink, mismatch repair genes (MSH2 and MSH3) and microsatellite 
instability in green, nucleotide excision repair genes (ERCC3 and GTF2H2) in purple and 
checkpoint genes (RB1 and) in blue shades, respectively.  
 
Table 3-1 List of miRNAs and their association with DNA repair. 
Cell Cycle 
Checkpoint
Base Excision 
Repair
RB1 GTF2H2 ERCC3 PARP1 DCLRE1A PARP1 BRCA1 RAD50 MSH2 MSH3 MSI
Let-7 miR-23b miR-192 miR-7 miR-15a miR-7 miR-7 miR-15a miR-21 miR-7 Let-7a
miR-7 miR-101 miR-31 miR-16 miR-31 miR-145 miR-16 miR-145 miR-21 miR-31
miR-34c miR-128 miR-130 miR-23b miR-130 miR-155 miR-128 miR-155 miR-192 miR-101
miR-101 miR-181c miR-182 miR-128 miR-182 miR-182 miR-155 miR-192 miR-145
miR-128 miR-192 miR-192 miR-145 miR-192 miR-196 miR-194 miR-155
miR-181c miR-212 miR-196 miR-155 miR-196 miR-210 miR-212 miR-181c
miR-192 miR-210 miR-212 miR-210 miR-212 miR-192
miR-194 miR-196b
miR-212 miR-212
Nucleotide 
Excision Repair
Mismatch RepairDouble Strand Break Repair
 
Genes involved in cell cycle checkpoint, nucleotide excision, base excision, double strand break 
and mismatch repair pathways and the miRNAs targeting these genes are listed. These 
associations were either published previously as discussed in section 1.4.2.2 or bioinformatics 
studies showed that these miRNAs target the mRNAs (http://www.targetscan.org/, 
http://www.microrna.org/microrna/home.do, http://mirdb.org/miRDB/). 
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3.1.2 mRNA and miRNA expression 
Both mRNA and miRNA expression were analysed in human oocytes and 
blastocysts. mRNA expression was successfully analysed in nine oocytes from 
6 women (average age of 32.6±6 years) and ten blastocysts from 8 couples 
(average age of the women 36.5±7 years) (Table 3.2). Similarly, expression of 
twenty miRNAs was examined in a total of 22 oocytes from 13 women (average 
age of 35.3±7) and 23 blastocysts from eight couples (average age of women 
36.3±5) (Table 3.2). For each mRNA analysis, ACTB was quantified as an 
internal control in each oocyte and blastocyst samples and for each miRNA 
analysis, RNU48 was quantified in each oocyte and blastocyst sample. 
 
Table 3-2 Patient and sample details used in the analysis of a) mRNA and b) miRNA 
expression. 
 
a) Patient and sample information used in the analysis of mRNA expression 
Patient ID
Sample number (Developmental stage of the oocytes and  
blastocysts)
Number of samples  
used for mRNA 
expression
4 4.6 (MI) 1
5 5.3 (MI) 1
10 10.2 (MI), 10.3 (MI), 10.4 (MI), 10.5 (MI) 4
22 22.1 (MII) 1
23 23.1 (MI) 1
24 24.1 (MII) 1
15 15.5 (3BA) 1
17 17.2 (3BC) 1
18 18.1 (5AA), 18.2 (5AA), 18.4 (5AA) 3
19 19.5 (1-2CC) 1
25 25.1 (4AB) 1
26 26.1 (1BB) 1
27 27.1 (1AA) 1
28 28.1 (5AA) 1  
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b) Patient and sample information used in the analysis of miRNA expression 
Patient ID
Sample number (Developmental stage of the oocytes and  
blastocysts)
Number of samples  
used for miRNA 
expression
1 1.1 (MI) 1
2 2.1 (MII) 1
3 3.1 (MI) 1
4 4.1 (MII), 4.2 (MII), 4.3 (MII), 4.4 (-MI), 4.5 (MII) 5
5 5.1 (MI), 5.2 (MII) 2
6 6.1 (MI), 6.2 (MII), 6.3 (MII) 3
7 7.1 (MI), 7.2 (MI) 2
8 8.1 (MI) 1
9 9.1 (MII), 9.2 (MII) 2
10 10.1 (MI) 1
11 11.1 (MI) 1
12 12.1 (MI) 1
13 13.1 (MI) 1
14 14.1 (2BB), 14.2 (2CB), 14.3 (2BB), 14.4 (3BB) 4
15 15.1 (2BB), 15.2 (1BB), 15.3 (3BB), 15.4 (2BB) 4
16 16.1 (2BB),16.2 (2BB) 2
17 17.1 (3BC) 1
18 18.1 (5AA), 18.2 (5AA), 18.3 (5AA), 18.4 (5AA), 18.5 (5AA), 18.6 (5AA) 6
19 19.1  (3BB), 19.2 (2AB), 19.3 (2BB), 19.4 (2BB) 4
20 20.1 (3BB) 1
21 21.1 (3BB) 1  
 
Patient ID, sample ID, developmental stage of the sample and number of samples used from 
this patient investigating a) mRNA and b) miRNA expression are listed. MI represents meiosis I 
and MII represents meiosis II. The blastocyst grading scheme is described in section 2.2.1. 
 
The expression of each mRNA and miRNA was analysed in a minimum of six 
individual samples with replicates of two (Table 3.3). Mainly samples were 
grouped according to the developmental stage to test the expression of one 
target, i.e. meiosis I (MI) and meiosis II (MII) stage oocytes and similar 
developmental stage blastocysts were grouped together. A negligible inter-
sample variation for the repeats was observed as discussed in sections 3.1.3 
and 3.1.4. 
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Table 3-3 Information for the repeat and replicate oocyte and blastocyst samples used in 
the analysis of mRNA and miRNA expression. 
 
a) Information of oocyte and blastocyst samples used in the analysis of mRNA expression. 
mRNA tested
RB1 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 15.5(2) 17.2(2) 18.1(2) 18.4(2) 19.5(2) 25.1(2) -
GTF2H2 4.6(2) 5.3(2) 10.5(2) 22.1(2) 23.1(2) 24.1(2) 17.2(2) 19.4(2) 25.1(2) 26.1(2) 27.1(2) 28.1(2) -
ERCC3 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 17.2(2) 18.1(2) 18.2(2) 18.4(2) 19.5(2) 25.1(2) -
PARP1 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 17.2(2) 18.1(2) 18.2(2) 18.4(2) 19.5(2) 25.1(2) -
DCLRE1A 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 17.2(2) 18.1(2) 18.2(2) 18.4(2) 19.5(2) 25.1(2) -
BRCA1 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 17.2(2) 15.5(2) 18.1(2) 18.4(2) 19.5(2) 25.1(2) -
RAD50 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 17.2(2) 18.1(2) 18.2(2) 18.4(2) 19.5(2) 25.1(2) -
MSH2 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 15.5(2) 17.2(2) 18.1(2) 18.4(2) 19.5(2) 25.1(2) -
MSH3 4.6(2) 5.3(2) 10.2(2) 10.3(2) 10.4(2) 10.5(2) 15.5(2) 17.2(2) 18.1(2) 18.2(2) 18.4(2) 19.5(2) 25.1(2)
DICER1 10.2(2) 10.3(2) 10.4(2) 22.1(2) 23.1(2) 24.1(2) 18.1(2) 18.4(2) 25.1(2) 26.1(2) 27.1(2) 28.1(2) -
Samples tested (replicates) in oocytes Samples tested (replicates) in blastocysts
 
 
b) Information of oocyte and blastocyst samples used in the analysis of miRNA 
expression. 
miRNA tested
hsa-let-7a 1.1(3) 2.1(3) 3.1(3) 4.1(2) 4.2(2) 4.3(2)  5.1(2) 14.1(3) 14.2(2) 14.3(2) 15.1(3) 15.2(2) 16.1 (2) -
hsa-miR-7-2 4.1(2) 4.2(2) 4.4(2)  5.1(2) 6.1(2) 7.1(2) - 14.1(2) 15.2(2) 16.1 (2) 16.2 (2) 17.1 (2) 18.1 (2) -
hsa-miR-15a 1.1(3) 2.1(3) 8.1(3) 4.1(2) 4.2(2) 4.4(2)  5.1(2) 15.1(2) 15.3(2) 16.1 (2) 18.2(2) 19.1(2) 20.1(2) -
hsa-miR-16 4.5(2) 5.2(2) 6.2(2) 6.3(2) 7.1(2) 9.1(2) - 14.1(2) 14.2(2) 15.2(3) 19.2(2) 19.3 (2) 19.4(3) -
hsa-miR-21 2.1(3) 3.1(3) 4.1(2) 4.2(2) 4.3(2)  5.1(2) 10.1(3) 14.2(2) 14.4(2) 15.1(3) 15.4(2) 16.1 (2) 17.1 (2) -
hsa-miR-23b 2.1(3) 4.1(2) 4.2(2) 11.1(2) 12.1(2) 10.1(2) 10.1(2) 14.4(2) 15.2(3) 15.3(3) 16.1 (2) 17.1 (2) 21.1 (2) -
hsa-miR-31 4.4(2) 4.5(2) 5.3(2) 6.1(2) 7.1(2) 9.2(3) 13.1(3) 18.1(2) 18.2(2) 18.3(2)  18.4(2)  18.5(2)   18.6(2) -
hsa-miR-34c 2.1(2) 4.3(2) 4.4(2) 10.1(2) 11.1(2) 12.1(2) - 14.4(2) 15.2(3) 15.4(2) 17.1 (2) 18.2(2) 21.1 (2) -
hsa-miR-101 4.4(2) 4.5(2) 5.2(2) 7.1(2) 7.2(2) 13.1(2) - 18.1(3) 18.2(2) 18.3(2)  18.4(2)  18.5(2)   18.6(2) -
hsa-miR-128 1.1(3) 2.1(3) 3.1(3) 4.3(2) 4.5(3) 9.2(2) - 14.1(3) 14.2(2) 14.3(2) 14.4(2) 15.1(3) 17.1 (2) -
hsa-miR-130 4.1(2) 4.2(2) 4.4(2) 5.1(2) 6.1(2) 7.1(2) - 14.1(2) 15.2(3) 16.1(2) 16.2(2) 17.1(2) 18.1(2) -
hsa-miR-145 2.1(3) 3.1(3) 7.2(2) 4.1(2) 4.2(2) 4.3(2)  5.1(2) 14.1(2) 14.2(2) 14.4(2) 15.1(3) 15.1(3) 16.2(2) 17.1(2)
hsa-miR-155 1.1(3) 3.1(3) 4.3(2) 4.5(2) 5.1(2) 5.1(2) 8.1(3) 14.2(2) 15.3(3) 16.1 (2) 16.2 (2) 18.1 (2) 19.1(2) -
hsa-miR-181c 4.5(2) 5.1(2) 6.1(2) 6.2(2) 6.3(2) 9.2(2) - 14.1(2) 14.2(2) 16.2 (2) 19.1(2) 19.3(3) 19.4(3) -
hsa-miR-182 2.1(3) 4.3(2) 4.4(2) 10.1(2) 11.1(2) 12.1(2) - 14.4(2) 15.3(3) 16.2 (2) 17.1(2) 18.2(2) 20.1(2) 21(2)
hsa-miR-192 4.5(2) 5.2(2) 6.1(2) 6.2(2) 6.3(2) 7.1(2) 9.1(2) 14.2(2) 16.1 (2) 16.2 (2) 19.2(2) 19.3(2) 19.4(2) -
hsa-miR-194 5.2(2) 6.1(2) 6.2(2) 6.3(2) 7.1(2) 9.1(2) - 14.1(2) 14.2(2) 16.2 (2) 19.2(2) 19.3(3) 19.4(3) -
hsa-miR-196 4.1(2) 4.2(2) 4.3(2)  5.2(2) 9.2(2) 13.1(2) - 18.1(2) 18.2(2) 18.3(2)  18.4(2)  18.5(2)   18.6(2) -
hsa-miR-210 4.4(2) 4.5(2) 5.2(2) 6.1(2) 7.2(2) 13.1(2) - 18.1(2) 18.2(2) 18.3(2)  18.4(2)  18.5(2)   18.6(2) -
hsa-miR-212 4.1(2) 4.2(2) 4.4(2)  5.1(2) 6.1(2) 7.1(2) - 14.1(2) 15.1 (2) 16.1(2) 16.2(2)  17.1 (2) 18.2(2) -
Samples tested (replicates) in oocytes Samples tested (replicates) in blastocysts
 
The sample IDs representing the samples (as shown in table 3.2) used to investigate the 
expression level of each a) mRNA and b) miRNA are listed. The expression of each mRNA and 
miRNA was analysed in six different samples in duplicates or triplicates shown in parenthesis. 
 
3.1.3 mRNA expression in human oocytes and blastocysts 
This study showed that all the genes involved in cell cycle checkpoint and DNA 
repair, PARP1, BRCA1, RAD50, MSH2, MSH3, GTF2H2, ERCC3, DCLRE1A, 
RB1, and the miRNA processing gene DICER, were expressed in both oocytes 
and blastocysts. The expression levels ΔCq, fold change and log2 ratio, of all 
the mRNAs analysed in this study relative to the control gene ACTB are shown 
in table 3.4. Negative controls of real time PCR with no cDNA samples were 
clear for all the experiments. Sample-sample variation was observed among 
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individual samples, such that slight variation in the level of expression was 
observed for the same mRNA in different oocyte and blastocyst samples. 
Standard deviation of this variation is shown in table 3.4. 
 
Table 3-4 ΔCq values and fold changes for mRNA expression in blastocysts compared 
with oocytes. 
a) List of mRNAs, individual ΔCq and average ΔCq values from 6 repeats in oocytes and 
blastocysts. 
 
mRNA 
Oocyte Blastocyst 
Normalised ΔCq 
values of duplicate 
PCRs from 6 
individual repeats  
Average 
normalised 
ΔCq values of 
duplicate PCRs 
from 6 
individual 
repeats (SD) 
Normalised ΔCq 
values of 
duplicate PCRs 
from 6 individual 
repeats  
Average 
normalised 
ΔCq values of 
duplicate 
PCRs from 6 
individual 
repeats (SD) 
RB1 
5.20, 5.22, 6.01, 
3.67, 4.55, 6.03  
5.12 (0.90) 
7.98, 12.01, 8.69, 
9.59, 11.13, 9.26  
9.78 (1.51) 
GTF2H2 
1.31, 0.49, 1.48, -
2.08, -2.12, 2.09  
0.69 (1.69) 
5.86, 7.76, 7.55, 
3.40, 4.59, 5.10  
5.71 (1.70) 
ERCC3 
2.86, 0.15, 0.27, -
0.35, -0.46, 0.59  
0.51 (1.21) 
6.76, 4.78, 5.93, 
5.34, 8.19, 6.79  
6.30 (1.21) 
PARP1 
2.81, 2.49, 1.98, 
1.14, 2.94, 3.09  
2.41 (0.73) 
8.18, 7.11, 6.68, 
7.27, 9.11, 8.19  
7.75 (0.89) 
DCLRE1A 
1.08, -0.48, -0.22, -
0.91, -0.12, -0.41  
0.13 (0.91) 
9.74, 8.97, 9.11, 
7.94, 10.88, 9.71  
9.39 (0.97) 
BRCA1 
2.58, 1.61, 1.65, 
1.19, 2.43, 2.79  
2.04 (0.64) 
7.59, 9.01, 7.78, 
10.23, 9.48, 9.62  
8.95 (1.05) 
RAD50 
3.45, 1.21, 0.87, 
0.54, 0.90, 2.77  
1.62 (1.19) 
9.02, 7.68, 9.01, 
7.78, 9.82, 9.35  
8.77 (0.86) 
MSH2 
0.93, 0.21, 0.23, 
0.49, 0,10, 1.44  
0.56 (0.52) 
5.78, 6.49, 5.61, 
7.41, 7.34, 6.95  
6.59 (0.77) 
MSH3 
2.86, 0.71, 0.83, 
0.24, 0.73, 2.52  
1.32 (1.09) 
7.79, 8.97, 8.52, 
10.15, 10.25, 9.99  
9.34 (1.00) 
DICER 
1.80, 1.06, 2.00, -
1.12, -0.78, -1.12  
0.31 (1.47) 
7.57, 8.29, 9.20, 
4.95, 4.82, 5.33  
6.33 (1.71) 
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b) List of mRNAs, fold difference in blastocyst compared with oocyte and log2 of fold 
difference. 
 
mRNA 
Fold difference (2ˆΔΔCq) 
in blastocyst compared with oocyte  
Log2 of fold difference  
RB1 25.37 4.67 
GTF2H2 29.91  4.90  
ERCC3 55.32 5.79 
PARP1 40.68 5.34 
DCLRE1A 615.84 9.27 
BRCA1 120.12 6.91 
RAD50 142.49 7.15 
MSH2 65.47 6.03 
MSH3 251.46 7.97 
DICER 65.05 6.02 
 
a) mRNAs and ΔCq values in oocytes and blastocysts are listed. Average normalised ΔCq 
values generated from six repeats with duplicate of each sample is shown. Standard deviation 
(SD) for each data point of ΔCq is shown in parenthesis. The greater Cq values reflect lower 
expression. b) mRNAs, fold difference and log2 of fold change in blastocyst compared with 
oocyte are listed. Fold change was calculated by relative quantification method (2^ΔΔCq). The 
log2 scale transformation of the fold change facilitates interpretation of the difference in 
expression between the two samples.  
 
One-way ANOVA with Dunnett’s multiple comparison post test was used to 
analyse the expression of all the normalised target mRNAs in the oocytes and 
blastocysts in comparison with GTF2H2, which is expressed the highest in 
blastocysts and one of the highest in oocytes (Cq values in Table 3.4 and 
Figure 3.2). In oocytes, high levels of expression were observed for GTF2H2, 
MSH2, MSH3, ERCC3, DCLRE1A and DICER, whereas in blastocysts, high 
expression levels were observed for GTF2H2, MSH2, ERCC3 and DICER.  
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Figure 3-2 Expression of all the normalised repair genes in comparison with GTF2H2. 
a) Oocyte b) Blastocyst
 
a) Oocyte b) Blastocyst
 
Quantification of target mRNAs compared to GTF2H2, which was shown to be expressed at the 
highest level in a) oocytes and b) blastocysts. ANOVA followed by Dunnett’s post test was 
applied to all the mRNA normalised to ACTB; where ****p<0.0001 indicates the most statistical 
significance, ***0.0001<p<0.001, **0.001<p<0.01, *0.01<p<0.05 less statistical significance and 
p≥ 0.05 indicates no statistical significance. The x-axis represents all the miRNAs analysed in 
this study and the y-axis represents the ΔCq values.  GTF2H2 is shown in purple, PARP1 in 
red, BRCA1 in pink, RAD50 in light pink, MSH2 in light green, MSH3 in dark green, ERCC3 in 
purple, DCLRE1A in mid pink, RB1 in aqua, and DICER1 in black shades, respectively. 
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Expression of each mRNA in oocytes compared with blastocysts was analysed 
by an unpaired two-tailed student’s T-test with the Welch correction. Expression 
levels of all these genes were significantly higher in oocytes compared with 
blastocysts (Figure 3.3, p < 0.05). 
 
Figure 3-3 mRNA expression levels quantified by real time PCR after normalisation with 
the endogenous control, ACTB. 
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Each gene was analysed in six individual oocytes and six individual blastocysts revealing 
significantly higher expression levels in the oocytes compared to the blastocysts with ***p<0.001 
for PARP1, MSH2, ERCC3, DCLRE1A and RB1, **p<0.012 for BRCA1, RAD50, MSH3 and 
DICER and *0.01<p<0.05 for GTF2H2. The x-axis represents blastocyst and oocyte samples 
and the y-axis represents the fold change. 
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3.1.4 MiRNA expression in human oocytes and blastocysts 
Expression of 20 miRNAs was quantified in oocytes and blastocysts. Of the 20 
miRNAs analysed, eleven (hsa-let-7a, hsa-miR-16, hsa-miR-21, hsa-miR-31, 
hsa-miR-101, hsa-miR-145, hsa-miR-182, hsa-miR-192, hsa-miR-194, hsa-
miR-210 and hsa-miR-212) were detected in oocytes. Eighteen miRNAs (hsa-
let-7a, hsa-miR-7-2, hsa-miR-15a, hsa-miR-16, hsa-miR-21, hsa-miR-23b, hsa-
miR-31, hsa-miR-34c, hsa-miR-101, hsa-miR-128, hsa-miR-130, hsa-miR-145, 
hsa-miR-155, hsa-miR-182, hsa-miR-192, hsa-miR-194, hsa-miR-210 and hsa-
miR-212) were detected in blastocysts, of which seven miRNAs; hsa-miR-7-2, 
hsa-miR-15a, hsa-miR-23, hsa-miR-34, hsa-miR-128, hsa-miR-130 and hsa-
miR-155 were only present in blastocysts. Two miRNAs; hsa-miR-181c and 
hsa-miR-196; were neither expressed in oocytes nor in blastocysts. All the ΔCq 
values, fold difference and log2 ratios of these miRNAs in oocytes and 
blastocysts are listed in table 3.5.  
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Table 3-5 Average normalised ΔCq values and fold changes for miRNA expression in 
blastocysts compared with oocytes. 
a) List of miRNAs, individual Cq and average Cq values from 6 repeats in oocytes and 
blastocysts. 
miRNA 
Oocyte Blastocyst 
Normalised ΔCq 
values of 
duplicate PCRs 
from 6 individual 
repeats  
Average 
normalised 
ΔCq from 6 
individual 
repeats (SD) 
Normalised ΔCq 
values of duplicate 
PCRs from 6 individual 
repeats  
Average 
normalised 
ΔCq from 6 
individual 
repeats (SD) 
let-7a 
6.9, 6.4, 5.1, 5.9, 
5.3, 6.9  
6.11 (0.81) 
8.78, 9.22, 13.88, 14.12, 
11.67, 10.98  
11.44 (2.00) 
miR-7-2 Not detected 
10.90, 12.22, 16.38, 
16.39, 11.76, 14.25, 
18.06  
13.93 (2.81) 
miR-15a Not detected 
8.32, 8.05, 9.24, 7.27, 
8.90, 8.30  
8.34 (0.69) 
miR-16 
-1.5, -2.5, -3.1, -
0.95, -1.85, -1.20  
-1.87 (0.91) 
0.48, 1.62, 0.71, 1.09, 
0.34, 0.51  
0.79 (0.48) 
miR-21 
5.7,  6.8, 6.1, 5.6, 
5.3, 5.4  
5.8 (0.61) 
5.82, 5.93, 7.13, 3.97, 
5.04, 6.04  
5.69 (1.06) 
miR-23b Not detected 
8.41, 8.38, 9.79, 8.11, 
10.94, 9.44  
9.17 (1.08) 
miR-31 
1.7, 1.6, 3.4, 2.5, 
3.0, 3.1, 2.4  
2.55 (0.72) 
6.30, 6.47, 5.61, 6.46, 
6.53, 6.21  
6.24 (0.33) 
miR-34c Not detected 
7.35, 8.40, 8.55, 8.72, 
7.55, 7.98  
8.03 (0.56) 
miR-101 
5.5, 6.7, 8.5, 8.5, 
10.0, 9.3  
8.26 (1.91) 
11.20, 10.31, 12.47, 
10.17, 10.46,10.3  
10.03 (0.92) 
miR-128 Not detected 
7.96, 6.67, 8.67, 8.48, 
8.89, 7.80  
8.09 (0.91) 
miR-130 Not detected 
8.09, 6.75, 6.84, 7.32, 
7.78, 7.36  
7.36 (0.52) 
miR-145 
7.95, 10.32, 9,38, 
6.11, 6.91, 7.17  
7.94 (1.59) 
10.81, 11.57, 12.42, 
12.16, 12.83, 11.90  
11.91 (0.64) 
miR-155 Not detected 
11.40, 9.12, 12.40, 
11.43, 11.23, 11.02  
10.97 (1.07) 
miR-181 Not detected Not detected 
miR-182 
6.33, 6.81, 6.20, 
6.00, 7.82, 5.85  
6.49 (0.72) 
5.11, 6.27, 6.15, 5.63, 
5.78, 7.75  
6.11 (0.90) 
miR-192 
2.42, 4.08, 2.32, 
2.71, 4.91, 4.25  
3.45 (1.1) 
1.87, 6.73, 4.81, 7.34, 
2.33, 2.51  
4.27 (2.38) 
miR-194 
6.07, 5.51, 4.42, 
6.05, 4.83, 5.7  
5.90 (0.67) 
3.42, 5.34, 4.18, 7.38, 
4.87, 4.51 (1.35) 
4.95 
miR-196 Not detected Not detected 
miR-210 
4.14, 7.65, 5.16, 
7.36, 4.64, 6.51  
5.91 (1.44) 
7.60, 7.17, 7.16, 9.01, 
7.83, 7.69  
7.75 (0.67) 
miR-212 
5.36, 8,71, 6.59, 
6.38, 4.96, 5.27  
6.29 (1.38) 
8.92, 9.93, 8.20, 7.56, 
9.83, 10.05  
9.08 (1.03) 
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b) List of miRNAs, fold difference in blastocyst compared with oocyte and log2 of fold 
change difference. 
miRNA 
Fold difference (2ˆΔΔCq) 
in blastocyst compared with oocyte 
Log2 of fold 
difference 
let-7a 14.39 3.85 
miR-7-2 N/A N/A 
miR-15a N/A N/A 
miR-16 6.63 2.73 
miR-21 0.59 -0.74 
miR-23b N/A N/A 
miR-31 12.84 3.68 
miR-34c N/A N/A 
miR-101 6.26 2.65 
miR-128 N/A N/A 
miR-130 N/A N/A 
miR-145 17.17 4.10 
miR-155 N/A N/A 
miR-181 N/A N/A 
miR-182 0.74 -0.43 
miR-192 1.52 0.60 
miR-194 0.52 -0.94 
miR-196 N/A N/A 
miR-210 2.37 1.24 
miR-212 7.47 2.90 
a) miRNAs and  ΔCq values in oocytes and blastocysts are listed. Average normalised ΔCq 
values generated from six repeats with two replicates of each sample is shown. Standard 
deviation (SD) for each data point of ΔCq is shown in parenthesis. The greater Cq values reflect 
lower expression. b) MiRNAs, fold change difference and log2 of fold change in blastocyst 
compared with oocyte are listed. Fold change was calculated by relative quantification method 
(2^ΔΔCq). The log2 scale transformation of the fold change facilitates interpretation of the 
difference in expression between the two samples. The negative log2 values indicated 
increased expression of the gene in the blastocyst compared with the oocyte. N/A stands for not 
applicable. 
 
The expression of each normalised miRNA was examined in comparison with 
hsa-miR-16, expressed highest in the oocytes and blastocysts, by one-way 
ANOVA with Dunnett’s multiple comparison post test. All the miRNAs tested 
were expressed at significantly lower levels compared to hsa-miR-16 (Cq 
values in Table 3.5 and Figure 3.4). 
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Figure 3-4 Expression of all the miRNAs in comparison with hsa-miR-16. 
 
Quantification of target miRNAs compared to hsa-miR-16 a) in oocytes and b) in blastocysts. 
ANOVA followed by Dunnett’s post test was applied to all miRNAs compared to hsa-miR-16. 
The x-axis represents all the miRNAs analysed in this study and the y-axis represents the ΔCq 
values. In oocytes the expression of hsa-miR-16 was at a higher expression level compared to 
the endogenous control RNU48 represented by a negative profile for this miRNA. MiRNAs were 
colour-coded according to their target genes as in figure 3.1, i.e. miRNAs targeting PARP1 is 
shown in red, BRCA1 in pink, RAD50 in mid pink, DCLRE1A in light pink, MSH2 in light green, 
MSH3 in dark green, ERCC3 in purple, GTF2H2 in lilac and RB1 in aqua shades, respectively. 
**** represents that the difference in level of expression of the miRNA from that of hsa-miR-16 is 
statistically significant (p<0.001). 
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Similar to the statistical analysis performed for mRNA expression analyses, 
unpaired two-tailed student’s T-test with the Welch correction was applied on 
eleven miRNAs expressed both in oocytes and blastocysts. For the rest of the 
nine miRNAs, statistical analysis could not be carried out since these miRNAs 
were not expressed in oocytes or in blastocysts. Expression levels of six 
miRNAs (for hsa-let-7a, hsa-miR-16, hsa-miR-31, hsa-miR-145, hsa-miR-210 
and hsa-miR-212) in oocytes were significantly higher than in the blastocysts 
(p< 0.01, Figure 3.5). Although hsa-miR-101 and hsa-miR-192 were expressed 
at higher levels in the oocyte, this increase was not significant. Similarly even 
though hsa-miR-21, hsa-miR-182 and hsa-miR-194 were expressed more in the 
blastocyst, this increased expression was also not significant (Figure 3.5) 
 
Figure 3-5 MiRNA expression levels quantified by real time PCR after normalisation with 
the endogenous control, RNU48. 
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Each gene was analysed in six individual oocytes and six individual blastocysts revealing 
significantly higher expression levels in the oocytes compared to the blastocysts in hsa-miR-31 
(****p<0.005), hsa-miR-16 (***p<0.05), hsa-let-7a (**p<0.001), hsa-miR-145 (*0.01<p<0.05), 
hsa-miR-210 (*0.01<p<0.05) and hsa-miR-212 (*0.01<p<0.05). The remaining five miRNAs 
(hsa-miR-21, hsa-miR-101, hsa-miR-182, hsa-miR-192 and hsa-miR-194) showed no significant 
difference in the levels of expression. The x-axis represents blastocyst and oocyte samples and 
the y-axis represents the fold change. 
 
3.1.5 Correlation between the expression of miRNAs and their 
target mRNAs 
Overall these results showed that the expression level of most of the miRNAs 
analysed and their target repair mRNAs are higher in oocytes than in 
blastocysts after normalisation with endogenous control transcripts 
(summarised in Table 3.6). In addition the question of whether those individual 
samples with higher miRNA levels might tend to have lower levels of the target 
mRNAs or perhaps a consistent correlation in the other direction was asked. 
Either of these findings might be suggestive that the target mRNA was being 
regulated primarily by its miRNA and perhaps provide insight into the 
mechanism. In order to investigate this, the expression levels of each miRNA 
(normalised using RNU48) and target mRNA (normalised using ACTB) were 
plotted against each other and a Pearson correlation test was applied. It was 
immediately apparent that there were both negative and positive correlations in 
the different comparisons and only a few showed statistical significance. In fact 
after correction for multiple testing none was statistically significant (threshold of 
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0.002 in oocytes and 0.001 in blastocyst). This data was summarised in Table 
3.6. 
3.1.6 Summary of miRNA and mRNA expression analysis 
Technical aspects 
- Real time PCR for a total of 31 oocytes and 33 blastocysts was 
successfully performed for mRNA and miRNA expression analyses. 
- The expression of 20 miRNAs and 10 mRNAs was successfully analysed 
in six individual oocyte and blastocyst samples, respectively.  
Biological aspects 
- A summary table shows a list of mRNAs and miRNAs detected in human 
oocytes and blastocysts (Table 3.6). MiRNAs expressed at significantly 
higher levels in oocytes compared blastocysts are listed.  
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Table 3-6 Summary table of mRNAs and miRNAs expressed in oocytes and blastocysts 
and the significant expression of mRNAs and miRNAs with correlation analysis. 
mRNAs miRNAs
RB1 RB1 let-7a let-7a RB1 let-7a
GTF2H2 GTF2H2 miR-16 miR-7-2 GTF2H2 miR-16
ERCC3 ERCC3 miR-21 miR-15a ERCC3 miR-31
PARP1 PARP1 miR-31 miR-16 PARP1 miR-145
DCLRE1A DCLRE1A miR-101 miR-21 DCLRE1A miR-210
BRCA1 BRCA1 miR-145 miR-23b BRCA1 miR-212
RAD50 RAD50 miR-182 miR-31 RAD50
MSH2 MSH2 miR-192 miR-34c MSH2
MSH3 MSH3 miR-194 miR-101 MSH3
DICER DICER miR-210 miR-128 DICER
miR-212 miR-130
miR-145
miR-155
miR-182
miR-192
miR-194
miR-210
miR-212
mRNAs 
expressed 
in oocytes
mRNAs 
expressed in 
blastocysts
MiRNAs 
expressed 
in oocytes
MiRNAs 
expressed in 
blastocysts
Significantly higher 
expression in oocytes 
relative to blastocysts 
of
 
Each mRNA and miRNA expressed in human oocytes and blastocysts are listed (first four 
columns). mRNAs and miRNAs showing significant higher expression levels in oocytes 
compared with blastocysts are listed. In the last two columns results of correlation analysis are 
shown. Significant direct and inverse correlation results were only observed in blastocysts and 
miRNAs. List of miRNAs and their target mRNAs with significant correlations are listed. 
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3.2 Discussion 
The level of gene expression is affected by many factors including miRNA 
regulation. Several studies have investigated the regulation of DNA repair gene 
transcripts by miRNAs in cell lines and in tissues. In this project, the possible 
correlation between the expression level of DNA repair gene transcripts and 
miRNAs in human oocytes and blastocysts was investigated.  
3.2.1 Expression of mRNAs 
The expression of one miRNA processing gene (DICER), one cell cycle 
checkpoint gene (RB1), four double strand break repair genes (PARP1, 
BRCA1, RAD50, DCLRE1A), two mismatch repair genes (MSH2, MSH3) and 
two nucleotide excision repair genes (GTF2H2, ERCC3) were analysed 
successfully by quantitative real time PCR (using TaqMan assays). The overall 
expression levels of these mRNAs were significantly higher in human oocytes 
compared to blastocysts. The high level of expression of all the repair genes in 
oocytes suggests that the early developing embryo is packed with transcripts to 
detect and initiate repair pathways if subjected to DNA damage. Although there 
are functional studies showing mismatch repair and double strand break repair 
in Xenopus oocytes and in extracts (Maryon and Carroll, 1989, Oda et al., 1996, 
Petranovic et al., 2000, Varlet et al., 1996, Labhart, 1999, Jeong-Yu and Carroll, 
1992), recent studies in mouse oocytes showed that damage is detected at MII 
oocytes, but the repair is impaired (Marangos and Carroll, 2012). Therefore, 
although the expression of repair genes were detected in oocytes and 
blastocysts, the functional activity of DNA repair pathways may vary due to the 
regulatory factors of repair genes and proteins, such as miRNA regulation at 
protein level. In oocytes where high expression levels of repair mRNAs were 
detected, it is possible that miRNAs destabilise translation causing impairment 
of repair pathways.  
3.2.2 Expression of miRNAs 
The expression of twenty miRNAs targeting the nine genes involved in different 
DNA repair pathways was analysed. The expression levels of 73% (6/11) of 
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these miRNAs (hsa-let7a, hsa-miR-16, hsa-miR-31, hsa-miR-145, hsa-miR-210 
and hsa-miR-212) were significantly higher in the oocytes compared with the 
blastocysts. This high expression of miRNAs in the oocytes may be required to 
degrade maternal mRNAs or stabilise some of their target genes during 
embryonic genome activation (Giraldez et al., 2006).  
3.2.3 Possible correlation of miRNA expression with mRNA 
expression 
The correlation analysis was performed for each miRNA and its target mRNA in 
order to investigate if the expression level of mRNA tends to vary depending on 
the expression level of miRNAs. Overall only a few miRNAs and mRNAs 
showed significant correlation (summarised in table 3.6) with both negative and 
positive correlations and no consistent pattern was observed. Furthermore 
following correction for multiple testing, no statistical significance was observed.  
The lack of any meaningful correlation in the expression levels of the miRNAs 
and their targets was perhaps not surprising. The small quantities of the 
samples prevented us from conducting the most meaningful comparisons, 
which would have been to look at the developmental trends. One of the 
possibilities to overcome this limitation would have been to pool samples of the 
same developmental stage and to investigate the expression of all the miRNAs 
and their targets using the same set of pooled samples and eliminate large 
sources of variation.  
3.2.4 Conclusion and future work 
The overall expression level of the repair genes was shown to be higher in 
oocytes compared to blastocysts as also shown by Jaroudi et al. (2009). 
Similarly, many of the miRNAs (6/11) looked at in this study were expressed 
significantly more in the oocytes compared to the blastocysts.  
Regulation of mRNAs involves complex mechanisms, amongst which are 
included the action of miRNAs. Adding to this complexity is that each miRNAs 
may have multiple mRNA targets, and also that each mRNA may be regulated 
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by more than one miRNA. The failure to detect any clear relationship in the 
patterns of expression is therefore not all that surprising. 
One of the main limitations of this study was the practical inability of following 
the expression of miRNA and mRNA through different developmental stages. 
Due to the scarcity of human samples and the expense of the expression 
analysis, only a limited number of miRNA and mRNA targets were analysed, 
furthermore in different oocyte and blastocyst samples. With hindsight the 
experimental design might have been improved. Another limitation was the 
small number of target genes including the house keeping gene analysed. 
Although genome wide expression analyses have been performed in human 
oocytes and preimplantation embryos; no gene has been identified as a robust 
housekeeping gene (or genes). Therefore more than one candidate 
housekeeping gene should have been included in the experimental design of 
this study. However this was not possible in this project due to the limited 
number of samples available and cost of the analyses.  
Further studies will aim to focus on expression of more miRNA and target 
mRNAs, preferably within the same oocyte and blastocyst samples. Once the 
expression profiles of miRNAs and DNA repair gene transcripts has been 
established, it may be possible to shed light as to whether there is any 
correlation between miRNA and their target mRNAs. Finally functional studies 
would be necessary to validate information on the regulatory roles of miRNAs 
on their target mRNAs.  
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4. Results and Discussion 
Differential allelic expression in preimplantation embryos and 
potential relation with differential methylation 
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4.1 Results 
Aims summary 
Differential expression of parental genes is suspected to be present in embryos 
due to the differential methylation of parental genomes observed in the early 
developing mouse embryos  (Dean et al., 2003, Tamaru and Selker, 2001, 
Jackson et al., 2002, Fuks et al., 2003). Parental expression of imprinting genes 
has been analysed in human embryos. However, there are no studies analysing 
differential parental expression of repair genes in preimplantation embryos. It is 
possible that differential gene expression is present in the early stages of 
human preimplantation embryos due to the differential methylation of parental 
genomes. 
The second aim of this project was to investigate if there was differential 
parental expression of ACTB, SNRPN, H19 and BRCA1 in human embryos due 
to the differential demethylation of the parental genomes. A further analysis was 
performed to investigate if the presence of maternally or paternally inherited 
BRCA mutations affects the development of the preimplantation embryos 
depending on the parental inheritance. Semi-quantitative mini-sequencing 
analysis was performed on the cDNA of embryos to target informative SNPs 
identified by sequencing the parental genomic DNA. The methylation status of a 
subset of embryos were confirmed by bisulfite conversion followed by 
methylation specific PCR.  
4.1.1 Sample selection 
Initial screening by sequencing identified informative SNPs within ACTB, 
SNRPN, H19 and BRCA1 for five couples (Figure 4.1, Appendix 7.3.1.1). Ten 
more couples were further tested by mini-sequencing targeting these selected 
SNPs. Overall, 15 couples were shown to be semi- or fully-informative for a total 
of five SNPs within four genes (Table 4.1). Twenty seven exonic regions within 
three more genes (GAPDH, UBE3A, IGF2) were sequenced, however none of 
the couples were informative for the SNPs analysed. 
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Figure 4-1 Sequencing panels obtained from genetic analyser ABI Prism
TM
 3100. 
 
 
 
 
 
 
Top panel shows the female partner of couple 29 who is heterozygote (G/A) and the bottom 
panel represents the male partner of couple 29 who is homozygote (G/G) for the SNP rs16941 
within BRCA1. 
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Table 4-1 Collective results of sequencing and mini-sequencing analyses showing the 
alleles at each SNP site analysed for fifteen couples. 
Female Male Female Male Female Male Female Male Female Male
29 G/A G/G T/T C/C C/T T/T G/A G/G C/T C/C
30 G/A G/A C/T C/C C/T C/C G/A G/G C/T C/C
31 G/A G/A T/T C/T C/T C/C A/A A/A C/T T/T
32 A/A G/A C/T C/T C/T C/C G/A A/A C/T T/T
33 G/A G/A T/T C/T C/T C/C A/A G/A C/C C/T
34 A/A A/A T/T T/T T/T C/T G/A G/G C/T T/T
35 G/A G/G C/T C/T C/T C/T G/G A/A C/C T/T
36 G/A A/A T/T T/T C/T C/T G/A G/A C/T C/T
37 A/C A/C C/T T/T T/T T/T A/A A/A T/T T/T
38 A/A A/A C/C C/T T/T T/T A/A G/A C/T T/T
39 A/A A/A T/T T/T C/T T/T A/A G/A T/T C/T
40 A/A A/A C/T C/T C/T T/T G/A G/G C/T T/T
41 A/A A/A T/T C/C T/T T/T G/A G/A C/T C/T
42 A/A A/A C/C C/T T/T T/T A/A A/A T/T T/T
43 G/A A/A C/T C/T C/C T/T G/A G/A C/T C/T
Couple 
ID
ACTB SNP site 
rs852423
SNRPN SNP 
site rs75184959
H19 SNP site 
rs11542721
BRCA1  SNP 
site rs16941
BRCA1  SNP 
site rs1060915
 
Couple ID, and the alleles present at the SNP site for ACTB, SNRPN, H19 and BRCA1 
analysed are shown in this table. For ACTB, a total of four couples (29, 32, 35 and 36) couples 
were shown to be semi-informative for the SNP rs852423, couples 29 and 41 were fully 
informative for SNRPN SNP 75184919, couples 30, 31, 33, 37, 38 and 42 were semi-
informative for SNRPN SNP 75184919, couples 29, 30, 33, 34, 39 and 40 were semi-
informative for H19 SNP rs115442721 and 42 was semi-informative for H19 SNP rs115442721 
and a total of ten couples were shown to be fully/semi-informative for BRCA1 SNPs rs16941 
and rs1060915. 
 
4.1.2 Quality and concentration of RNA and DNA extracted from 
human preimplantation embryos 
Optimisation of total RNA extraction for the investigation of differential gene 
expression was carried out on isolated clumps of lymphocytes from an 
anonymous donor consisting of 150, 100 and 50 cells. Initially two different kits, 
AllPrep DNA/RNA Micro Kit, Qiagen (A), UK and Absolutely RNA® Nanoprep 
kit, Agilent (B), were tested for total RNA extraction. The successful RNA 
extraction from lymphocyte clumps was assessed by Nanodrop quantification 
(Table 4.2). The ratio of the absorbance at 260nm and 280nm was expected 
and found to be more than 2ng/µl indicating pure and good quality RNA sample. 
Total RNA and DNA from surplus embryos were obtained using AllPrep 
DNA/RNA Micro Kit.  
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Table 4-2 Summary of initial RNA extraction optimisation experiments. 
 
Sample                            
number 
Number of 
lymphocytes 
from each clump 
Kit used 
for 
extraction 
260/280 
ratio 
Concentration 
(ng/µl) 
1 50 A 0.01 2.4 
2 50 A 6.94 1.1 
3 50 A 1.95 1.7 
4 100 A 0.02 6.7 
5 100 A 1.66 3.6 
6 100 A 2.37 5.6 
7 100 A 1.43 3.7 
8 100 B 2.05 6.4 
9 100 B 1.64 9.9 
 
RNA extraction using clumps of cells, kits used, NanoDrop readings including 260/280 ratio and 
concentrations of the extracted RNA. It was observed that as the RNA extraction involved more 
cells, the concentration of RNA was increased. 
 
Total RNA and DNA were extracted from 95 embryos derived from 15 couples 
to investigate the parental differential expression of ACTB, SNRPN, H19 and 
BRCA1 (Table 4.3). The Agilent 2100 Bioanalyzer was used to quantify RNA 
(Figure 4.2, Appendix 7.3.1.2). RIN values for both cleavage and morula stage 
embryos (***p= 0.0009) were considerably lower compared to blastocyst 
samples (**** p< 0.0001). However, there was no significant difference in the 
RNA concentration of cleavage, morula and blastocyst stage embryos 
(Appendix 7.3.1.2, p=0.1). DNA contamination of these RNA samples was 
tested by amplifying an intronic and exonic region of DMPK gene and no 
contamination was detected in any of the cDNA samples obtained from these 
embryos. The overall DNA concentration in embryos at cleavage, morula and 
blastocyst was at similar levels (Appendix 7.3.1.2). 
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Figure 4-2 Assessment of RNA samples from human embryos using the Agilent 2100 
Bioanalyzer Pico chip electrophoresis. 
 
28S RNA
1 2 3
18S RNA
1
2
3
a) b)
 
 
a) Electropherograms of embryos 1, 2 and 3 showing the 18S and 28S rRNA. The 
electropherogram for the sample 3 indicates a poor quality of RNA. b) Peaks in the individual 
electropherograms of embryos 1, 2 and 3 on Pico chip. 
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Table 4-3 Patient and embryo information for the analysis of differential gene expression. 
29 BRCA1 1 Affected
2 Affected
3 Affected
4 Affected
5 No PGD
6 No PGD
7 Affected
8 Affected
9 Affected
10 Affected
11 Affected
12 Affected
13 Affected
14 No BRCA2  mutation
15 Affected
16 Affected
17 No BRCA2  mutation
18 Affected
19 Affected
20 Inconclusive
21 Inconclusive
22 Inconclusive
23 Inconclusive
24 No MLH1  mutation
25 Inconclusive
26 Affected
27 Affected
28 Affected
29 No PGD
30 No APC  mutation
31 Affected
32 No APC  mutation
33 Affected
34 Affected
35 No APC  mutation
36 Affected
37 Affected
38 No result
39 No PGD
40 No APC  mutation
41 Affected
42 Affected
43 No result
44 Affected
45 No result
46 No PGD
PGD outcome
34 APC
32 BRCA2
33 MLH1
30 BRCA1
31 BRCA1
Patient Disorder
Embryo 
ID
 
47 Affected
48 Maternal only
49 No NF1  mutation
50 No NF1  mutation
51 Affected
52 No NF1  mutation
53 Affected
54 Affected
55 Affected
56 Affected
57
Maternal only for 
chromosome 13
58 Affected
59 Affected
60 No RB1  mutation
61 Affected
62 Affected
63 Affected
64 Inconclusive
65 Affected
66 Affected
67 Affected
68 Affected
69 Inconclusive
70 No PRKAR1
71 Affected
72 Inconclusive
73 No result
74 No result
75 Affected
76 Affected
77 Inconclusive
78 Affected
79 Affected
80 Affected
81
Paternal only for 
chromosome 19
82 Inconclusive
83
Paternal only for 
chromosome 19
84 Affected
85 Inconclusive
86 Inconclusive
87 No result
88 Affected
89 Affected
90 Affected
91 No DMPK  mutation
92 Affected
93 Affected
94 No result
95 Affected
Patient Disorder
Embryo 
ID
35 NF1
PGD outcome
36 RB1
37 Men2b
38
PRKAR1
A
39 DMPK
40 DMPK
41 DMPK
42 DMPK
43 DMPK
 
Couple and embryo IDs, disorder, affected partner and developmental stages of the embryos 
are listed. PGD results were also shown for each embryo for the particular single gene disorder 
for which it was diagnosed. 
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4.1.3 Differential expression of parental genes in preimplantation 
embryos 
A results summary including the list of genes analysed (ACTB, SNRPN, H19 
and BRCA1), number of embryos showing differential expression favouring 
paternal and maternal transcripts and the number of embryos excluded from the 
analysis are shown in table 4.4. Statistical analysis was performed by applying 
a student’s T-test to all the embryos examining preferential paternal expression 
relative to preferential maternal expression (Figure 4.3). The difference between 
the parental allelic peak height ratios of SNRPN and BRCA1 transcripts was 
statistically significant (Figure 4.3). 
Expression of the house keeping gene, ACTB, was observed to be similar 
between maternal and paternal transcripts in all the embryos that were 
successfully analysed (Table 4.4 and Figures 4.3, 4.4, 4.5). There was no 
significant difference in the expression levels of maternal and paternal ACTB 
transcripts (Figure 4.4). 
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Figure 4-3 Overall differential expression analysis of paternal and maternal transcripts for four genes in human embryos. 
 
SNRPN BRCA1H19ACTB
 
 
The differential expression of ACTB, SNRPN, H19 and BRCA1 was analysed in all the embryos at cleavage, morula or blastocyst stages. In heterozygotes, there 
was no significant difference in the level of the parental transcripts of ACTB (p=0.2). Paternal SNRPN transcripts were expressed at significantly higher levels than 
the maternal transcripts (*p= 0.01). Although higher levels of maternal H19 transcripts were detected in embryos, this difference was not statistically significant 
(p=0.4) in the embryos analysed. However, paternal BRCA1 (*p= 0.03) was significantly higher relative to the maternal transcripts (*p= 0.03) in the embryos. 
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Figure 4-4 Differential parental expression analysis of ACTB transcripts on cDNA from embryos examined at SNP rs852423 by mini-sequencing 
(SNaPshot™).  
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The couple ID and embryo numbers are shown at top of each panel separately. The peak height, which represents the amount of cDNA product from each allele, is 
also labelled. Blue peak represents allele G and green allele A, respectively. Each embryo is showing that the parental ACTB transcripts are expressed at similar 
levels, where the ratio of maternal to paternal ACTB transcript was approximately 1:1. The x-axis shows the alleles detected at the SNP and the y-axis shows the 
peak heights. The embryos analysed in this study were mainly shown to express both parental alleles for the imprinted genes, however the paternal SNRPN and the 
maternal H19 transcripts were preferentially expressed in the majority of the embryos analysed as expected.  
 Results for differential allelic expression and embryo development 
 
151 
 
Overall, more than half of the embryos (*p=0.01; 56.5%, 13/23, Figure 4.3) 
preferentially expressed the paternal copy of SNRPN and 39% (9/23) had 
strictly monoallelic expression for the paternal transcript (Table 4.4 and Figures 
4.5, 4.6). As the embryos developed to the blastocyst stage, the monoallelic 
expression and the differential expression favouring the paternal transcript 
increased such that differential expression of paternal SNRPN transcript was 
61% (8/13) up to the morula stages whereas it was 70% (7/10) at the blastocyst 
stage. Similarly, the maternal transcript of H19 was preferentially expressed in 
60% (9/15) of the embryos and 78% (7/9) were strictly monoallelic for the 
maternal transcript. Differential expression of the H19 transcript followed a 
similar trend as SNRPN, where 43% (3/7) had more maternal H19 transcript 
compared to the paternal transcript at morula stage. This differential expression 
rose to 75% (3/4) at blastocyst stage. Sixty percent (3/5) of the embryos at the 
cleavage stage showed differential expression favouring the maternal H19 
transcript. There was no statistical significance of differential parental 
expression of H19 when stage of embryo development was considered together 
(p=0.4; Figure 4.3). One embryo (embryo 83) was shown to have only the 
maternal copy of H19 by haplotype analysis (Table 4.4 and Figures 4.5, 4.7) 
which accounted for the detection of the maternal H19 transcript only in the 
SNaPshot assay. 
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Figure 4-5 Bar chart of differential gene expression analyses in embryos at cleavage, morula and blastocyst stages. 
a) b)
c) d)
 
a) Differential expression of ACTB showing similar expression levels at cleavage, morula and blastocyst stage embryos. b) Overall differential 
expression of SNRPN. It was shown that at cleavage and morula stages, almost half of the embryos preferentially expressed the paternal SNRPN 
transcript. As the embryos developed to the blastocyst stage, paternal SNRPN predominated the embryo. c) Overall differential expression of parental 
H19 transcripts. It was observed that in cleavage, morula and blastocyst stages, maternal H19 transcripts predominated the embryo. As the embryos 
developed to the blastocyst stage, the preferential expression of H19 transcript was considerably increased. d) Differential expression of BRCA1 in 
embryos. Differential expression of paternal BRCA1 transcript was more persistent at cleavage stage embryos compared to the morula and blastocyst 
stage embryos.  
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Figure 4-6 Differential parental expression analysis of SNRPN transcripts on cDNA from embryos examined at SNP rs75184959 by mini-
sequencing (SNaPshot™). 
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The couple ID and embryo numbers are shown at top of each panel separately. When the expression levels were low, an additional enlarged image 
within the same panel was placed. The peak height for each allele is also labelled. Black peak represents allele C and red allele T, respectively. The x-
axis shows the alleles detected at the SNP and the y-axis shows the peak heights. a) Embryos showing differential expression for the paternal transcript 
of SNRPN (including monoallelic expression of the paternal SNRPN). When both parental SNRPN transcripts were detected, the ratio of paternal to 
maternal SNRPN transcripts was shown to be more than or equal to 2:1.  b) Embryos showing differential expression for the maternal transcript of 
SNRPN, where the ratio of maternal to paternal SNRPN transcripts was shown to be more than or equal to 2:1. c) Embryos showing similar parental 
SNRPN expression, where the ratio of maternal to paternal SNRPN transcripts was approximately 1:1.  
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Figure 4-7 Differential parental expression analysis of H19 transcripts on cDNA from embryos examined at SNP rs11542721 by mini-sequencing 
(SNaPshot™). 
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The couple ID and embryo numbers are shown at top of each panel separately. The peak height for each allele is also labelled. Black peak represents allele C and 
red allele T, respectively. The x-axis shows the alleles detected at the SNP and the y-axis shows the peak heights. a) Embryos showing differential expression for 
the maternal H19 transcript (including monoallelic expression of the maternal H19). When both parental H19 transcripts were detected, the ratio of maternal to 
paternal H19 transcripts was shown to be 2:1 or higher. b) Embryos showing similar expression levels of parental H19 transcripts, where the ratio of maternal to 
paternal H19 transcript was approximately 1:1. 
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Two different SNPs were analysed to investigate differential expression of 
BRCA1, one located in exon 11 and one located in exon 12. However, in 16 
embryos the pattern of the differential expression of parental BRCA1 transcripts 
was not concordant at these two SNPs, such that an embryo with a preferential 
expression for the paternal BRCA1 transcript at one locus was observed to 
have a preferential maternal expression in the other locus analysed. Therefore, 
these embryos were excluded from the analysis. An additional two embryos 
were excluded from the analysis for BRCA1 since they were shown to have a 
gain of chromosome 17 (embryos 69 and 72) reflected by the differential 
expression favouring the paternal BRCA1 transcript by SNaPshot analysis.  
Overall, there was a significant differential parental expression for BRCA1 in 
different stages of preimplantation embryos (*p=0.03, Table 4.4). The 
differential expression of the paternal BRCA1 transcript was higher at cleavage 
stage embryos compared to the other stages (Figure 4.5). Sixty six percent 
(10/15) of the embryos arrested at the cleavage stage expressed the paternal 
BRCA1 transcript more compared to the maternal (Figure 4.8 and 4.9). This 
was reduced to 55% (10/18) of embryos at the morula and to 50% (7/14) at the 
blastocyst stage.  
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Figure 4-8 Differential expression analysis of parental BRCA1 transcripts with preferential paternal expression on cDNA from embryos by 
mini-sequencing (SNaPshot™). 
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The couple ID and embryo numbers are shown at top of each panel separately. When the expression levels were low, an additional enlarged image 
within the same panel was placed. The peak height for each allele is also labelled. Blue peak represents allele G, green is allele A, black is allele C and 
red is allele T, respectively. The x-axis shows the alleles detected at the SNP and the y-axis shows the peak heights. The paternal BRCA1 transcript 
was shown to be preferentially expressed, where the ratio of paternal to maternal BRCA1 transcripts was shown to more than or equal to 2:1. 
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Figure 4-9 Differential expression analysis of parental BRCA1 transcripts on cDNA from embryos examined by mini-sequencing (SNaPshot™). 
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The couple ID and embryo numbers are shown at top of each panel separately. The peak height for each allele is also labelled. Blue peak represents allele G, green 
is allele A, black is allele C and red is allele T, respectively. The x-axis shows the alleles detected at the SNP and the y-axis shows the peak heights. a) Embryos 
showing differential expression favouring the maternal BRCA1 transcript. The ratio of maternal to paternal BRCA1 transcripts was shown to be more than or equal to 
2:1. b) Embryos showing similar expression for BRCA1 transcript. The ratio of maternal to paternal BRCA1 transcripts was approximately 1:1. 
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Table 4-4 Summary of results for differential gene expression analysis in cDNA from embryos. 
Paternal Maternal Similar
ACTB 30 36.7 (11) 0 0 100 (11) 0 73.7 (14) 0 17 (5)
SNRPN 34 67 (23) 56.5 (13)* 17 (4) 26 (6) 0 32 (11) 0 0
H19 48 33 (15) 20 (2) 60 (9)* 13 (4) 6.25 (1) 17 (8) 0 50 (24)
BRCA1 75 64 (49) 58 (29) 19 (9) 22 (11) 4 (2) 14 (11) 10 (5) 0
% of embryos with aneuploidy in 
chromosomes of genes analysed 
(number of embryos)
% of embryos showing 
differential expression favouring: 
(number of embryos)
% of embryos with inconclusive 
result due to uninformativity of 
the SNP analysed (number of 
embryos)
Genes 
analysed
Number of 
embryos 
included for the 
study
% embryos with 
amplification failure 
(number of embryos)
%  of embryos with 
ADO (number of 
embryos)
% of informative 
haplotypes (number 
of embryos)
 
 
The genes analysed for differential expression, percentage of informative haplotypes where each parental allele was distinguished, percentage of embryos with 
differential gene expression favouring the paternal and maternal transcripts and embryos that were excluded from the analysis due to the aneuploidy status, 
uninformative state of SNP or amplification failure, were listed. BRCA1 was analysed at two SNPs and the results shown here were collective from both SNPs. In ten 
embryos differential expression of BRCA1 at two SNP sites did not agree and these were not included in the analysis. *Only the paternal expression of SNRPN was 
observed in 9/13 embryos and only the maternal expression of H19 was observed in 7/9 embryos. 
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4.1.4 Assay sensitivity 
Mini-sequencing analysis, SNaPshot assay, used for the quantification of 
differential parental expression, was validated by real time PCR. Additional 
validation involved aneuploidy screening for chromosomes 7, 11, 15 and 17 by 
haplotyping and aCGH to verify that the observed differential expression 
between the parental transcripts was not due to any gain or loss of the 
chromosome in the embryo. The final validation involved analysis of the 
methylation status of ACTB, H19 and BRCA1 in the embryos that were shown 
to have a differential gene expression. 
4.1.4.1 Real time PCR quantification 
cDNA from all the embryos showing differential parental expression for any of 
the genes analysed (ACTB, SNRPN, H19 and BRCA1) were quantified by real 
time PCR. The Cq values represent the start of the exponential phase and 
ranged from 32 to 44 with the mean of 36 for ACTB, 34 for SNRPN, 41 for H19 
and 35 for BRCA1, respectively (Figure 4.10, Appendix 7.3.1.3). Therefore real 
time PCR analysis confirmed that after the initial PCR (40 cycles) prior to mini-
sequencing analysis, the samples were still at the exponential phase and 
examination of correct differential analysis had been performed. 
Figure 4-10 Quantitative analysis of ACTB in duplicate sample. 
Cq= 34.6
Cq= 35.1
 
Cq value of the same sample in duplicate is shown. The two Cq values of the duplicate samples 
are relatively close, 
 
 Results for differential allelic expression and embryo development 
 
163 
 
4.1.4.2 Aneuploidy screening 
Informative short tandem repeat polymorphic markers were identified between 
partners for chromosomes 7, 11, 15 and 17 (Appendix 7.3.1.4). The number of 
embryos analysed and the details of heterozygosity of the embryos for all the 
chromosomes analysed are listed in table 4.5. The copy number of 
chromosome 11 could not be verified in the embryos obtained from three 
couples since there were no informative polymorphic markers. Similarly copy 
number of chromosome 15 could not be verified in embryos obtained from three 
couples and copy number of chromosome 17 in embryos obtained from one 
couple, respectively. Three out of twenty one embryos that could not be 
analysed for the copy number of chromosome 11 by PCR were analysed by 
aCGH and the normal copy number of this chromosome was confirmed. 
Similarly, for 5/20 embryos where the copy number of chromosome 15 could 
not be verified by PCR were shown to be euploid for chromosome 15 by aCGH. 
A total of 26 embryos were analysed by aCGH. Twelve embryos were shown to 
be euploid and the rest of the embryos showed various aneuploidies where two 
embryos (embryo number 69 and 72) were shown to have a gain of 
chromosome 17 (Figure 4.11). These embryos were excluded from the 
differential expression analysis. Aneuploidy rate in embryos with BRCA 
mutations were at similar level with the aneuploidy rate in embryos with no 
known BRCA mutations. 
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Table 4-5 Summary of results for haplotype analysis for the chromosomes of 7, 11, 15 and 17 in cDNA from embryos. 
 
Chromosomes 
analysed
Number of 
embryos included 
for the study
% of informative 
haplotypes (number 
of embryos)
% of heterozygous embryos 
(number of embryo)
% of homozygous 
embryos with ADO 
(number of embryo)
% of embryos with inconclusive 
result due to uninformative 
polymorphic locus (number of 
embryo)
% of embryos with 
amplification failure 
(number of embryo)
7 30 86.7 (26) 86.7 (26) 0 0 13 (4)
11 34 53 (18) 94 (17) 3 (1) 21 (7) 26 (9)
15 48 25 (12) 91 (11) 9 (1) 71 (34) 4 (2)
17 75 68 (51) 94 (48) 6 (3) 4 (3) 19 (21)  
Table summarises information for aneuploidy screening for four chromosomes (7, 11, 15 and 17) by haplotype analysis. Percentage of informative haplotypes, 
where each parental allele was distinguished, percentage heterozygote and homozygote embryos and embryos excluded from haplotyping analysis are 
summarised. 
 
 
 
 
 
 
 Results for differential allelic expression and embryo development 
 
165 
 
Figure 4-11 Array CGH profiles for two embryos. 
 
Panel a: 
    
 
Panel b: 
 
Aneuploidy screening was analysed by aCGH. Panel a shows a euploid embryo, number 68, 
and panel b represents embryo 69 with a gain of chromosome 17. 
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4.1.4.3 Differential methylation analysis 
Methylation analysis was performed to confirm the differential gene expression 
in a subset of embryos by methylation specific PCR following bisulfite 
conversion. Due to insufficient starting material, the amount of DNA obtained 
from a single embryo, and bisulfite treatment being deleterious for DNA, 
sequencing analysis on the converted DNA could not be performed. Promoter 
regions of three genes, ACTB, H19 and BRCA1, were amplified by nested PCR 
as described in section 2.3.2.11.4. When monoallelic expression of one parental 
transcript was observed by SNaPshot analysis, a hemi-methylated profile 
should be observed since only one parental transcript is present. When both 
parental transcripts were expressed at similar levels by SNaPshot analysis, an 
unmethylated profile should be observed representing both parental transcripts 
at similar levels.  
Methylation analysis of ACTB in five embryos (embryo numbers 8, 11, 12, 13 
and 14) showed that these embryos were homogenously unmethylated. 
Therefore methylation profile of ACTB confirmed the expression profile 
observed by SNaPshot analysis showing similar expression levels of parental 
transcripts.  
The methylation status of H19 was analysed in eight embryos. Methylation 
analysis of embryos 2 and 74 showed that these embryos were hemi-
methylated. Methylation status of these two embryos confirmed the SNaPshot 
analysis that only showed the maternal transcript of H19. For embryo 82, an 
unmethylated profile was observed. This was reflected by the equal parental 
H19 transcripts observed by SNaPshot analysis. Therefore, methylation 
analyses of these three embryos (embryos 2, 74 and 82) confirmed the 
expression profiles of H19 transcripts determined by SNaPshot analysis. 
However, in five embryos (embryo numbers 19, 30, 39, 79 and 80), differential 
expression and methylation analyses were not concordant. Four embryos 
(embryos 19, 30, 79 and 80) were shown to have an unmethylated profile where 
 Results for differential allelic expression and embryo development 
 
167 
 
three were observed to be monoallelic for the maternal H19 transcript and one 
was differentially expressed by SNaPshot analysis. One embryo (embryo 39) 
was shown to be fully methylated, whereas SNaPshot analysis showed that this 
embryo expressed only the paternal copy of H19.  
The methylation status of BRCA1 was analysed in 31 embryos. Fifty eight 
percent of the embryos (embryo numbers 1, 2, 9, 13, 14, 15, 19, 20, 26, 30, 36, 
38, 65, 70, 74, 76, 80 and 82) were successfully analysed and BRCA1 was 
shown to be hemi-methylated in all the embryos confirming the differential 
expression of parental transcript observed by SNaPshot analysis (Figure 4.12). 
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Figure 4-12 Agarose gel electrophoresis of embryos showing partial methylation for a) 
H19 and b) BRCA1. 
a) b)
 
Lanes 1 for images a) and b) represent 100 base pair ladder and the rest of the lanes represent 
the methylation PCR product results of DNA obtained from embryos following bisulfite 
conversion. Embryo numbers are labelled for each lane and the PCR directed towards the 
methylated DNA is represented as “methylated” and the unmethylated DNA as “unmethylated”. 
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Developmental stage of embryos with BRCA mutations 
The developmental progression of 16 embryos with paternally inherited BRCA 
mutations and 15 with maternally inherited BRCA mutations were analysed on 
day 5/6 post fertilisation (Table 4.6). It was shown that half of the embryos 
(8/16) with paternally inherited BRCA mutations were arrested at the cleavage 
stage on day 5/6 post fertilisation. Of these embryos, only 12.5% (2/16) reached 
to the blastocyst stage. Embryos with maternally inherited BRCA1 mutations 
developed at a significantly greater rate compared to the embryos with 
paternally inherited BRCA mutations (Figure 4.13). Fifty three percent of the 
embryos with maternally inherited BRCA1 mutations reached to blastocyst 
stage on day 5/6 post fertilisation.  
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Table 4-6 Patient and embryo details used for the analysis of developmental progression. 
Patient Disorder
Affected 
partner
Embryo 
ID
Morphology on day 5/6
1 Premorlula
96 3 cells
2 Morula
3 Vaculated with distinct cells
4 6 cells
97 Hatching blastocyst
98 6 cells
99 4 cells
7 15 cells
8 10 cells
10 Morula ~20 cells
11 15 cells
12 Morula ~20 cells
13 Pre-morula ~20 cells
15 Morula
18 Blastocyst
100 Blastocyst
101 Blastocyst
102 Blastocyst
103 5-7 cells
104 5-7 cells
105 Morula
106 Blastocyst
107 Fragmented morula
108 Blastocyst
109 Hatched blastocyst
110 8 cells, degenerate
111 Hatched Blastocyst
112 Fragmented morula
113 Blastocyst
114 4 cells
45 BRCA1 Female
46 BRCA1 Female
32 BRCA2 Male
44 BRCA1 Female
29 BRCA1
Male
30 BRCA1 Male
 
Couple and embryo IDs, disorder, the affected partner and developmental stages of the 
embryos on day 5/6 post fertilisation are listed. All the embryos were shown to carry the 
mutation following PGD for BRCA1 or BRCA2. The developmental progression of the embryos 
with paternally inherited BRCA mutations were compared to the embryos with maternally 
inherited BRCA mutations on day 5/6 post fertilisation. 
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Figure 4-13 Developmental stage of embryos carrying paternally inherited BRCA 
mutations compared to maternally inherited BRCA mutations. 
 
 
Developmental stage of embryos with BRCA mutations were analysed by Chi squared test. 
Significantly fewer embryos developed to the later stages of preimplantation development 
(morula and blastocyst stages) on day 5/6 post fertilisation compared to the embryos carrying 
maternally inherited mutations (*p=0.01). It was observed that more embryos with paternally 
inherited BRCA mutations were arrested at the cleavage stage, whereas more embryos with 
maternally inherited BRCA mutations reached to the blastocyst stage. 
 
 
4.1.5 Summary of differential parental gene expression analysis 
Technical aspects 
- Extraction of RNA and DNA and synthesis of cDNA from a total of 95 
embryos obtained from couples undergoing PGD was successfully 
performed. 
- Sequencing analysis identified five couples who were informative for an 
SNP within ACTB, eight couples for H19, eight couples for SNRPN and 
ten couples for BRCA1, respectively. 
- Semi-quantitative analysis of differential parental gene expression was 
performed successfully by targeting the informative SNPs in the 
embryos.  
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- The sensitivity of the SNaPshot assay was validated by performing real 
time PCR on the cDNA samples which confirmed that after the initial 
PCR, cDNA obtained from the embryos were still at an exponential 
amplification phase. To further validate the assay, aneuploidy status of 
the chromosomes 7, 11, 15 and 17 were investigated and three 
aneuploid embryos for these chromosomes were excluded from the 
analysis.  
Biological aspects 
- Table 4.7 summarises the differential expression patterns observed for 
ACTB, SNRPN, H19 and BRCA1 in human embryos. Methylation status 
of a subset of these embryos was also summarised for ACTB, H19 and 
BRCA1. The developmental stage of embryos carrying maternally 
inherited and paternally inherited BRCA mutations was also summarised. 
Table 4-7 Summary table for gene expression and developmental progression analyses. 
Parental 
origin
ACTB SNRPN H19 BRCA1
Methylation 
status
ACTB H19 BRCA1 Stage
Maternal 
origin
Paternal 
origin
Similar 100 26 26 11 Unmethylated 100 62.5 - Cleavage 27 50
Maternal - 17 60 19 Methylated - 12.5 - Morula 20 37.5
Paternal - 57 13 58
Hemi- 
methylated
- 25 100 Blastocyst 53 12.5
Differential parental expression levels of (%) Methylation analysis (%) Developmental stage in BRCA 
affected embryos depending on 
 
Similar levels of parental transcripts for the house keeping gene, ACTB, were observed in the 
preimplantation embryos. Both parental transcripts of the imprinted genes, SNRPN and H19, 
were observed in a number of embryos. Overall, there was a significant difference in the 
differential parental expression favouring the paternal transcript of SNRPN in embryos at 
cleavage, morula and blastocyst stages. However, the difference in differential parental 
expression of H19 was not significant. At the early stages of preimplantation embryo 
development, it was shown that there is a differential expression of BRCA1. This preferential 
expression was reduced as the embryos reached to blastocyst stage. Methylation analysis by 
bisulfite conversion followed by methylation specific PCR confirmed the expression pattern 
obtained by SNaPshot analysis for ACTB in 5/5 embryos, H19 in 3/8 embryos and BRCA1 in 
18/18 embryos. Significantly more embryos with maternally inherited BRCA mutations 
developed to the later stages of preimplantation development (up to the blastocyst stage) 
compared to the embryos carrying paternally inherited BRCA mutations. 
Discussion for differential allelic expression and embryo development 
 
173 
 
4.2 Discussion 
Differential methylation of parental genomes was observed in mouse 
preimplantation embryos (Dean et al., 2003, Tamaru and Selker, 2001, Jackson 
et al., 2002, Fuks et al., 2003). Studies investigated mono-allelic expression of 
imprinted genes in mice (Ferguson-Smith et al., 1993, Szabo and Mann, 1995, 
Smith et al., 2012) with a limited number of studies in human embryos (Monk 
and Salpekar, 2001, Huntriss et al., 1998, Adjaye et al., 1999). However, 
differential expression of other genes, such as repair genes, in embryos has not 
been analysed widely. 
In the second part of this project differential expression of one housekeeping 
gene (ACTB), two imprinted genes (SNRPN and H19) and one double strand 
break repair gene (BRCA1) was investigated in preimplantation embryos. A 
further analysis focused on the embryos with BRCA mutations to investigate if 
the embryo development is affected by the sex of the partner passing on the 
mutation. 
4.2.1 Differential expression 
Analysis of differential parental gene expression in embryos required a 
polymorphism where paternal and maternal alleles could be distinguished. To 
identify informative polymorphisms between each partner the exonic regions of 
genes of interest from patients undergoing PGD were screened by sequencing. 
One of the main difficulties in this study was finding a heterozygote 
polymorphism that allowed parental allelic discrimination. Once the informative 
SNPs were identified for the couples, semi-quantitative analysis targeting these 
SNPs in the embryos was carried out by mini-sequencing (SNaPshot) assay.  
A total of 95 embryos were analysed to investigate the differential parental 
expression in four genes. Transcripts of ACTB, SNRPN, H19 and BRCA1 were 
detected at all stages of preimplantation development. Thirteen embryos with 
BRCA mutations and 82 with no mutations or other mutations; MLH1, NF1, 
RB1, Men2b, APC, PRKAR1A and DMPK; were analysed to investigate the 
differential parental expression of the four genes. The parental transcripts of the 
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house-keeping gene ACTB were shown to be at similar levels in 11/11 at 
different stages of preimplantation embryo development. 
4.2.1.1 Imprinting analysis 
Differential gene expression of two imprinted genes SNRPN (maternally 
imprinted) and H19 (paternally imprinted) was analysed in this study. Imprinted 
genes are expressed in a parent of origin manner, where only the paternal 
transcripts of the maternally imprinted genes or the maternal transcripts of the 
paternally imprinted genes were expected to be expressed in the embryos. 
Differential expression of the SNRPN favouring the expression of paternal copy 
was detected in the majority of the embryos (*p=0.01; 56.5%, 13/23) analysed. 
Expression of the maternal copy of SNRPN was observed in 71% (14/23) of the 
embryos consisting of 4-10 cell, morula and blastocyst stage embryos. The 
origin of this expression may be due to an incomplete degradation of the 
maternal transcript from the oocyte. Previous studies also showed that SNPRN 
expression is detected in human oocytes and embryos. However, mono-allelic 
expression of the paternal allele was observed by the 4-cell stage (Monk and 
Salpekar, 2001, Huntriss et al., 1998).  
Contradictory results for the expression of H19 in the human oocytes and 
preimplantation embryos have been reported. Some studies have shown 
expression of both parental alleles in slow growing embryos or morphologically 
poor embryos (Ibala-Romdhane et al., 2011). Although one study showed 
expression of H19 in one out of five blastocysts, H19 transcripts were not 
detected in cleavage stage embryos (Monk and Salpekar, 2001). This explains 
the low detection levels of H19 transcripts in the embryos analysed in this study. 
In the embryos where H19 was detected, 60% (9/15) showed an increased 
maternal H19 transcript with 78% (7/9) being strictly monoallelic (p=0.4). Similar 
to the SNRPN, some embryos showed both parental transcripts of H19. The 
embryos showing paternal alleles could be due to the partial resetting of the 
imprints in the sperm (Ibala-Romdhane et al., 2011).  
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Studies have suggested that developmentally delayed embryos show an 
unexpected expression and methylation profile (Ibala-Romdhane et al., 2011). 
In this study, embryos with similar parental expression of H19 (embryos 43 and 
82) and SNRPN (embryos 3, 17, 26, 27, 28, 43, 87, 88 and 89) developed at a 
slower rate where seven embryos were between 5-10 cell stage and two at 
morula stage on day 5/6 post fertilisation. Additionally, none of the embryos that 
reached to the blastocyst stage showed similar parental expression for these 
two imprinted genes. This observation was supported, such that the slow 
developing embryos were shown to have a balanced pattern of methylated and 
unmethylated strands of H19DMR (Khoueiry et al., 2012).   
The time of monoallelic expression of the imprinted genes was reported to vary 
during preimplantation embryo development (Huntriss et al., 1998). Expression 
of both parental transcripts of the imprinted genes could be due to the late onset 
of the monoallelic expression of these genes. This could be embryo specific 
such that the monoallelic expression may vary between embryos or in human 
preimplantation embryos this may be at a later stage which was observed in 
some of the imprinted genes in humans, such as IGF2, SNPRN and MEST 
(Huntriss et al., 1998, Lighten et al., 1997).  
4.2.1.2 BRCA1 expression 
Identifying SNPs where couples were informative (heterozygote or homozygote 
for different alleles) were proved to be difficult. Mainly one partner was 
heterozygote and the other partner was homozygote sharing one allele. 
Therefore some embryos were excluded from the analysis since only the 
shared allele was detected following mini-sequencing (SNaPshot) analysis. In 
order to investigate parental differential expression of BRCA1 in these embryos, 
two different SNPs located on exon 11 and exon 12 were shown to be 
informative and included in the analysis. However, ten embryos were excluded 
from the analysis since differential expression of parental BRCA1 did not agree 
between these two SNPs analysed within exons 11 and 12 of BRCA1, 
respectively. In 3/10 embryos with differential parental BRCA1 profile within the 
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two exons the female partner was heterozygote. The difference observed in the 
parental expression at two exons could be due to maternal mRNA that is still in 
the process of degradation. This difference could also be caused by alternative 
splicing of BRCA1, which was shown to have multiple isoforms skipping exon 5, 
exons 2-10, exons 9-11, exon 11 only (Δ11), exons 14-17 and exons 14-18 
(Tammaro et al., 2012, Orban and Olah, 2003, Lixia et al., 2007, Wilson et al., 
1997). If one of these spliced isoforms of BRCA1 involving/excluding exon 11 
were present in the embryos, this may cause the failure of amplification in exon 
11, such as in embryo number 27, and led to altered differential expression 
profiles between exon 11 and 12. Additionally, studies showed that alternate 
spliced forms of mRNAs may introduce new miRNA binding sites for their target 
mRNAs leading to unusual regulation and therefore expression of mRNAs 
(Salmena et al., 2011). Expression of only the spliced form of exon 11, Δ11, 
was shown to be embryonic lethal in mouse embryos (Ludwig et al., 1997) and 
over-expression of this mRNA led to apoptosis due to failure of mitosis 
(Bachelier et al., 2002). Additionally embryos with full length BRCA1 transcripts 
were shown to repress several genes that were not observed in the embryos 
with the Δ11 isoform (Tammaro et al., 2012). 
SNaPshot assay sensitivity 
Previous studies validated the use of allele peak heights at an SNP site to 
investigate the allelic imbalance for BRCA1 and BRCA2 (Caux-Moncoutier et 
al., 2009). Additional validation was carried out in this project. Real time PCR 
confirmed that the samples were evaluated at a quantitative state and therefore 
the differential expression observed was not due to an amplification bias. The 
chromosome copy number of the genes analysed was detected to ensure that 
the detected differential expression was not due to an aneuploidy in embryo. 
The aneuploidy rate of 26 embryos was analysed by aCGH and the rate of 
aneuploidy incidence was investigated in embryos with BRCA mutations. It has 
been reported that embryos with mutations in double strand break repair genes 
may lead to an increased aneuploidy rate (Fragouli and Wells, 2012). However, 
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in this study no correlation was observed for the aneuploidy rate in embryos 
with BRCA mutations. A subset of embryos were analysed for the methylation 
status of BRCA1 and all these embryos were hemi-methylated. Therefore, 
differential expression of parental genome may be due to the methylation 
mechanism of BRCA1. Sixty two percent (5/8) of the embryos analysed for the 
methylation status of H19 were not concordant with the differential expression 
analysis by SNaPshot assay. This conflict may be caused by other factors 
affecting both the expression and methylation status of the imprinted genes, 
such as miRNA regulation and acetylation (Huang et al., 2011). 
4.2.2 Development stage of embryos with BRCA mutations 
Embryos with paternally inherited mutations were shown to develop significantly 
slower compared to embryos with maternally inherited mutations. This may be 
due to the methylation status of the embryos at the early stages of 
preimplantation embryo development. Since the paternal genome undergoes a 
rapid demethylation starting at the early stages of preimplantation embryos, 
embryos with paternally inherited BRCA mutations and defective homologous 
recombination repair pathway may be prevented from developing to the later 
stages of preimplantation development. However, embryos with maternally 
inherited BRCA mutations may compensate with the mutation due to the 
presence of the paternal genome with no mutation present in the early 
developing embryo that can initiate the homologous recombination repair. 
4.2.3 Conclusion and future perspectives 
This preliminary study showed that SNRPN, H19 and BRCA1 were differentially 
expressed in preimplantation embryos. Further studies will involve analysis of 
other genes including repair genes and control genes to confirm the differential 
expression. 
It was observed that if an embryo carried paternally inherited BRCA mutation, 
this affected the developmental progression of the embryo to a greater extent 
than a maternally inherited BRCA mutation. This suggests that when the 
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paternal transcript present in the embryo carries a mutation, the embryo is more 
vulnerable to stress due to rapid demethylation of the paternal genome and the 
gradual demethylation of the maternal genome. Therefore they are more likely 
to undergo abnormal development. Further extrapolation of this data suggests 
that the risk of transmitting a BRCA mutation may be modulated by the parental 
origin of the mutation. Further studies with increased sample size will be carried 
out. It would also be interesting to analyse the developmental progression of 
other embryos with mutations in other double strand break repair genes and 
other repair genes. 
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5. Results and Discussion 
Functional assay development for mismatch repair 
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5.1 Results 
Aims summary 
Expression and proteomic studies were performed in human oocytes and 
blastocysts. However presence of a transcript or protein does not show that 
these transcripts and proteins are functionally active. Therefore, functional 
studies play a significant role in determining which pathways are capable of 
performing DNA repair in oocytes and embryos. The aim of the last part of this 
study was to develop a sensitive functional assay to measure the mismatch 
repair efficiency in oocytes and blastocysts. Heteroduplex constructs were 
formed using long oligonucleotides (5.1.1) and the repair of this heteroduplex to 
homoduplex was assessed semi-quantitatively by SNaPshot assay. The repair 
efficiency was estimated by calculating the peak height ratio of the repaired 
sequence of the homoduplex to the unrepaired sequence of the heteroduplex. 
5.1.1 Formation of nicked and non-nicked homo/heteroduplexes 
Two forward oligonucleotides with the same sequence but different alleles at 
the SNP site rs1981929 (allele G for one sequence of 180 bases and allele A 
for the other sequence of 180 bases) and a complementary sequence of 180 
bases with the allele T corresponding to the MSH2 SNP site rs1981929 were 
designed. Homo/heteroduplexes were constructed using these complementary 
sequences.  
A nicked homo/heteroduplex molecule was also constructed to investigate if 
mismatch repair is nick-directed. A nicked heteroduplex was constructed using 
the G sequence of 180 bases and two complementary sequences; Ta of 55 
bases and Tb of 125 bases (Table 2.10).  
Prior to mismatch repair reaction, successful formation of the 
homo/heteroduplexes was confirmed by detecting the alleles at the SNP site by 
mini-sequencing (SNaPshot™) using two different conditions to ensure that the 
correct sequences was used to form the construct and to ensure that one 
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sequence was not present in excess compared to the other (Section 2.3.2.1). In 
the denatured samples the alleles at the SNP site rs1981929 of the 
homo/heteroduplex constructs were observed, such that alleles C and A were 
detected for the G-T heteroduplex and A and T alleles for the A-T homoduplex, 
respectively. However, when the samples were not denatured, alleles at the 
SNP site rs1981929 were only detected if there was excess sequence present 
in the mixture. This analysis showed small peaks for sequence G 
(corresponding to C allele in SNaPshot assay) in the heteroduplex construct 
mixture and sequence A and T in the homoduplex mixture indicating some 
excess sequences in the mixture (Figure 5.1). However since the excess 
sequences were present in minute amounts, they were negligible. This ensured 
that when the repair efficiency was assessed, if any sequences from the 
heteroduplex construct were detected, these were due to the unrepaired 
heteroduplex constructs and not because of an excess of sequence from the 
heteroduplex construct. 
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Figure 5-1 Analysis of correct formation of homo/heteroduplex constructs using two 
different mini-sequencing (SNaPshot) conditions. 
A(3824)
C(2003)
C(119)
A(4633)
T(4956)
A(125)
T(183)
a)
c)
b)
d)
 
Confirmation of a) heteroduplex and b) homoduplex formation by SNaPshot assay by three 
cycles of denaturation, annealing and extension steps. This condition ensured that the correct 
sequences were used for the formation of hetero/homoduplex constructs. Confirmation of c) 
heteroduplex and d) homoduplex formation by optimised SNaPshot cycling conditions excluding 
the initial denaturation step followed by three cycles annealing and extension steps at low 
temperatures. These confirmed that there were no excess sequences in the reaction mixture 
was only a small amount of unused sequence left following the hetero/homoduplex construct 
formation. Since the C sequence was present at low levels, an additional enlarged image was 
included (panel c). For both heteroduplex and homoduplex constructs, mini-sequencing 
(SNaPshot) analysis showed that a small amount of excess sequence is left in the reaction. The 
peak height of sequence C which represents the approximate amount of the excess strand was 
only 119 (panel c), 183 for sequence T and 125 for sequence A (panel d), respectively. 
 
5.1.2 Functional assay development for mismatch repair 
5.1.2.1 Use of commercially available nuclear extracts 
The repair efficiency was assessed by exposing the nicked and non-nicked 
homo/heteroduplexes to the nuclear extracts (HeLa S3 and LoVo carrying an 
MSH2 mutation, Active Motif, Ca) as described in section 2.4.2.1. Since HeLa 
nuclear extract is known to repair mismatches, with the correct reaction 
conditions, such as concentration of constructs and extracts and correct 
incubation time, repair of heteroduplex to homoduplex should be observed. 
Different concentrations of nicked homo/heteroduplexes (3.33-0.33µM final in 
the mismatch repair reaction) were exposed to 14-1.33µg nuclear extracts (final 
Results for functional assay development for mismatch repair 
 
183 
 
in the mismatch repair reaction) for 1 to 23 hours. These conditions and the 
results are shown in figure 5.2, 5.3 and table 5.1.  
Repair of both nicked G-Tn and non-nicked G-T heteroduplex to G-C 
homoduplex was detected in one hour using 13.35µg of nuclear extract. As the 
concentration of the nuclear extract was lowered, the repair efficiency was 
reduced. As expected as the time of incubation increased, the repair efficiency 
was also increased, such that when the time of incubation was increased to 3, 6 
(Figure 5.3), 15 and finally to 23 hours, the repair efficiency was improved even 
using as small as 1.33µg nuclear extracts. Higher concentrations of nuclear 
extract and/or higher incubation time were required for the mismatch repair 
deficient LoVo extract (100% repair efficiency with1.43 g HeLa nuclear extract 
for 23 hours) to repair the heteroduplex with similar efficiencies as the HeLa 
nuclear extract (100% repair efficiency with1.33 g HeLa nuclear extract for 15 
hours). 
Figure 5-2 Mini-sequencing (SNaPshot) analysis panels examining the mismatch repair 
efficiency of G-Tn after nuclear extract exposure for 1, 3 and 6 hours. 
a) b) c)
G(10)
A(2495)
C(923)
A(3676)C(1851)
G (5035)
A(7322)C(7055)
A(7426)
G(6104)
A(7512)C(7132)
A(7194)C(7194)
i)
iii)
i)
iii)
i)
iii)
GTn, 1 hour GTn, 3 hours GTn, 6 hours
HeLa
No extract
C(7004)
G(57)
A(4541)
C(2005)
G(4618)
A(7319)C(7055)
G (4398)
A(7443)
C(7093)
ii) ii) ii)LoVo
 
Black, blue and green peaks represent the C, G and A alleles, respectively. The peak heights 
(corresponding to the fluorescence intensity) are shown in parenthesis. (a)-(c) i. SNaPshot™ 
analysis of G-Tn exposure to HeLa nuclear extract for 1, 3 and 6 hours, respectively. (a)-(c) ii. 
SNaPshot™ analysis of G-Tn exposure to LoVo (mismatch repair deficient) nuclear extract for 
1, 3 and 6 hours, respectively. (a)-(c) iii. SNaPshot™ analysis of G-Tn incubated in the absence 
of any nuclear extracts for 1, 3 and 6, respectively. As the time of incubation increased, the 
mismatch repair efficiency was also increased observed by the higher peak heights. Repair in 
the presence of HeLa nuclear extract was increased compared to the mismatch repair in the 
presence of LoVo nuclear extract. 
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Table 5-1 Summary of all the mismatch repair reactions by HeLa and LoVo nuclear 
extracts. 
a) Summary table of repair efficiency of heteroduplex construct to homoduplex after HeLa 
nuclear extract exposure 
Heteroduplex 
construct
Concentration of 
constructs (µM)
Concentration of 
HeLa (µg)
Time of 
incubation 
(hours)
Repair 
efficiency 
(Repaired/ 
unrepaired)
GTn 3.33 13.35 1 5%
GTn 1.67 13.35 1 1%
GTn 1.67 10.05 1 3%
GTn 1.67 6.75 1 17%
GTn 1.67 3.3 1 19%
GTn 1.67 1.95 1 1%
GT 1.67 1.33 1 0%
GTn 1.67 1.33 1 0%
GTn 1.67 1.33 3 70%
GTn 1.67 1.33 6 80%
GTn 1.67 1.33 15 100%
GTn 0.83 1.33 23 0%
GT 0.83 1.33 23 22%
GTn 0.67 1.33 23 4%
GT 0.67 1.33 23 50%
GTn 0.33 1.33 23 5%
GT 0.33 1.33 23 13%  
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b) Summary table of repair efficiency of heteroduplex construct to homoduplex after LoVo 
nuclear extract exposure 
Heteroduplex 
construct
Concentration of 
constructs (µM)
Concentration of 
LoVo (µg)
Time of 
incubation 
(hours)
Repair 
efficiency 
(Repaired/ 
unrepaired)
GTn 3.33 14.4 1 6%
GTn 1.67 14.4 1 0%
GTn 1.67 10.8 1 4%
GTn 1.67 7.2 1 42%
GTn 1.67 3.6 1 29%
GTn 1.67 2.1 1 9%
GT 1.67 1.43 1 0%
GTn 1.67 1.43 1 1%
GTn 1.67 1.43 3 64%
GTn 1.67 1.43 6 71%
GTn 1.67 1.43 15 99%
GTn 0.83 1.43 23 100%
GT 0.83 1.43 23 27%
GTn 0.67 1.33 23 4%
GT 0.67 1.33 23 10%
GTn 0.33 1.33 23 4%
GT 0.33 1.33 23 13%  
a) Summary table of repair efficiency of heteroduplex construct to homoduplex after HeLa 
nuclear extract exposure. b) Summary table of repair efficiency of heteroduplex construct to 
homoduplex after LoVo (mismatch repair deficient) nuclear extract exposure. In order to find the 
optimal concentrations of heteroduplex constructs and nuclear extracts with correct incubation 
times, series of optimisation experiments were performed. These tables summarise the final 
concentrations of nicked and non-nicked heteroduplex constructs, (a) HeLa and (b) LoVo 
nuclear cell extract concentrations and time of exposure for the mismatch reaction. The 
efficiency of mismatch analysed by SNaPshot™ reaction was shown as a percentage of the 
ratio of repaired/unrepaired sequence of the heteroduplex. GT represents the non-nicked 
heteroduplex complex and GTn represents the nicked heteroduplex constructs. 
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Figure 5-3 Scatter plot summarising different concentration of heteroduplex (G-T) and 
nuclear extracts HeLa and LoVo and time of incubation against percentage of repair 
ratios. 
a) Scatter plot of HeLa nuclear extract concentration and repair efficiency of 
heteroduplex construct 
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b) Scatter plot of LoVo nuclear extract concentration and repair efficiency of 
heteroduplex construct 
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Optimisation results for mismatch repair assay using a) HeLa and b) LoVo nuclear cell extracts 
are shown in a scatter plot. The x-axis represents the concentration of extracts and the y-axis 
represents the percentage of repair ratio (percentage of repaired sequence/unrepaired 
sequence). Concentration of heteroduplex constructs and time of incubation for each data point 
are labelled. As the concentration of construct was decreased, the repair efficiency was also 
decreased. However, the repair efficiency was increased as the time of incubation was also 
increased. It was observed that although for some conditions, the repair efficiency of the 
mismatch repair deficient LoVo nuclear extract was similar with the HeLa nuclear extract, 
generally the repair efficiency was higher for HeLa nuclear extracts. 
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To ensure that exposing heteroduplex constructs to nuclear extracts in 
mismatch repair reagents for long hours does not cause any degradation of 
both the heteroduplex sequences and the nuclear extracts, a control sample, 
homoduplex, was constructed. The same reaction conditions were also applied 
to this homoduplex, such that the nicked (A-Tn) and non-nicked (A-T) 
homoduplex constructs were exposed to the nuclear extracts of the same 
concentration and incubation time. Figure 5.4 illustrates the SNaPshot™ 
analysis after the exposure of A-Tn homoduplex to nuclear extracts for 3 and 15 
hours showing A and T alleles (corresponding to T and A sequences, 
respectively). No degradation of the sequences observed. 
 
Figure 5-4 Mini-sequencing (SNaPshot) analysis panels examining the mismatch repair 
efficiency of A-Tn after nuclear extract exposure for 3 and 15 hours. 
a) b)
A(7289)T(7162)
A(7302)T(7207)
A (7383)T(7131)
A(9747)T(4146)
A(4945)T(3565)
A(7347)T(7140)
i)
ii)
iii)
i)
ii)
iii)
HeLa
LoVo
No extract
ATn, 3 hours ATn, 15 hours
 
Red and green peaks represent the T and A alleles, respectively. The peak heights 
(corresponding to the fluorescence intensity) are shown in parenthesis. (a) and (b) i. 
SNaPshot™ analysis of A-Tn after 3 and 15 hours of HeLa nuclear extract exposure showing 
the T and A alleles, respectively. (a) and (b) ii. SNaPshot™ analysis of A-Tn after 3 and 15 
hours of LoVo nuclear extract exposure showing the T and A alleles, respectively. (a) and (b) iii. 
SNaPshot™ analysis of A-Tn after incubation for 3 and 15 hours in the absence of nuclear 
extracts showing the T and A alleles, respectively. 
 
5.1.2.2 Use of commercially available whole cell extracts 
The aim of this project was to assess mismatch repair efficiency in oocytes and 
blastocysts. Since obtaining nuclear extracts from these samples are difficult, 
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the mismatch repair reaction was optimised using commercially available whole 
cell extracts. The nicked and non-nicked homo/heteroduplexes were exposed to 
HeLa whole cell extract (Table 5.2, Figures 5.5 and 5.6). Different 
concentrations of G-Tn and G-T heteroduplexes (0.83-0.33µM) were exposed to 
5-2.5µg HeLa whole cell extract for 23 hours, respectively. As shown in figure 
5.6, as the concentration of G-T was decreased, the repair efficiency was also 
decreased. The optimisation conditions are listed in table 5.2. 
Figure 5-5 Mini-sequencing (SNaPshot) analysis panels examining the mismatch repair 
efficiency of G-T heteroduplex at different concentrations of commercially available 
whole cell extract. 
b)
i)
ii)
c)
i)
ii)
0.67 µM GT, 23 hours 0.33 µM GT, 23 hours
a)
i)
ii)
0.83 µM GT, 23 hours
A(7343)
C(3718)
C(4354)
A(7313)
C(6017)
A(7276)
G(414)
A(7228)
C(5651)
C(5989)
A(7028)G(294)
A(6998)
C(5510)
HeLa WCE
No extract
 
The peak heights (corresponding to the fluorescence intensity) are shown in parenthesis. Black, 
blue and green peaks represent the C, G and A alleles, respectively. (a)-(c) i. SNaPshot™ 
analysis of 0.83µM, 0.67µM and 0.33µM G-T after 23 hours of HeLa whole cell extract 
exposure, respectively. T sequences are shown to be repaired to C sequence (complementary 
G peak, black). (a)-(c) ii. SNaPshot™ analysis of 0.83µM, 0.67µM and 0.33µM G-T that was 
incubated for 23 hours in the absence of any whole nuclear extracts showing unrepaired 
heteroduplex sequences, respectively. Mismatch repair was observed at 0.67µM and 0.33µM of 
G-T heteroduplex to G-C homoduplex. The repair efficiency was lower when the heteroduplex 
concentration was reduced from 0.67µM to 0.33µM. There was no repair in the absence of 
whole cell extract. 
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Table 5-2 Summary table of repair efficiency of heteroduplex construct to homoduplex 
after HeLa whole cell extract exposure. 
Heteroduplex 
 construct
Concentration 
of constructs 
(µM)
Concentration of 
HeLa whole cell 
extract (µg)
Time of 
incubation 
(hours)
Repair 
efficiency 
(Repaired/ 
unrepaired)
GTn 0.83 5 23 34%
GTn 0.67 5 23 5%
GT 0.67 5 23 6%
GTn 0.33 5 23 3%
GT 0.33 5 23 4%
GTn 0.33 2.5 23 0%
GT 0.33 2.5 23 0%  
This table summarises the final concentrations of the nicked and non-nicked heteroduplexes, 
final concentrations of whole cell extracts and time of exposure for the mismatch repair reaction. 
The efficiency of mismatch repair analysed by SNaPshot™ reaction was shown as a 
percentage of the ratio of repaired/unrepaired sequence of the heteroduplex. GT represents the 
non-nicked heteroduplex complex and GTn represents the nicked heteroduplex constructs. 
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Figure 5-6 Scatter plot summarising different concentration of heteroduplex (G-T) and 
HeLa whole extract against percentage of repair ratios. 
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Optimisation results for mismatch repair assay using HeLa whole cell extracts are shown in a 
scatter plot. The x-axis represents the concentration of HeLa whole cell extract and the y-axis 
represents the percentage of repair ratio (percentage of repaired sequence/unrepaired 
sequence). The mismatch repair reaction was performed for 23 hours for different concentration 
conditions. Concentration of heteroduplex constructs for each data point is labelled. It was 
observed that as the concentration of the whole cell extract was reduced, the repair efficiency 
was also reduced. When the concentration of HeLa whole cell extract was lowered to 2.5µg, no 
repair was observed. 
 
5.1.3 Mismatch repair in oocytes and blastocysts 
The final part of this study focused on assessing mismatch repair efficiency in 
oocytes and blastocysts. For all the reactions, mismatch repair was assessed in 
two controls, one positive with HeLa extract and one negative with no extract. In 
the presence of HeLa whole cell extract, mismatch repair of the G-T 
heteroduplex to G-C was observed in all the reactions; whereas no repair was 
detected in the absence of whole cell extract. In some samples, mismatch 
repair was assessed in an additional negative control where mismatch repair 
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buffer involving dNTPs, ATP and glutathione was excluded from the analysis. 
Similarly no repair was observed in the absence of dNTPs, ATP and 
glutathione. 
5.1.3.1 Use of protein extracts from mouse blastocysts 
Protein was extracted from ten and fifteen pooled mouse embryos, respectively. 
Mismatch repair reaction was applied as optimised for the whole cell extracts 
with 0.33µM heteroduplex G-Tn and 73% (11µl of protein extract in 15µl 
mismatch repair mixture) protein in the presence of mismatch repair buffer. 
However, no repair was observed from two mismatch repair reactions using the 
protein extracts from 10 and 15 pooled mouse embryos, respectively. 
5.1.3.2 Use of whole cell extracts from oocytes and blastocysts 
Mismatch repair efficiency was assessed in pooled mouse oocytes and 
blastocysts and pooled human blastocysts using the optimised reaction 
conditions. Both mouse and human blastocysts were at similar developmental 
stage. However, differences in the repair efficiency of mouse and human 
blastocysts may be observed. This could be due to higher amount of proteins 
present in the mouse embryos. It may also be possible that higher repair 
efficiency may be observed if the extraction was performed at the earlier stages 
of embryo development due to the presence of maternal protein in the embryo. 
Whole cell extraction was carried out from pooled 5 and 10 mouse oocytes, and 
4 and 8 pooled mouse blastocysts, respectively. G-T heteroduplex molecules 
(0.33µM) were exposed to the whole cell extract obtained from these pooled 
oocytes and blastocysts for 23 hours at 37ºC. Mismatch repair was not 
observed in any of the oocyte samples. Mismatch repair of G-T heteroduplex to 
G-C homoduplex was observed in whole cell extract obtained from pooled 
mouse blastocysts of four and eight, respectively. The peak height observed for 
the repaired C sequence was at much lower level compared to the unrepaired 
heteroduplex sequences indicating that although mismatch repair took place, 
not all the G-T heteroduplex was repaired. However, the peak height of repaired 
allele C in eight pooled oocytes was doubled compared to the peak height of C 
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allele observed in four pooled blastocysts indicating an increased efficiency for 
the repair.  
Whole cell extract was obtained from eleven pooled human embryos. G-Tn 
heteroduplex molecule (final concentration of 0.33µM) was exposed to the 
whole cell extract for 23 hours at 37ºC. Mismatch repair of G-Tn heteroduplex to 
G-C homoduplex was detected. However mismatch repair in human blastocysts 
was at a lower efficiency compared to the mouse blastocysts (Table 5.3 and 
Figure 5.7). 
 
Figure 5-7 Mini-sequencing (SNaPshot) analysis panels examining the mismatch repair 
efficiency of G-T heteroduplex in whole cell extract from pooled 11 human embryos. 
25(28)
A(7198)
C(2900)
G
G(23)
 
G-T heteroduplex was shown to be repaired to G-C. However, the repair efficiency was low 
since the C and A alleles corresponding to G-T sequences of the heteroduplex were still present 
in the reaction mixture. Since the repair was low, the G allele peak height was also low; 
therefore an additional enlarged image within the same panel was placed. Black, blue and 
green peaks represent the C, G and A alleles, respectively. The alleles and the peak heights in 
parenthesis (corresponding to the fluorescence intensity) are shown. 
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Table 5-3 Summary of the mismatch repair reactions by whole cell extracts obtained from 
pooled mouse oocytes, blastocysts and human blastocysts. 
Oocytes Blastocysts
GTn (Mouse) 0.33 5 (5840) - 23 0%
GTn (Mouse) 0.33 10 (8700) - 23 0%
GTn (Mouse) 0.33 - 8 (2770) 23 19%
GTn (Mouse) 0.33 - 4 (1115) 23 6%
GTn (Human) 0.33 - 11(8392) 23 0.3%
Heteroduplex 
construct
Concentration 
of constructs 
(µg/µl)
Number of 
oocytes/blastocysts 
pooled (mg/ml)
Time of 
incubation 
(hours)
Repair 
efficiency 
(Repaired/ 
unrepaired)
 
This table summarises the concentrations of the nicked heteroduplex constructs, number of 
oocytes and the initial concentrations of the whole cell extract obtained from mouse and human 
oocyte/blastocyst samples and time of exposure for the mismatch repair reaction. The efficiency 
of mismatch repair analysed by SNaPshot™ reaction was shown as a percentage of the ratio of 
repaired/unrepaired sequence of the heteroduplex. It was shown that there was no repair in 
pool of 5 and 10 mouse oocytes. Repair of G-T heteroduplex to G-C homoduplex was observed 
in whole cell extracts obtained from pool of 8 and 4 mouse blastocysts. Mismatch repair of G-T 
heteroduplex to G-C homoduplex was also observed in 11 pooled human blastocyst whole cell 
extract. However the repair efficiency in the human blastocysts was considerably lower 
compared to the mouse blastocysts. 
 
 
5.1.4 Summary of functional assay for mismatch repair 
Technical aspects 
- Homo/heteroduplex molecules were successfully constructed using 
commercially available long oligonucleotides. 
- Reaction to assess the efficiency of mismatch repair was initially 
optimised using commercially available mismatch repair efficient (HeLa) 
and mismatch repair deficient (LoVo) nuclear extracts.  
- Mismatch repair reaction was then optimised on commercially available 
HeLa whole extracts. 
- The optimal conditions for mismatch repair reactions were incubation of 
1.67 M of heteroduplex construct with 1.33 g HeLa nuclear extract for 
15 hours (100% repair efficiency). Slightly higher concentration of 
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mismatch repair deficient LoVo nuclear extract (1.43 g) with increased 
incubation time (23 hours) was required for 100% repair efficiency. 
- The highest repair efficiency (34%) was obtained when 0.83 M 
heteroduplex construct was incubated with 5 g HeLa whole cell extract 
for 23 hours. 
Biological aspects 
- Mismatch repair was successfully assessed in mouse oocytes, 
blastocysts and human blastocysts. There was no mismatch repair 
detected in mouse oocytes. 
- Mismatch repair efficiency in mouse blastocysts was shown to be more 
efficient in repairing G-T and G-Tn heteroduplex constructs compared to 
human blastocysts. These preliminary results suggest that mismatch 
repair may be functionally more active in mouse blastocysts compared to 
human blastocysts.  
Discussion for functional assay development for mismatch repair 
 
195 
 
5.2 Discussion 
DNA repair efficiency in gametes and preimplantation embryos is not well 
established. Therefore, gene expression and proteomic analyses play a crucial 
role to deduce which DNA repair pathways may be active in human oocytes and 
embryos. However, these analyses alone are not sufficient to assess repair 
efficiency since many genes and proteins are involved in a fully functioning 
repair pathway. Functional studies provide a better understanding of the repair 
capacity of DNA repair pathways. The aim of the last part of this project was to 
develop a sensitive functional assay to assess the activity of mismatch repair 
proteins initially in cell free content and then in preimplantation embryos. 
The initial step of this project was to form the nicked/non-nicked heteroduplex 
constructs using oligonucleotides. Repair efficiency of G-T heteroduplex was 
analysed in this study since it has been shown that this mismatch is repaired 
efficiently by mismatch repair efficient cells, such as HeLa S3 extracts (Hays et 
al., 2005, Holmes et al., 1990, Thomas et al., 1991). Additionally C to T point 
mutations were shown to be predominant in bacteria due to the deamination of 
cytosines in the non-transcribed DNA strand which was also shown to be the 
case in human genome by evolutionary analyses (Beletskii and Bhagwat, 1996, 
Mugal et al., 2009, Franco-Zorrilla et al., 2007, Riggs and Jones, 1983, Brown 
and Jiricny, 1988, Heywood and Burke, 1990a, Heywood and Burke, 1990b). 
Two nuclear extracts were selected for this project, one mismatch repair protein 
efficient (HeLa S3) and another mismatch repair protein deficient involving a 
deletion within the MSH2 gene (LoVo) (Umar et al., 1994). These extracts are 
stable when they are stored at -80˚C up to six months (manufacturer’s protocol). 
The nicked heteroduplexes at different concentrations (3.3-0.33µM) were 
incubated for 1, 3, 6, 15 and 23 hours in the presence of these two nuclear 
extracts at different concentrations (14-1.33µg) and in the absence of any 
nuclear extract or mismatch repair buffer as negative controls. Since this 
technique was being optimised to be applied in preimplantation embryos, the 
amount of nuclear extract was fundamental to the success of the assay. The 
Discussion for functional assay development for mismatch repair 
 
196 
 
total amount of protein in mammalian oocytes and preimplantation embryos has 
been shown to be between 162ng to 50µg in preimplantation embryos (Grealy 
et al., 1996, Thompson et al., 1998). The final concentration of both nicked/non-
nicked heteroduplexes and the final amount of the nuclear extract was reduced 
to 0.33µM and 1.33µg compared to previous assays that required 100ng 
substrate and 100µg nuclear extract for the mismatch repair reaction, 
respectively (Wang and Hays, 2002). Results of this study showed repair of 
both nicked G-Tn and non-nicked G-T heteroduplexes to G-C homoduplexes in 
the presence of HeLa and less efficiently in LoVo nuclear extracts. Studies 
showed that the G-T mismatches were preferentially repaired to G-C 
homoduplex (Wiebauer and Jiricny, 1989, Bill et al., 1998). Although the repair 
efficiency was lower for 1 hour exposure compared to 3, 6 and 15 hour 
exposures, the repair was still detected.  
In theory, any nuclear extract that is mismatch repair deficient should not repair 
the mismatches. However, studies have reported mismatch repair in the 
presence of LoVo nuclear extracts in Saccharomyces cerevisiae showing that 
MSH3 can function as an alternate for MSH2 (Marsischky et al., 1996, Strand et 
al., 1995) in endometrial cancer cell lines (Umar et al., 1994), human colon 
carcinoma cell lines (Lei et al., 2004) and in mouse embryo fibroblasts 
(Edelmann et al., 1996). Another explanation of this mismatch repair activity is 
that other DNA repair mechanisms, such as base excision repair or nucleotide 
excision repair, may take part in the repair when mismatch repair is not active 
(O'Regan et al., 1996, Huang et al., 1994). Studies also identified a thymine 
DNA glycosylase that is specific for repairing the G-T mismatches to G-C in 
bacteria (Sohail et al., 1990) and in mammalian cells (Wiebauer and Jiricny, 
1989, Wiebauer and Jiricny, 1990, Bill et al., 1998) that could be responsible for 
the repair in mismatch repair deficient cells. Any of these possibilities may take 
part in the repair of G-T heteroduplex to G-C homoduplex in LoVo nuclear 
extracts. Studies have shown that when the mismatched DNA was incubated 
with mismatch repair deficient cells for short periods, such as fifteen minutes, 
the mismatch repair efficiency was not as good as the repair by mismatch repair 
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efficient cells that may indicate the need of longer time for repair in the absence 
of mismatch repair system (Lei et al., 2004).  
Studies suggest that there is differential repair efficiency and biased repair. 
Several factors can affect the repair direction and the efficiency, such as the 
sequence of the strand, different mismatches, methylation status and DNA 
nicks (Brown and Jiricny, 1988, Hare and Taylor, 1985b, Hare and Taylor, 
1985a, Grilley et al., 1990, Bishop and Kolodner, 1986, Thomas et al., 1991, 
Fang and Modrich, 1993). Different repair efficiencies depending on the 
mismatches were observed in circular plasmids in monkey and human cells 
(Brown and Jiricny, 1988), such that the repair of C-C and G-G mismatches 
were better compared to the repair efficiency of C-T and A-G mismatches. In 
contrast, a more recent study suggested that the repair efficiency of A-G and C-
T mismatches was higher (Miller et al., 1997). Conflicting studies suggest that 
the single-base mismatches did not have a significant effect on the repair 
efficiency (Bill et al., 1998).  
Another factor that was suggested to have an effect on the DNA repair 
efficiency was the presence of other nearby mismatches that may induce co-
repair and it was proposed that this would increase the repair efficiency (Bill et 
al., 1998, Carraway and Marinus, 1993, Weng and Nickoloff, 1998). The results 
of this study showed that both the nicked and non-nicked heteroduplexes were 
repaired at a similar repair efficiency indicating that the repair was not nick-
directed. Studies suggested that nicks may improve the repair efficiency and the 
repair is initiated from the nick (Thomas et al., 1991, Holmes et al., 1990, Fang 
and Modrich, 1993, Umar et al., 1994, Miller et al., 1997, Taghian et al., 1998). 
Conflicting studies in monkey COS-7 (CV-1 in Origin and carrying the SV40 
genetic material) cells suggested that nicks did not have an effect in directing 
the strand repair (Heywood and Burke, 1990a, Heywood and Burke, 1990b). 
Additional studies supported this by showing equal mismatch repair efficiency 
with nicked and intact plasmid DNA in in vivo studies (Lei et al., 2004). The 
similarity of the mismatch repair activity between nicked and intact plasmid DNA 
could be due to fast ligation of the nick followed by the repair of the mismatch. 
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Studies supported this hypothesis such that mismatch repair was more efficient 
in the presence of DNA ligase 3 with nicked plasmid DNA (Tomkinson et al., 
1993).  
In addition to assessing DNA repair of nicked/non-nicked mismatches, a control 
sample, nicked/non-nicked homoduplexes (A-Tn and A-T), was analysed under 
the same conditions. Same concentrations of homoduplex, nuclear extract and 
time of incubation were applied to these samples. As expected, for all the 
analysis the only alleles that were detected were A and T following the 
SNaPshot™ analysis. This proved that addition of mismatch repair reagents did 
not yield any bias in the reaction and the longer incubation times for the 
mismatch repair reaction did not lead to degradation of the strands. 
The second part of this study involved optimising this assay to detect mismatch 
repair activity using whole cell extracts. Similar to the nuclear extracts, whole 
cell extracts should be stable for six months (manufacturer’s protocol). Different 
concentrations of G-Tn and G-T heteroduplexes were exposed to HeLa whole 
cell extract for up to 23 hours. The results have shown that as the concentration 
of the nicked/non-nicked heteroduplex was lowered, the efficiency of the repair 
was also lowered. When nicked/non-nicked heteroduplex was exposed to lower 
concentrations (2.5µg) of HeLa whole cell extract, there was no repair.  
The final part of this study involved assessment of mismatch repair in oocytes 
and blastocysts. Mismatch repair was assessed using protein extracts obtained 
from pooled mouse blastocysts. However no repair was observed suggesting 
that other polymerases were required for the mismatch repair to take place. 
Therefore, whole cell extracts were obtained from pooled mouse oocytes and 
blastocysts and human blastocysts. Both these extracts were suspected to be 
stable for six months. However to avoid any degradation, the whole cell extracts 
from oocytes and blastocysts were used immediately. No mismatch repair 
activity was detected in pooled mouse oocytes suggesting that although repair 
transcripts are present in the oocytes (Latham et al., 1992, Shi et al., 1994), 
they may not be active. Repair of the heteroduplex was detected both in pooled 
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mouse and human blastocysts. However, the repair efficiency of the blastocysts 
was considerably lower compared to the mismatch repair observed in 
commercially available nuclear and whole cell extracts. This was expected 
since amount of protein present in mammalian oocytes and blastocysts is very 
small (0.1µg in oocytes and 0.16-50µg in preimplantation embryos) (Grealy et 
al., 1996). 
Conclusion and Future work 
A simple and sensitive assay was developed to detect mismatch repair 
efficiency in oocytes and blastocysts. This method has advantages over the 
previously developed assays since small amounts of proteins can be used with 
this assay that enables mismatch repair assessment in embryos. This construct 
can easily be modified to detect different/multiple mismatches with different 
lengths in addition to modifying the construct into assessing insertion deletion 
loops with different sizes. Preliminary studies in repairing insertion deletion 
loops using PCR generated samples were carried out in the presence of 
nuclear extracts (Personal communications with Dr Jaroudi). By optimising this 
technique to a single cell level, mismatch repair activity can be investigated in 
embryos derived from patients with known repair mutations. 
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DNA repair is likely to play a crucial role in preimplantation embryo 
development. However both gametes and blastocysts have complex DNA repair 
mechanisms and the activity of DNA repair genes and proteins is not well 
established. Genes involved in DNA repair have been shown to be expressed at 
the early stages of mammalian development. The regulation of gene expression 
is highly complex. Amongst those factors involved in this regulation are miRNAs 
and DNA methylation.  
The first aim of this study was to analyse differences in expression of 
microRNAs and their target mRNAs involved in repair. This preliminary study 
showed that the levels of expression of most of the repair gene mRNAs are 
higher in oocytes than blastocysts and many of the miRNAs followed the same 
trend. A correlation test between the levels of expression of the miRNAs and 
their target mRNAs in the oocyte samples and in the blastocyst samples aimed 
to investigate a possible regulatory role of the selected miRNAs on candidate 
mRNAs coded by genes involved in DNA repair pathways. However, there was 
no clear cut pattern of differences in relative expression and a definite 
conclusion for the correlation analysis could not be drawn. This was likely due 
to the limited size and number of available samples. However, this project 
provided some data to guide future experiments in the selection of target genes 
and miRNAs. The ideal experiment design would be to analyse the expression 
of more miRNAs involved in DNA repair genes in the same oocyte and 
blastocyst samples, which could ultimately provide a better understanding of the 
regulatory roles of miRNAs on gene expression. 
This study further focused on the expression of BRCA1 in human 
preimplantation embryos and the developmental progression of embryos with 
BRCA mutations. It was shown that methylation affects the expression of genes 
during preimplantation embryo development. Parental BRCA1 transcripts were 
differentially expressed in embryos that may be caused by the differential 
demethylation of the parental genomes. Because of this differential 
demethylation, it was observed that inheriting a mutation from one parent had a 
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greater impact compared to inheriting the mutation from the other parent. This 
study showed that embryos with paternally inherited BRCA mutations 
developed slower compared to the maternally inherited BRCA mutations. The 
main limitation of this study was the small number of embryos with BRCA1 and 
BRCA2 mutations that were collected. Collection of more of these samples in 
the future will enable a more definite conclusion on the developmental 
progression of the embryos depending on the parental transmission of BRCA 
mutations to be drawn. Similarly, analysis of more embryos for other genes, 
including additional house keeping genes, will shed light to differential 
expression due differential parental demethylation status of the embryos. This 
study showed key findings in gene expression of BRCA1 and imprinted genes 
SNRPN and H19. A basis for future experiments was established and the 
current knowledge of variations in the gene expression due to the regulation of 
genome wide parental methylation in preimplantation embryos will be 
expanded. A more detailed analysis of genes involved in DNA repair will provide 
crucial information on the predicted embryo development progression when a 
couple is undergoing PGD for any mutations in repair genes. It may be possible 
to generalise a conclusion such that inheritance of paternal BRCA mutations 
impairs the embryo development and therefore is less likely to be transmitted to 
the next generation. Expression analyses and immunostaining studies play a 
vital role to demonstrate which DNA repair genes and proteins are present in 
the oocytes and embryos; however they cannot be fully associated with the 
activity of DNA repair mechanisms. The only way to assess the activity of the 
proteins involved in the complex repair pathways is by functional assays. 
Therefore the last part of this study focused on developing an easy and 
sensitive functional assay to assess mismatch repair activity in oocytes and 
blastocysts. This functional assay provides a total outcome for DNA repair 
activity including several factors, such as gene expression, protein functioning 
and any environmental factors. The mismatch repair functional assay developed 
in this study is unique for the amount of protein it requires to detect mismatch 
repair and it also provides an easy interpretation by mini-sequencing analysis. 
However, this assay still requires further optimisation to achieve sensitive 
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detection of mismatch repair in single human oocytes and blastocysts. 
Therefore, this study formed the basis of future studies to optimise a sensitive 
functional assay used in human preimplantation embryos and understand the 
repair capacity of these embryos. 
In summary, expression of DNA repair genes is important to detect DNA 
damage and initiate the appropriate repair. Functional assessment of repair 
pathways provide better understanding of which ones are active in the early 
stages of preimplantation embryo development and predict which embryos have 
a better chance in preimplantation development and implantation.  
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7.1 Appendix to introduction 
7.1.1 Potential correlation analysis between miRNA and their 
target repair transcripts in human oocytes and 
preimplantation embryos  
MiRNAs expressed in gametes and preimplantation embryos in mouse, human 
and bovine and list of their target genes including repair pathways they are 
associated with are shown in this table. The expression of miRNA in gametes 
and preimplantation embryo development is represented by “”. If the 
expression level of miRNA compared to the previous stage of the development is 
increased (i.e. increased level at the 4-cell stage than the 2-cell stage), this 
increased expression level is represented by “↑”. If the expression level of 
miRNA compared to the previous stage of the development is decreased, this 
reduced expression level is represented by ↓. If there has not been any studies 
analysing the expression of a miRNA at that particular stage of preimplantation 
embryo development, this was shown as blank (Yang et al., 2009, Tang et al., 
2007, Amanai et al., 2006, McCallie et al., 2009, Mondou et al., 2012, Ro et al., 
2007, Xu et al., 2011, Rosenbluth et al., 2012). 
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a) Expression profiles of miRNAs in gametes and embryos and their target base 
excision repair genes. 
miRNA Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
miR-22 UNG,MDC1 Mouse  ↑ ↑ ↑
miR-96 MBD4 Mouse  ↓ ↑ ↑
Mouse  ↓ ↓ ↓
Bovine 
miR-101a
TDG, FANCM, 
POLH,REV3L, UBE2A
Mouse  ↓ ↑ ↑
miR-101b
TDG, NEIL1, 
FANCM,POLH, REV3L
Mouse  ↓ ↑ ↑
miR-103
NEIL1, TDG -103-a,POLH- 
103-as
Mouse    ↓ ↑ ↑ ↑
Mouse    ↓ ↑ ↓
Bovine 
miR-204 UNG- 5p,POLH, POLK Mouse  ↓ ↓ ↑ ↑ ↑
miR-211 UNG,POLH, POLK Mouse  ↓ ↑ ↓ ↑ ↓
Mouse    ↓ ↑ ↓
Bovine 
miR-296 MBD4 Mouse  ↓ ↑ ↑
OGG1
TDP1 Mouse    ↑ ↓ ↑
ERCC6, DCLRE1B, RAD9A
miR-223 PARP1
miR-298
miR-107 TDG, NEIL1
miR-98
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b) Expression profiles of miRNAs in gametes and embryos and their target nucleotide 
excision repair genes. 
miRNA Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
Mouse    ↓ ↓ ↓
Bovine 
Mouse    ↑ ↑ ↑
Bovine 
Mouse     ↑ ↑
Bovine 
Mouse    ↓ ↓ ↓
Bovine 
Human 
miR-20b
RPA2b,CHAF1A,UBE2,FA
NCD2,POLQ, POLH
Bovine 
miR-23a
CCNH, 
RAD23B,RAD1,DCLRE1A, 
UBE2V2,POLH, FANCD2
Mouse    ↓ ↓ ↓
Mouse    ↓ ↓ ↓
Bovine 
Mouse  ↓ ↑ ↑
Bovine 
miR-134 ERCC6, RAD18 Mouse     ↑ ↑
miR-144 GTF2H2 Mouse    
miR-152 GTF2H1 Mouse  ↑ ↓ ↑
Mouse  ↓ ↑ ↑
Bovine 
Mouse  ↑ ↓ 
Bovine 
Human 
Mouse  ↑ ↑ ↓
Bovine 
miR-199b-5p RAD23B Mouse  ↓ ↑ ↓
miR-215 ERCC4 (XPF) Mouse    
miR-218 CETN2,RAD1 Mouse  ↓ ↑ ↓
miR-221
ERCC4 (XPF),RRM2B, 
FANCD2
Mouse    ↓ ↑ ↓
miR-222
ERCC4 (XPF),RRM2B, 
FANCD2
Mouse    ↓ ↓ ↓
miR-323 DDB1 Mouse  ↑ ↓ ↑
miR-324-3p RPA1 Mouse ↓ ↑ ↑
miR-345 RPA1 Mouse 
miR-33 ERCC4(XPF)-33a, ERCC6 Mouse    
Mouse    ↓ ↓ ↑
Bovine 
miR-345 RPA1 Mouse  ↑ ↑ ↓
Human 
Bovine 
Bovine 
Human 
Mouse  ↑ ↓ ↓
Bovine 
miR-423 DDB2 (LHX3)- 423-5p Bovine 
Mouse ↓
Bovine 
miR-454 GTF2H1, ERCC4,FANCA Human 
miR-483 GTF2H1 Bovine 
miR-512-3p ERCC4,POLK Human 
miR-888 GTF2H2,TDP1 Human 
miR-1260 DDB1,RAD18, FANCC Bovine 
CCNH, 
RAD23B,H2AX,RAD1, 
DCLRE1A, POLH, 
FANCD1
ERCC4, GTF2H1, FANCA
RAD23B,POLI, POLQ, 
ATM, FANCM
ERCC4 (XPF), 
POLK,RAD18, UBE2B
↑ ↑ ↑miR-450 Mouse 
ERCC4 (XPF), GTF2H1- b-
5b,UBE2A-b-5p, POLQ- 
b-3p
miR-381
miR-424
ERCC6, RAD23B, 
DDB2(LHX3)
GTF2H1,TP53
miR-372
ERCC4, POLK,UBE2B, 
RAD18
miR-342 MMS19L (MMS19) - 3P
miR-373
miR-181c
miR-192 ERCC3, ERCC4
miR-199a-5p RAD23B
miR-23b
miR-130a
miR-15b
ERCC6, RAD23B, DDB2 
(LHX3),CHEK1
RAD23B,CHEK1,Wip1miR-16
miR-10b GTF2H1
miR-10a GTF2H1
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c) Expression profiles of miRNAs in gametes and embryos and their target double 
strand break repair genes. 
miRNA Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
miR-1 BRCA1, TDP1 Mouse  ↓ ↑ ↓
miR-9
MRE11A, PRKDC, 
POLE, POLI
Mouse  ↓ ↓ ↑
miR-18
RBBP8, DCLRE1C, 
ATM
Mouse   ↓ ↑ ↑
H2AX, Mouse    ↓ ↓ ↓
H2AFX Human  ↓
miR-34a EME1 Mouse ↑ ↑ ↑ ↑
XRCC2 Mouse   ↑ ↑ ↓
FANCF Human  
Mouse     ↑ ↑
Bovine 
BRCA1- 3p Mouse    ↑ ↑ ↑ ↑ ↑
MDC1- 5p Bovine  ↑ ↓ ↑ ↓ ↓
RAD52 Mouse    ↑
UBE2N Bovine 
RAD52 Mouse    ↑
UBE2N Bovine 
Mouse  ↑ ↓ ↓
Bovine 
miR-139 EME1- 5p Mouse  ↓ ↑ ↓
Mouse    ↑ ↑ ↑ ↓ ↓
Bovine 
EME1- 3p
POLH
Mouse  ↑ ↓ ↑
Bovine 
miR-148b GTF2H1 Mouse  ↑ ↓ ↑
miR-150 PRKDC,POLH Mouse  ↓ ↑ ↓
LIG4- 3p Mouse  ↓ ↑ ↓
FANCA- 5p Human 
Mouse    
Bovine 
miR-154
MRE11,PCNA, 
UBE2A,TDP1,LIG4
Mouse    
BRCA1 Mouse  ↓ ↓ 
POLI Bovine 
RAD51L1- 193a Mouse  ↓ ↑ ↑ ↓
DCLRE1C(193a-5p) Human (a-5p) (b)
RAD51
FANCL
miR-203
DCLRE1B,RAD18,RA
F51,ATM,POLI
Mouse  ↓ ↑ ↑
miR-224
BRCA1, 
RAD51L1,TDP
Mouse  ↑ ↑ ↓
miR-299 DMC1- 3p Mouse ↑ ↑ ↑
RAD21
REV3L, POLK
miR-377 LIG4 Mouse    
Mouse  ↓  
Bovine 
MRE11A Mouse    
FANCM Bovine 
Mouse    
Bovine 
miR-449 EME1-449a Mouse  ↑ ↓ 
miR-625 NBN (NBS1) Human 
miR-765 RAD52B Bovine 
miR-1224-
5p
RAD50 Bovine 
Artemis,UBE2N, 
ATR,EXO1
miR-384
miR-412 RAD51L1
miR-383
miR-363 Bovine 
miR-190
miR-193
miR-198 Bovine 
Artemis
miR-138 H2AX
miR-151
miR-153 BRCA1
miR-24
miR-34b
miR-34c EME1- 5p
miR-125a
miR-128a
miR-128b
miR-140
miR-148a GTF2H1
miR-143 Bovine 
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d) Expression profiles of miRNAs in gametes and embryos and their target mismatch 
repair genes. 
miRNA Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
Mouse    ↓ ↑ ↓
Bovine 
miR-26b MSH3-5p,POLH, ATM, FANCD2 Mouse  ↓ ↑ ↓
Mouse  ↑ ↓ ↑
Bovine 
Mouse  ↓ ↑ ↓
Bovine 
miR-219
MLH3- hsa-miR-219-2-3p,UBE2N - 5p, 
DUT- 1-3p
Mouse  ↓ ↓ ↓
miR-291-
3p
MSH2 Mouse  ↑ ↑ ↑
miR-340
MLH3,NBN (NBS1), RAD50, Artemis, 
RRM2B, POLI, REV3L, HEL308
Mouse  ↓ ↓ ↓
miR-370 MLH3 Mouse  ↑ ↓ ↓
POLH,ATM, FANCD2, MSH3 (5p)
MSH2, MSH6, MLH1, FANCD2, 
FANCF, CHAF1A, DCLRE1A
miR-155
miR-149 MLH3
miR-26a
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e) Expression profiles of miRNAs in gametes and embryos and their target double strand 
break repair and nucleotide excision repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
NER ERCC6 (CSB) Mouse    ↓ ↓ ↓
Human  ↓
Bovine 
Mouse    ↓ ↓ ↓
Bovine 
DSBR (NHEJ) DCLRE1B Human  
Mouse    ↓ ↓ ↓
Bovine 
DSBR (NHEJ) DCLRE1B Human  
NER ERCC6 (CSB) Mouse    ↓ ↓ ↓
DSBR (NHEJ) DCLRE1B Bovine 
NER ERCC6 (CSB)
DSBR (NHEJ) DCLRE1B
NER ERCC6 (CSB) Mouse   ↓ ↓ ↓
DSBR (NHEJ) DCLRE1B Bovine 
NER ERCC6 (CSB) Mouse  ↓ ↓ ↓
DSBR (NHEJ) DCLRE1B Human  ↑
NER ERCC6 (CSB)
DSBR (NHEJ) DCLRE1B
NER
ERCC6, GTF2H1, 
RAD23B, DDB2 (LHX3)
Mouse  ↓ ↑ ↑
DSBR (HR) RAD50 Bovine 
Damage response CHEK1 Human 
NER ERCC4 Mouse  ↓ ↑ ↑
DSBR (HR) RAD51L1, RBBP8 Human  
NER ERCC4 Mouse    ↓ ↑ ↑
Bovine 
Human  ↓
NER ERCC4 (XPF) - 3p
RAD6 pathway UBE2V2-  3p
DSBR (NHEJ) DCLRE1C- 3p
DSBR (HR) BRCA1 Mouse  ↓ ↑ ↑ ↑ ↑
NER GTF2H1-5p Bovine  ↑ ↑ ↑ ↑
NER RAD23B
DSBR sensor H2AX
DSBR (HR) RAD51L1
DSBR (NHEJ) PRKDC
DNA polymerases REV3L
RAD6 pathway RAD18
Chromatin Structure H2AFX
miR-15a
↑
miR-19b
DSBR (HR) RBBP8
miR-28 Mouse
 ↑
  
↑ ↑
miR-127
miR-19a
miR-145
Mouse    ↓
Bovine  ↑ ↑
let-7a
DSBR (NHEJ) DCLRE1B
let-7b
NER ERCC6 (CSB)
let-7c
NER ERCC6 (CSB)
let-7d
let-7e Mouse
 ↓
   ↓
let-7f
let-7g
let-7i Mouse ↓ ↓
↓ ↓
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miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
NER RAD23B- b-3p
DSBR (HR)
BRCA1, BRCA2- a and b-
5p
Suspected DNA 
repair function
RECQL5 a and b-5p
Human (miR-
146b-5p)

NER GTF2H1
DSBR (HR) RAD50
Suspected DNA 
repair function
NEIL3
DSBR (HR) NBN (NBS1)
NER ERCC6 (CSB) Mouse  ↓ ↓ ↑
NER RAD23B- 188-3p
DSBR (NHEJ) XRCC5- 5p
DNA polymerases POLH
Damage response MDC1- 188-5p
NER
ERCC6 (CSB), RAD23B, 
DDB2 (LHX3)
DSBR (HR) RAD50
Cell cycle checkpoint 
control
Wee1
NER
GTF2H1(a, b), ERCC4 
(XPF)
DSBR (HR) RAD51L1- 301a and b
Genes defective and 
sensitivity to DNA 
damaging agents
ERCC4, FANCA- a&b
NER DDB2 (LHX3)
DSBR (HR) RAD51L1
NER ERCC6- 5P, GTF2H1- 3P
DSBR (HR) MRE11A- 5p
Chromatin Structure CHAF1A- 3P
Suspected DNA 
repair function
DCLRE1B- 5P
Genes defective and 
sensitivity to DNA 
damaging agents
BLM, FANCC- 3P, 
FANCM- 5P
HR PARP1, RAD51B- 3p
NER GTF2H2
Cell cycle checkpoint 
control
CDK14
RAD6 pathway UBE2A
NER RAD23B Mouse    
DSBR (HR) NBN (NBS1)
Damage response RAD17 Bovine 
DSBR
RAD51B, ATM (miR-519-
a)
Bovine (miR-
519e)

NER ERCC4 (miR-519-a)
DNA polymerases
POLH, POLQ (miR-519-
a)
RAD6 pathway UBE2B, RAD18
DNA polymerases POLK
NER ERCC4
DSBR RBBP7
NER ERCC4
HR RAD50
Rad6 Pathway UBE2A, UBE2H
miR-146
Mouse  ↓ ↓ ↑
↓ ↑ ↑miR-183 Mouse 
miR-185
↑ ↓
Bovine 
miR-188
Mouse    ↓
miR-195 Mouse  ↓ ↑ ↓
 ↓ ↑ ↑miR-301 Human
↓ ↓miR-328 Mouse  ↓
↑ ↑miR-338 Mouse  
miR-371-
5p
Bovine 
miR-410

miR-519
Human (miR-
519a)
miR-520
Human (miR-
520c-3p, d-3p)
miR-1246 Bovine 
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f) Expression profiles of miRNAs in gametes and embryos and their target nucleotide 
excision repair and base excision repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
NER GTF2H1, RAD23B
BER NEIL2
RAD6 pathway UBE2V2 Human 
NER GTF2H1, RAD23B Mouse  ↓ ↓ ↓
BER NEIL2 Human 
RAD6 pathway UBE2V2 Bovine 
NER GTF2H1, RAD23B Mouse    ↓ ↓ ↓
BER NEIL2 Bovine 
RAD6 pathway UBE2V2 Human 
NER GTF2H1, RAD23B Mouse    ↑ ↑ ↑ ↑
Bovine 
Human  
NER GTF2H1, RAD23B Mouse    ↓ ↓ ↓
BER NEIL2 Bovine 
RAD6 pathway UBE2V2 Human 
NER GTF2H1, RAD23B
BER NEIL2
RAD6 pathway UBE2V2 Human 
NER ERCC4, GTF2H1
BER PARP1
Genes defective and 
sensitivity to DNA 
damaging agents
FANCA Bovine 
NER GTF2H1
BER NEIL2
NER XPC Mouse  ↓ ↑ ↓
BER PARP2 Human 
miR-130b
Mouse  ↑
miR-132 Mouse  ↑ ↑ ↑
↑ ↑
↓
miR-30c
RAD6 pathway UBE2V2
miR-30d
miR-30e
Mouse
 ↓
 ↓ ↑
miR-141
↓ ↑
miR-30a-5p
miR-30b
miR-30a-3p
Mouse
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g) Expression profiles of miRNAs in gametes and embryos and their target base excision 
repair and double strand break repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
BER SMUG1
DSBR (HR)
NBN (NBS1), RAD50, 
BRCA1
DNA polymerases POLI
DSBR (HR)
BRCA1- 216b, DMC1- 
216b
BER MBD4
RAD6 pathway UBE2V2
BER TDG
DSBR (HR) MRE11A- 320a
DSBR (NHEJ) XRCC5 (a-d)
Repair of DNA-
protein crosslinks
TDP1 (a-d)
Genes with 
suspected DNA repair 
function
APTX
Genes defective and 
sensitivity to DNA 
damaging agents
FANCF (a-d) Mouse    ↓ ↑ ↓
BER TDG- 5p
DSBR (HR) DMC1- 5p, RAD50- 5p
Damage response 
genes
CHEK1- 5P
Suspected DNA 
repair function
DCLRE1B- 3P
BER PARP1
DSBR (HR) MRE11A
Suspected DNA 
repair function
RECQL5
DSBR (HR) RAD51L3 Bovine  ↑ ↑ ↓
BER PARP1 Human
miR-496
↑ ↓miR-335 Mouse ↓
↑ ↓miR-331 Mouse  ↓

miR-320
Human
miR-216 Mouse  ↑
↑ ↑
↓ ↑
miR-186 Mouse  ↓
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h) Expression profiles of miRNAs in gametes and embryos and their target mismatch 
repair, double strand break repair and nucleotide excision repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
MMR MSH2 Mouse  ↓ ↑ ↑
DSBR (HR) RAD51L3 Bovine 
NER RPA2 Human  
MMR MLH3
DSBR (HR) RAD51L1, XRCC2
NER GTF2H1
MMR MLH3, MSH6
NER CCNH
DSBR (HR)
NBN (NBS1), 
RAD50, RBBP8
NER GTF2H3- 3P
DSBR (NHEJ) LIG4- 3P
DSBR (HR) NBN (NBS1)- 3P
MMR MSH3- 5P
NER ERCC6
MMR MSH4
DSBR (NHEJ) XRCC4
RAD6 pathway UBE2B
Suspected DNA 
repair function
DCLRE1B
Genes defective and 
sensitivity to DNA 
damaging agents
FANCF
MMR MSH4
NER ERCC6
DSBR (NHEJ) XRCC4
RAD6 pathway UBE2B
Suspected DNA 
repair function
DCLRE1B
Genes defective and 
sensitivity to DNA 
damaging agents
FANCF Bovine 
 
miR-380-
5p
Mouse  
 
miR-380-
3p
Mouse 
miR-337 Mouse   ↑ ↑

miR-142-
3p
Mouse
miR-21
 ↑ ↑ ↑
  
miR-129-
5p
Mouse
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i) Expression profiles of miRNAs in gametes and embryos and their target nucleotide 
excision repair, base excision repair and double strand break repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
NER ERCC6
BER TDG
DSBR (HR) MRE11A
Damage response genes RAD1
NER ERCC6
DSBR (HR) MRE11A
BER TDG
Damage response genes RAD1
NER ERCC6
BER TDG
DSBR (HR) MRE11A
Damage response genes RAD1
NER RAD23B
BER APEX2
DSBR (HR) RAD51- 124a and b
Damage response genes RAD17 Bovine 
NER XPC
BER PARP2
DSBR (HR) BRCA1
Suspected DNA repair 
function
RECQL5, XPC
Genes defective and 
sensitivity to DNA 
damaging agents
ATM
DSBR (HR) RAD50, BRCA1 Mouse   ↑ ↑
NER GTF2H1
BER NEIL2
NER ERCC6 (CSB), GTF2H2
BER TDG
DSBR (HR) MRE11A
DNA polymerases POLH, PCNA
Genes defective and 
sensitivity to DNA 
damaging agents
ATM
NER GTF2H1- 3P
BER TDG- 3P
DSBR (NHEJ) LIF4- 3P
Bovine
Mouse ↓↓↓
↑ ↓miR-330 Mouse  
↓ miR-217 Mouse  ↑
miR-212
Human 
↓ ↓ ↓miR-200a Mouse 
  ↑ ↓ ↑
miR-124a
Mouse 
miR-29c Mouse ↑ ↑ ↑
↓
↑
miR-29b
↓miR-29a Mouse  ↓
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j) Expression profiles of miRNAs in gametes and embryos and their target genes involved 
in all repair pathways; mismatch repair, double strand break repair, nucleotide excision 
repair and base excision repair genes. 
miRNA DNA repair pathways Target repair mRNA Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
MMR MSH3
DSBR (HR) RAD51L1
DNA polymerases POLH
MMR MS2
DSBR (HR) RAD52
MMR MSH4 Mouse    ↓ ↓ ↑
NER ERCC8 (CSA) Bovine 
NER ERCC4 (XPF) - 3p
MMR MSH6- 3p
Suspected DNA 
repair function DCLRE1B-3P
MMR MSH3
BER PARP1
DSBR (NHEJ) XRCC5
BER PARP1 ↓ ↓ ↓
 ↑ ↓
miR-31 Mouse 
↓ ↓ ↓
miR-7 Mouse 
miR-182
miR-409 Mouse 
miR-210 Mouse   ↑ ↑ ↓
  ↑ ↑miR-136 Mouse  
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k) Expression profiles of miRNAs in gametes and embryos that are not involved in DNA 
repair. 
Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
miR-7b Mouse    
miR-16-5p Mouse 
miR-17 Human 
Human 
Bovine 
Mouse      ↑
Bovine 
miR-99b Mouse    ↑ ↑ ↑
Mouse  ↑ ↑ ↓
Bovine 
miR-126 Bovine 
miR-126-3p Mouse  ↓ ↑ ↑
miR-126-5p Mouse  ↑ ↑ ↓
miR-133a Mouse    ↑ ↑ ↑
miR-133b Mouse    ↑
miR-184 Mouse    ↓ ↓ ↑
miR-187 Mouse  ↑ ↑ ↓
miR-189 Mouse    
miR-196a Mouse  ↓ ↑ ↑
miR-196b Mouse   ↑ ↑
miR-201 Mouse    
miR-202 Mouse  ↑ ↓ ↑
miR-202-5p Bovine 
Mouse  ↓ ↓ ↑
Bovine 
Mouse    ↓ ↓ ↑
Bovine 
Mouse  ↓ ↑ ↓
Bovine 
miR-213 Mouse    
Mouse    ↓ ↓ ↓
Bovine 
miR-290 Mouse  ↓ ↑ ↑ ↑ ↑
miR-290-5p Bovine 
miR-291-5p Mouse ↑ ↑ ↑
Mouse  ↓ ↑ ↑
Bovine 
miR-292-5p Mouse  ↑ ↑ ↑ ↑
miR-293 Mouse  ↓ ↑ ↑
miR-294 Mouse  ↓ ↑ ↑
miR-295 Mouse  ↓ ↑ ↑
miR-322-3p Mouse  ↑ ↓ ↑
miR-322-5p Mouse  ↑ ↑ ↑
miR-324-5p Mouse  ↓ ↑ ↓
miR-325 Mouse   
miR-326 Mouse  ↓ ↑ ↑
Mouse    ↑ ↓ ↑
Bovine 
miR-205
miR-122a
miR-99a
miR-30
miRNA
Expression of miRNAs in gametes and preimplantation embryo development
miR-329
miR-292-3p
miR-214
miR-206c
miR-207
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Species Oocyte Sperm Zygote 2-cell 4-cell 8-cell Morula Blastocyst
Mouse  ↓ ↑ ↑
Bovine 
miR-339-5p Human 
miR-344 Mouse   ↑ ↑
miR-346 Mouse  ↑ ↓ ↓
miR-350 Mouse  ↑ ↑ ↓
miR-351 Mouse  ↑ ↑ ↑
miR-371-3p Human 
miR-374 Human 
Mouse     
Bovine 
Mouse  ↓ ↓ 
Bovine 
miR-455-3p Bovine 
miR-467a Bovine 
miR-470 Bovine 
Bovine 
Human 
miR-486-5p Human 
miR-512-5p Bovine 
miR-517 Human 
miR-518b Bovine 
miR-541 Bovine 
miR-542-5p Bovine 
miR-547 Bovine 
miR-602 Human 
miR-638 Bovine 
miR-662 Human 
miR-663 Bovine 
miR-705 Bovine 
miR-709 Bovine 
miR-712 Bovine 
miR-720 Human 
miR-721 Bovine  
miR-768 Human 
miR-762 Bovine  
miR-886-3p Human 
miR-923 Bovine 
miR-939 Bovine 
miR-1228-3p Bovine 
Human 
Bovine 
Bovine 
Human 
miR-1280 Bovine 
miR-1308 Bovine 
miR-1826 Bovine 
Expression of miRNAs in gametes and preimplantation embryo development
miR-1274
miR-1275
miR-484
miR-411
miR-375
miR-339
miRNA
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7.2 Appendix to materials and methods 
7.2.1 Differential gene expression in preimplantation embryos 
and potential relation with differential methylation 
7.2.1.1 Oligonucleotides 
Primer names, sequences, chromosomal locations and PCR product sizes that 
are used for sequencing to identify informative SNPs for differential gene 
expression analysis in embryos are listed. Sequences were obtained from 
Ensembl; ACTB (ENSG00000075624, Ensembl release 60), GAPDH 
(ENSG00000111640, Ensembl release 60), SNRPN (ENSG00000128739, 
Ensembl release 60), UBE3A (ENSG00000114062, Ensembl release 60), IGF2 
(ENSG00000167244, Ensembl release 60), H19 (ENSG00000130600, Ensembl 
release 60) and BRCA1 (ENSG00000012048, Ensembl release 60) on the 
Ensembl genome browser.  
a) Primer information used for sequencing 
Primer Primer sequence 
Chromosome
: Locus 
Product 
size 
(bp) 
ACTBex7 F 5'-AACACTGGCTCGTGTGACAA-3' 7:5568239: 
5568860 
236 
ACTBex7 R 5'-GGGGTGTTGAAGGTCTCAAA-3' 
ACTBex7b F 5'-GTTGCTATCCAGGCTGTGCT-3' 7:5567732: 
5568351 
283 
ACTBex7b R 5'-CCATCTCTTGCTCGAAGTCC-3' 
ACTBex7c F 5'-CGACCAGTGTTTGCCTTTTA-3' 7:5568839: 
5569758 
356 
ACTBex7c R 5'-AGGGCGCTTTCTCTGCAC-3' 
ACTBex8 F 5'-ATCATTGCTCCTCCTGAGC-3' 7:5566729: 
5567648 
495 
ACTBex8 R 5'-TGTGGACTTGGGAGAGGACT-3' 
GAPDHex6 F 5'-AAGGGCCCTGACAACTCTTT-3' 12:6646936: 
6647855 
245 
GAPDHex6 R 5'-CTTGACACAAGCCCAGCTTC-3' 
UBE3Aex9a F 5'-TCTGCTGCTGCTATGGAAGA-3' 15:25616110:2
5616729 
326 
UBE3Aex9a R 5'-GGCAAAGCCATTTCCAGATA-3' 
UBE3Aex9b F 5'-TCAATAAACCAAACTTTTTGAATG-3' 15:25618171:2
5619191 
355 
UBE3Aex9b R 5'-GAATGCAGTGGCACCATTT-3' 
UBE3Aex9c F 5'-ACATTGTATAGCCCCACAGATT-3' 15:25582800:2
5583423 
335 
UBE3Aex9c R 5'-AACAAATCATCAGGTTGATCTACAG-3' 
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UBE3Aex16 F 5'-TGGCTACTGTGCCTTGTGTT-3' 15:25582163:2
5583382 
438 
UBE3Aex16 R 5'-TGCATTTTTCCTGCCAATTT-3' 
UBE3Aex16b F 5'-CCATCACGTATGCCAAAGG-3' 15:25583715:2
5584335 
304 
UBE3Aex16b R 5'-TGTAACACTTTCACGCAAAAA-3' 
SNRPNex6 F 5'-ATAATTTGTCGGGCCAACCT-3' 15:25154649:2
5155271 
287 
SNRPNex6 R 5'-TGGGGTTTGTTAAAGTTGTTAAG-3' 
SNRPNex6b F 5'- AGCACATGTAATCGGCAACA-3' 15:25154085:2
5155305 
287 
SNRPNex6b R 5'- AGGTTGGCCCGACAAATTAT-3' 
SNRPNex12 F 5'- CCTCTGCAGGCTCCATCTAC-3' 15:25219149:2
5219768 
151 
SNRPNex12 R 5'- ATTGCTGTTCCACCAAATCC-3' 
SNRPNex13 F 5'-TTGAGTATCAGCTGAAGATGAGC-3' 15:25219748:2
5220368 
329 
SNRPNex13 R 5'-TGGTGGAATCATGACCAAAA-3' 
SNRPNex17 F 5'-TGCATCGCTTTGACTGTTTC-3' 15:25222786:2
5223411 
222 
SNRPNex17 R 5'-TCTCATCAGAGATTCAAGTTCGTC-3' 
SNRPNex18 F 5'-CCACCAAGACCTTAGCATACTG-3' 15:25223502:2
5224126 
250 
SNRPNex18 R 5'-TGATTTGAATCAACTGCTTAATAGG-3' 
IGF2 F 5'-CCTTCAGCCTGCCTCAGC-3' 11:2181930: 
2182552 
238 
IGF2 R 5'-CCTGCAGGTCCTCTGCCT-3' 
IGF2ex11 F 5'-GACAACTTCCCCAGATACCC-3' 112153834: 
2154753 
370 
IGF2ex11 R 5'-GGACTGGGTCAGGAGAAGC-3' 
H19a F 5'- GTTTCCCCCGTCCCTTCT-3' 112015815: 
2017038 
327 
H19a R 5'-CAGTGTTTATTGATGATGAGTCCA-3' 
H19b F 5'-TTACTTCCTCCACGGAGTCG-3' 112016950: 
2017675 
340 
H19b R 5'-GACACGTGGGTGGGATGG-3' 
BRCA1ex9F 5'-CTCTTCAGGAGGAAAAGCACA-3' 17:41251643:4
1252263 
287 
BRCA1ex9R 5'-ACTTCCCAAAGCTGCCTACC-3' 
BRCA1ex11a F 5'-GGGTTTTGCAAACTGAAAGA-3' 17:41244732:4
1245353 
269 
BRCA1ex11a R 5'-TGGTTAACTTCATGTCCCAATG-3' 
BRCA1ex11b F 5'-AAGGCTGAATTCTGTAATAAAAGC-3' 17:41246324:4
1246947 
250 
BRCA1ex11b R 5'-TCACTTCTGGAAAACCACTCA-3' 
BRCA1ex11c F 5’-CAAAAGCACCTAAAAAGAATAGGC-3’ 
17:41245094:4
1245719 
347 
BRCA1ex11c R 
5’-AAGTTCACTGGTATTTGAACACTTAG-
3’ 
BRCA1ex11d F 5’-CATTGGGACATGAAGTTAACCA-3’ 17:41244430:4
1245653 
364 
BRCA1ex11d R 5'-CAAAACCTAGAGCCTCCTTTGA-3' 
BRCA1ex11e F 5'-TCAAAGGAGGCTCTAGGTTTTG-3' 17:41244039:4
1244860 
373 
BRCA1ex11e R 5'-GCTTGAATGTTTTCATCACTGG-3' 
BRCA1ex11f F 
5'-TGATGGTGAAATAAAGGAAGATACT-
3' 
17:41243559:4
1244383 
356 
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b) Annealing sites of the primers used for determining the differential allele 
expression. The primer IDs as listed in table 7.2.2.1.a are shown for each 
region. Yellow and red coloured regions represent the primer annealing 
sites. Salmon-coloured regions indicate the position of exons. 
Highlighted letters other than the four bases (A, C, T or G) represent the 
SNPs. These annealing sites were obtained from Ensembl for each 
region with the Ensembl release: ACTB (ENSG00000075624, Ensembl 
release 60), GAPDH (ENSG00000111640, Ensembl release 60), 
SNRPN (ENSG00000128739, Ensembl release 60), UBE3A 
(ENSG00000114062, Ensembl release 60), IGF2 (ENSG00000167244, 
Ensembl release 60), H19 (ENSG00000130600, Ensembl release 60) 
and BRCA1 (ENSG00000012048, Ensembl release 60) on the Ensembl 
genome browser.  
ACTB (ENSG00000075624): ACTB_a in yellow, ACTB_b in red. 
5568915 CGACATGGAGAAAATCTGGCACCACACCTTCTACAATGAGCTGCGTGKGSCKYCCSAGGA 5568856 
5568855 GCACCCCGTGCTGCTGACCGAGGCCCCCCTGAACCCCAAGGCCAACCGCGAGAAGATGAC 5568796 
5568795 CCAGGTGAGTGGCCCGCTAYCTCTTCTGGTGGCSGCCTCCCTCCTTCCTGGCCTCCCGGA 5568736 
BRCA1ex11f R 5'-CCTGGTTACTGCAGTCATTTAAG-3' 
BRCA1ex12 F 5'-TCATTTAATGGAAAGCTTCTCAAAG-3' 
17:41234330: 
41234954 
290 
BRCA1ex12 R 
5'-AAAGGGGAAGGAAAGAATTTTG-
3' 
BRCA12RNAonl
yF 5'-AGCAGGAAATGGCTGAACTA-3' 17:41234126: 
41234745 
130 
BRCA12RNAonl
yR 5'-TCTGATGTGCTTTGTTCTGG-3' 
BRCA1ex15 F 5'- AATTGGTGGCGATGGTTTT -3' 17:41226016: 
41226638 
290 
BRCA1ex15 R 5'- TGTTTGTTCCAATACAGCAGATG-3' 
BRCA1ex17 F 5'- AATTGGTGGCGATGGTTTT -3' 
17:41222715: 
41223334 
175 BRCA1ex17 
F 
5'-AATTCTGGCTTCTCCCTGCT -3' 
BRCA1ex18 F 5'-TAACTAGTATTCTGAGCTGTGTGCT-3' 
17:4280654: 
4281875 
290 BRCA1ex18 
R 
5'- AGTGATTCTCCTGCCTCAGC -3' 
BRCA1ex9 F 5'-CTCTTCAGGAGGAAAAGCACA-3' 
17:41251643:4
1252263 
290 BRCA1ex9 
R 
5'-ACTTCCCAAAGCTGCCTACC-3' 
Appendix to Materials and Methods 
 
Section 2.2.2.3                                                                                                              248  
 
5568735 GCTGCGCCCTTTCTCACTGGTTCTCTCTTCTGCCGTTTTCCGTAGGACTCTCTTCTCTGA 5568676 
5568675 CCTGAGTCTCMTTTGGAACTCTGCAGGTTCTATTTGCTTTTTCCCAGATGAGCTCTTTTT 556861 
5568615 CTGGTGTTTGTCTCTCTGACTAGGTGTCTAAGACAGTGTTGTGGGTGTAGGTACTAACAC 5568556 
5568555 TGGCTCGTGTGACAAGGCCATGAGGCTGGTGTAAAGYGGCCTTGGAGTGTGTATTAAGTA 5568496 
5568495 GGYGCACAGTAGGTCTGAACAGACTMCCCATCCCAAGACCCCAGCACACTTAGCCGTGTT 5568436 
5568435 CTTTGCACTTTCTGCATGTCCCCCGTCTGGCCTGGCTGTCCYCAGTGKCTTCCCCMGTGT 5568376 
5568375 GACATGGTGYATCTCTGCCTTACAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTA 5568316 
5568315 CGTTGCTATCCAGGCTGTGCTRTCCCTKTACGCCTCTGGCCGTACCACTGGCATCGTGAT 5568256 
5568255 GGACTCCGGTGACGGGGTCACCCRCACTGTGCCCATCTACGARGGGTATGCCCTCCCCCA 5568196 
5568195 TGCCATCCTGCGTCTGGACCTGGCTGGCCKGGACCTGACTGACTACCTCATGAAGATCCT 5568136 
5568135 CACCGAGCGCGGCTACAGCTTCACCACCACGGCCGARCGGGAAATCGTGCGTGACATTAA 5568076 
5568075 GGAGAAGCTGTGCTMCGTCGYCCTGGACTTCGAGCAAGAGATGGCCACGGCTGCTTCCAG 5568016 
 
ACTB (ENSG00000075624): ACTBc 
5569455 CCAGTGTTTGCCTTTTATGGTAATAACGCGGCCGGCCCGGCTTCCTTTGTCCCCAATCTG 5569396 
5569395 GGCGCGCGCCGGCGCCCCCTGGCGGCCTAAGGACTCGGCGCGCCGGAAGTGGCCAGGGCG 5569336 
5569335 GGGGCGACYTCGGCTCACAGCGCGCCCGGCTATTCTCKCAGCTMACMATGGATGATGATA 5569276 
5569275 TCGCCGYGYTSGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGGCGACG 5569216 
5569215 ATGYCCCCCGGGCCGTCTTCCCCTCCATCGTGGSGYGCCCCAGGCACCAGGTAGGGGAGC 5569156 
5569155 TGGCTGGGTGGGGCAGCCCCGGGAGCGGGCGGGAGGCAAGGGCGCTTTCTCTGCACAGGA 5569096 
ACTB (ENSG00000075624): ACTBex8 
5567535 CTTCYCTYCTCAGATCATTGCTCCTCCTGAGCGCAAGTACTCCGTGTGGATCGRCGGCTC 5567476 
5567475 CATCCTGGCYTCRCTGTCCACCTTCCAGCAGATGTGGATCAGCAAGCAGGAGTATGACGA 5567416 
5567415 GTCCGGCCCCTCCATCGTCCACCGCAAATGCTTCTAGGCGGACTATGACTTAGTTGCGTT 5567356 
5567355 ACACCCTTTCTTGACAAAACCTAACTTGCGCAGAAAACAAGATGAKATWGGCATGGCTTT 5567296 
5567295 ATTKGTTTTTTTTGTTYTKTTTTGGKTTTTTTTTTTTTTTTGGCTTGACTCAGGATTTAA 5567236 
5567235 AAACTGGAACGGTGAAGGTGACAGCAGTCGGTTGGAGCGAGCATCCCCCAAAGTTCAYAA 5567176 
5567175 TGTGGCCGAGGACTYTGATTGCACATTGTTGTTTTTTTAATAGTCATTCCAAAWATGAGM 5567116 
5567115 TGCGTTGKTAYAGGAARTCCCTTGCCATCCTAAAAGCCACCCCACTTCTCTCTAAGGAGA 5567056 
5567055 ATGGCCCAGTCCTCTCCCAAGTCCACACAGGGGAGRTGATAGCATKGCTTTCGTGTAART 5566996 
GAPDH (ENSG00000111640): GAPDHex6 
6647233 AAAAAGGGCCCTGACAACTCTTTTCATCWTCTAGGTATGACAACGAATTTGGCTACAGCA 6647292 
6647293 WCAGGGTGGTGGACCTCATKGCCCACATGGCYTCCAAGGAGTAAGACCCYTGGACCAYCA 6647352 
6647353 GCCCCAGCAAGAGCACAAGAGGAAGAGAGAGACCYTCACTRYTGGGGAGTCCCTGCCACA 6647412 
6647413 CTMAGTCCYCCACCACAYTGAATCTCCCCTCCTCAMAGTTKCCATGTAGACCCCTTGAAR 6647472 
6647473 AGGGGAGGGGCCTAGGGAGCCGCACCTTGTCATGTACCATCAATAAAGTACCCTGTGCTC 6647532 
6647533 AACCDGTTACTTGTCCTGTCTTATTCTAGGGTCTRGGGCAGAGGGGAGGGAAGCTGGGCT 6647592 
6647593 TGTGTCAAGGTGAGACATTCTTSCTGGGGAGRGACCTGGTATGYTCTCCTCAGACTGAGG 6647652 
BRCA1 (ENSG00000012048): BRCA1ex9  
41251970 CAAGTTTCTCTTCAGGAGGAAAAGCACAGAACTGGCCAAYAATTGCTTGACTGTTCTTTA 41251911 
41251910 CCATACTGTTKMGCAGGAAACCAGTYYCAGTGTCCAACTCYCTAACCTTVGAACTSTGAG 41251851 
41251850 AMCTCTGAGGACAAAGCAGYRGATACAACCTCAAAAGACRTCTGTCTACATTGAATTGGD 41251791 
41251790 WAAGGGTCTCAGGTTTTTTAAGKATTTAATAATAATTGCTGGATTCCTTATCTTATAGTT 41251731 
41251730 TTSCCAAAAATCTTGGTCATAATTTGTATTTGTGGTAGGCAGCTTTGGGAAGTGAATTTT 41251671 
BRCA1 (ENSG00000012048): BRCA1ex11a  
41245340ACAGTTWAASTGTBTAATAATGCYGAAGACCCCAAAKATCTCATGTTAAGTGGAGAAAG 41245281 
41245280GGTTTTGCAAACTGAAAGATCTGTAKRGAGTAGCAGTATTTCAYTGGTACCTGGTACTGA41245221 
41245220TTAWGGCACTCAGGAAAGTRTCKYGTTACTGGAARTTAGCRCTCTAGGGAAGGYAAAAAY41245161 
41245160AGAACCAAAWAAATGWGTGAGTYAGTGTRCAKCATTTGAAWACCCCAAGKGACTAATTCR41245101 
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41245100TGGTTGTTCCRAAGATAATAGAAATKWCACAGAARGCTTTAAGTATCCATTGGGACATGA41245041 
41245040AGTTAACCACAGTYGGGRARCAARCATAGAAATRGAAKAAAGTGAACTTGATGYTCAGTA41244981 
BRCA1 (ENSG00000012048): BRCA1ex11b 
41246660AMWRAATGTAGAMAAGGCTGAATTCTGTAATAAAAGCAMACAGCCTGGCTTAGCARGGRG41246601 
41246600CCAACATAACAGATGGVCTGGWAGTAAGGAAACATGTAATGATAGSYRKACTCYCAGCAC41246541 
41246540AGAAAAARAGGTAGATCTGAATGCTKATYCCCTGTGTKAGAGAAAAGAATGRAATARRYA41246481 
41246480GAAACTGCCATGCYCAGAGAATCCTAGAGATACTKAAGATGTTCCTTGGATAACACTAAA41246421 
41246420TARCAGCATKCAGAAAGTTAATGAGTGGTTTTCCAGAAGTGATGAACTGTTAGGTTCTGA41246361 
BRCA1 (ENSG00000012048): BRCA1ex11c  
41245760CKAATTAAATATSCACAATTCAAAAGCACCTAAAAAGAATAGGCTGRGGAGGWAGTCTTC 41245701 
41245700TRCCAGGCATATTCATGYKCTTDAACTAGTRRTCAGTAGAAATCTRARCHCAYSTAATTG 41245641 
41245640TACYGAATTGCAAATTSATRGTTGTTMTAGCAGTGAABAGATAAAGAAAAAAAAGKWCAA 41245581 
41245580CCARRTSCCAGTCAGGCRCAGCAGAAASCTAYAAYTCAYGRAAGGTAAAGAACCTGCAAC 41245521 
41245520TGGAGCCAAGAAGAGTAACAAGCCAAATGAACMGACAAGTAAAAGACATRACAGYKATRC 41245461 
41245460TTTCCCAGAGCTGAAGTKAACRAATGCACCTGRTTMTTTTACTAAGTGTTCAAATACCAG 41245401 
BRCA1 (ENSG00000012048): BRCA1ex11d  
41245100TGGTTGTTCCRAAGATAATAGAAATKWCACAGAARGCTTTAAGTATCCATTGGGACATGA 41245041 
41245040AGTTAACCACAGTYGGGRARCAARCATAGAAATRGAAKAAAGTGAACTTGATGYTCAGTA 41244981 
41244980BTTGCAGAATACATTCRAGGTTKCAAAGYRCCAGTSATTTGCTCCGTTTTCAAATCCAGG 41244921 
41244920AAATRCAGAAGAGGAATGTGCARCATTCTCTGCCYACTCTRKGTCCTTAAAGAAACAAAG 41244861 
41244860TCCARAAGTCACTTTTGAATGTKAACAAAAGGAAGAAAATCAAGGRAAGAATKAGTCTAA 41244801 
41244800TATCAAGCCTRYAYAGACAGTTAATMTCACTGCARGCTTTCYTGTGGTTGGTCAGAAAGA 41244741 
41244740TAAGCCRGTTKATAATGCCAAATGWAGTATCAAAGGAGGCTCTAGGTTTTGTCTATCATC 41244681 
 
BRCA1 (ENSG00000012048):  BRCA1ex11e  
 
41244740TAAGCCRGTTKATAATGCCAAATGWAGTATCAAAGGAGGCTCTAGGTTTTGTCTATCATC 41244681 
41244680TCAGWTCAGAGGCAACRAAACTGGACTCATTACTCCAAATAAAMATGGASTTTTACAAAA 41244621 
41244620CCCATATYRTATACCACCACTTTTTCCCATCAAGTCATYTGTTAAAACTAAATGTAAGAA 41244561 
41244560AAATCTGYTAGAGGAAAACTTTGAGGAACATTCARTRTCACCTGAAAGAGAADWGGGARA 41244501 
41244500TKAGAACRTTCCAAGTACAGTGAGCACAATTARCYRTAATAACATTAGAGAAAATGTTTT 41244441 
41244440TAAAGRAGCCARCTCAAGCAATRTTAATGAAGTAGDYTCCAGTACTAATGAAGTGGGCTC 41244381 
41244380CRGTATTAATGMAATAGGTTCCAGTGATGAAAACATTCAAGCARAACTAGGTRGAAACAS 41244321 
BRCA1 (ENSG00000012048): BRCA1ex11f  
41244080TGGTGAAATAAAGGAAGATACTAGTTTTGCTGAAAATGACATTAAGGRAAGTTCTGCTGW 41244021 
41244020TTTTAGCAAAAGCRYCYAGAAAGGAGAGCTTARCAGGAGTCCTAGCCCTTTCAYCCRTAH 41243961 
41243960ACATTTGGCTYASRGKTACYRAAGARGGGCCWAGRAATTAGAGTCCTCAGAAGAGAACTT 41243901 
41243900ATCTWGTRAGGATGAAKAGCTTCCCTGCTTCCAACACTTGTKAYTTGGTARAGTAAACAA 41243841 
41243840TATACCTTCTYAGTMTRCTAGGCATAGCACCRTTGCTASCKAGTGTCTGTCTAAGAACAC 41243781 
41243780AGAGGAGAATTTATTRTCATTGAAGAATASCTTAAATGACTGCAGTAACCAGGTARTATT 41243721 
BRCA1 (ENSG00000012048): BRCA1ex12 in yellow and 
BRCA1ex12_RNAonly in red 
41234660 ATATTTTCATTTAATGGAAAGCTTCTCAAAGTATTTCATTTTCTTGGTGYCATTTATYRT41234601 
41234600 TTTTGAAGCAGAGGGATACCAYGCAAYRTAACCYGRTAAAKCTCCAGCAGGAAATGGCTG41234541 
41234540 AACTAGARGCTGTGTTASAAYAGYRTGGGAGCCAGCCTTCTAACAGCTACYCTTCCMTCA41234481 
41234480 TAAGTGACTCYTCTGCSCTTGAGGACCTGSRAAATCCAGAACAAAGCACATCAGAAAAAG41234421 
41234420 DKGTGYATTGTTGGCCRAACACTGATATCTTAAGCAAAATTCTTTCCTTCCCCTTTATCT41234361 
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BRCA1 (ENSG00000012048): BRCA1ex15  
41226590 TGTCCTTTCACAATTGGTGGCGATGGTTTTCTCCWTCCATTTATCTTTCTRRGTCATCCC 41226531 
41226530 CTTCTAAATGCYYATCATTAGATGAYASGTGRTACATGCACAGTTGCTCTGGGAGTCTTY 41226471 
41226470 AGAATAGAAACTRCCCATCTCAAGAGRAGCTCRTTAAGGTTGTTGATGTGGAGGAGCRAC 41226411 
41226410 AGCTGKAAGAGTCTGGGCYACACDATTTGACRGAAAYATCTTACTTGCCAAGGCAASATC 41226351 
41226350 TAVRTWATATTTCATCTGCTGTATTGGAACAAACACTTTGATTTTACTCTGAATCCTACA 41226291 
41226290 TAAAGATATTCTGGTTAACCAACTTTTAGATGTACTAGTCTATCATGRACACTTTTGTTA 41226231 
41226230 TACTTAATTAAGCCCACTTTAGAAAAATAGCTCAAGTGTTAATCAAGGTTTACTTGAAAA 41226171 
41226170 TTATTGAAACTGTTAATCCATCTATATTTTAATTAATGGTTTAACTAATGATTTTGAGGA 41226111 
41226110 TGAGGGAGTCTTGGTGTACTCTAAATGTATTATTTCAGGCCAGGCATAGTGGCTCACRCC 41226051  
 
BRCA1 (ENSG00000012048): BRCA1ex17  
41223410 AACTAAGCTACTTTGGATTTCCACCAACACTGTATTCATGTACCCATTTTTCTCTTAACC 41223351 
41223350 TAACTTTATTGGTCTTTTTAATTCTTAACAGAGACCAGAACTTTGTAATTCAACATTCAT 41223291 
41223290 CGTTGTGTAAATTAAACTTSTCCCRWTSYTTTCRRAGKGAACYCYTTACCTGGAATCTGG 41223231 
41223230 ARTCAGCCTCTTCTCTGATGACCCTGAATCTGRTCCTTYTGAAGACAGAGCCCCAGAGTC 41223171 
41223170 AGCTCRTGTTGGCAACATACCATCTTYARCCTCTGCATTGAAAGTTCCCCAAYTGAAAGT 41223111 
41223110 TGYAGAATCTGCYCAGAGTYCARCTGCTGCTCATACTRCTGATACTGSTGGKTATAATGC 41223051 
41223050 AATKGAAGAAAGYGTGAGCAGGGAGAAGCCAGAATTGACAVCTTCAACAGRARGSGWCAA 41222991 
 
BRCA1 (ENSG00000012048): BRCA1ex18  
 
41219810 TGCTACRTAGGTAAACATATGCCATGGKGRRATAACTAGTATTCTGAGCTGTGTGCTASA 
41219751 
41219750 GGTAACTCATGATAATGGRATATTTGAYTTAATTTCAGWWGCYCRTGTACWAGTTTGCCA 41219691 
41219690 GAAAACACCACATCACTTTAACTAATCTAATTACTRWAGAGACTAYTCATGTTGTTATGA 41219631 
41219630 AAAHRGDYRTASCAAGAACCTTTACAGAATACCTTGCATCTGCTGCATAAAACCACATGA 41219571 
41219570 GGCGAGGCACRGTGGCGCATGCCTGTAATCGCAGCACTTTGGGAGGCCGAGGCGGGCAGA 41219511 
41219510 TCACGAGATTAGGAGATCGAGMCCATCCTGGCCAGCATGGTGAAACCCCGTCTCTACTAA 41219451 
41219450 AAAATAAAAAAATTAGCTGGGTGTGGTCGCRTGCGCCTGTAGTCCCAGCTACTYGTGAGG 41219391 
41219390 CTGAGGCAGGAGAATCACTTGAACCGGGGAGATGGAGGTTGCAGTGAGCMGAGATCATGC 41219331 
SNRPN (ENSG00000128739): SNRPNex6 
25154594 TCACCTCCACTTGGCCTTCATAGATCTTGTCCATGCCAAAMCTACTGAGAAGCCTGCGGG 25154653 
25154654 CYAGCGGCAGGCCAGTACAATATGCTGCAGCATAATTTGTCGGGCCAACCTTCACACCAT 25154713  
25154714 ATTTTGGCAGTTCGTGTGCATATGCTGTGCAGACTATCATATCCCMYTCTMTATGGGCAT 25154773 
25154774 AAGCAATCTGACAAATGATATCTCTGTTTGTTACACGAACTATCATCCTGTATTTGAGTG 25154833 
25154834 TGTTGTATTTATTTTTATCCTGTATCACCAAGCGTTTCCGAGTATCGTAATCAGTTTTAC 25154893 
25154894 CCTCTCATCATCGTCTYCTAAATTTCACTTGGTATCTCTTAAAGTAGGSCTTATTCTTAA 25154953 
25154954 CAACTTTAACAAACCCCATCCTGCAGAACAGAGACCYGCGTCCACAGCTCAACAGAGACC 25155013 
SNRPN (ENSG00000128739): SNRPNex6b 
25154294 ATTGAGAGAACTGTTTCTTGTAAGCATTTTCATCTTCTTCCATTAAGTAGCACATGTAAT 25154353 
25154354 CGGCAACATTCTGGCCCATGATGTGCTTCCGGTGTACTTCTGCATTAAATTCCTTGCTTT 25154413 
25154414 CAGAACCATAACCAGGGAATTGTTTGGTACTGTGAGGKATAGACAAGCCTCCATCCACAG 25154473 
25154474 CTYCCTTCAGGGCACCRAAAACTTTATTGCCAGTGGTAGTTCTGGCAAGGCCTGCMTCCA 25154533 
25154534 AATAGCAGGTAAAGGCACTTGGCTGACCATCAATGCTTTCCACARTGTATTCATCGCCAG 25154593 
25154594 TCACCTCCACTTGGCCTTCATAGATCTTGTCCATGCCAAAMCTACTGAGAAGCCTGCGGG 25154653 
25154654 CYAGCGGCAGGCCAGTACAATATGCTGCAGCATAATTTGTCGGGCCAACCTTCACACCAT 25154713 
SNRPN (ENSG00000128739): SNRPNex12 
25219334 GAAGCTAGTATGAGAGGAAGGATGTTTTTGAACGTGTCTGTCATAGTGATTTTCATGCAA 25219393 
25219394 AATTGTCTGCCTGTTTTAAAACATGGTAGATTGCAGTGCAGCTTTAACATGCTTTCCTCT 25219453 
25219454 GCAGGCTCCATCTACTSTACTMTTTGAAGCTTCTGCCCAGCTKGCATTGTTTCTAGGAGAA 25219513 
25219514 CGTCATACCTTTATCTATAGCCTTCCCCTAGGTCTTCAGAAGCATCAARTTTTAACTGTG 25219573 
25219574 GACRTTGGATTTGGTGGAACAGCAATCATGGTAAGCTGTRTGATAAGGCTGAGGGTTRAA 25219633 
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SNRPN (ENSG00000128739): SNRPNex13 
25219694 ATGTTAGAAATAAGGATACATCCATGGATATGGATTCTCATTGCATTGAGTATCAGCTGA 25219753 
25219754 AGATGAGCTGATTTTTTTATTTTTATTTTTTTCAGRCGGGGTCTTGCTCTGTYTCCCAGT 25219813 
25219814 CTGGAGTGCAGTGGTGCGRTCTTGGCTCACTGCAACCCTGGGTTCAAGAGATTCTCGTGC 25219873 
25219874 CTCAGCCTCTTTATTAGARACAGGGTTTCACTGTGTTGGCCAGGCTGGTCTCAGGCTCCT 25219933 
25219934 GACCTCYGGTGATCCACYCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGATG 25219993 
25219994 AGCCACTGTGCCTGGCCATGAGAAATGTTTCATGATGTGAGAAAATACAGGAGTTTTTGG 25220053 
25220054 TCATGATTCCACCAGTGGTGAAGGACTGTCCTGCAGATGATGGACTCTCAGGTCAGATTA 25220113 
SNRPN (ENSG00000128739): SNRPNex17 
25222874 ATAATGTGAAGGTTTGCATCGCTTTGACTGTTTCCCGCCCTGCCTTCTCAGGTAATGACT 25222933 
25222934 CCACAGGGAAGAGGCACTGTAGCAGCTGCTGCTGTTGCTGCGACYGCCAGTATTGCTGGA 25222993 
25222994 GCCCCAACACAGTACCCACCAGGACGGGGCACTCCGCCCCCACCBGTCGGCAGAGCAACC 25223053 
25223054 CCACCTYCAGGTAAGGGATTGGTGAACACGAAGACGAACTTGAATCTCTGATGAGAGATA 25223113 
SNRPN (ENSG00000128739): SNRPNex18 
25223534 TGTTTCTATTTCCTTTCCAGGTCCACCTCCCCCAGGAATGCGTCCACCAAGACCTTAGCA 25223593 
25223594 TACTGTTGATCCATCTCAGTCASTTTTTCCCCTGCAATGCGTCTTGTGAAATTGTGTAGA 25223653 
25223654 GTGTTTGTGAGCTTTTTGTTCCCTCATTCTGCATTAATAATAGCTAATAATAAATGCATA 25223713 
25223714 GAGCARTTAAAYTGTGAGGTACTGTTGTATATATTTTTTTGCCTGTTGATTTTGATGAGA 25223773 
25223774 KCTTAAGTTACTGTGGATGAGGGTGATGCCTATTAAGCAGTTGATTCAAATCATATTCTC 25223833 
25223834 TTTAATTCTTAGGATAAAAAGGTTTTCTGCTATCTAA 
 
UBE3A (ENSG00000114062): UBE3Aex9a forward in yellow, a reverse and b 
forward in yellow and b reverse in red  
25616988 ATGTTCTCTTTTTTCCTCTGATTTTCTAGATGTGACTTACTTAACAGAAGAGAAGGTATA 25616929 
25616928 TGAAATTCTTGAATTATGTAGAGAAAGAGAGGATTATTCCCCTTTAATCCGTGTTATTGG 25616869 
25616868 AAGAGTTTTTTCTAGTGCTGAGGCWTTGGTACAGAGCTTCCGRAAAGTTAAACAACACWC 25616809 
25616808 CAAGGAAGAACTGAAATCTCTTCAAGCAAAAGATGAAGACAAAGATGAAGATGAAAAGGA 25616749 
25616748 AAAAGCTGCATGTTCTGCTRCTGCTATGGAAGAAGACTCAGAAGCWTCTTCYTCAAGGAT 25616689 
25616688 AGGTGATAGCTCACMGGGAGACAACAATTTGCAAAAATTAGGCCCTGATGATGTGTCTGT 25616629 
25616628 GGATATTGATGCSATTAGAAGGGTCTACACCAGATTGCTCTCTAATGAAAAAATTGAAAC 25616569 
25616568 TGCCTTTCTCAATGCACTTGTATATTTGTCACCTAACGTGGAATGTGACTTGACGTATCA 25616509 
25616508 CARTGTATACTCYCGAGATCCTAATTATCTGAATTTGTTCATTATCGKAATGGAGAATAG 25616449 
25616448 AAATCTCCACAGTCCTGAATATCTGGAAATGGCTTTGCCATTATTTTGCAAAGCGATGAG 25616389 
25616388 CAAGCTACCCCTTGCAGCCCAAGGAAAACTGATCAGAYTGTGGTCTAAATACAATGCAGA 25616329 
25616328 CCAGATTCRGAGAATGATGGAGACATTTCAGCAACTTATTACTTATAAAGTCATAAGCAA 25616269 
25616268 TGAATTTAACASTCRAAATCTAGTGAATGATGATGATGCCATTGTTGCTGCTTCGAAGTG 25616209 
25616208 CTTGAAAATGGTTTACTATGCAAATGTAGTGGGAGGGGAAGTGGACACAAATCACARTGA 25616149 
25616148 AGAAGAYGATGARGAGCCCATCCCWGAGTCCAGCGAGCTGACACTTCAGGAACTTYTGGG 25616089 
25616088 AKAAGAAAGAAGAAACAAGAAAGGTCCTCGAGTGGAYCCCCTGGAAACTGAACTTGGTGT 25616029 
25616028 TAAAACCCTGGATTGTCGAAAACCACTTATCCCTTTTGAAGAGTTTATTAATGAACCACT 25615969 
UBE3A (ENSG00000114062): UBE3Aex9c 
25583148 AATGAAACTATTACTCCTAMGAATTACATTGTATAGCCCCACAGATTAAATTTAATTAAT 25583089 
25583088 TAATTCAAAACATGTTAAACGTTACTTTCATGTACTATGGAAAAGTACAAGTARGTTTAC 25583029 
25583028 ATTACTGATTTCCAGAAGTAAGTAGTTTCCCCTTTCCTAGKCTTCTGTGTATGTGATGTT 25582969 
25582968 GTTAATTTCTTTTATTGCATTATAAAATAAAAGGATTATGTATTTTTAACTAAGGTGAGA 25582909 
25582908 CATTGATAYATCCTTTTGCTACAAGCTRTAGCTAATGTGCTGAGCTTGTGCCTTGGTGAT 25582849 
25582848 TGATTGATTGATTGACTGATTGTTTTAACTGATTACTGTAGATCAACCTGATGATTTGTT 25582789 
UBE3A (ENSG00000114062): UBE3Aex16 
25583208 GAAAAAGATGGCTACTGTGCCTTGTGTTACTTAATCATACAGTAAGCTGACCTGGAAATG 25583149 
25583148 AATGAAACTATTACTCCTAMGAATTACATTGTATAGCCCCACAGATTAAATTTAATTAAT 25583089 
25583088 TAATTCAAAACATGTTAAACGTTACTTTCATGTACTATGGAAAAGTACAAGTARGTTTAC 25583029 
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25583028 ATTACTGATTTCCAGAAGTAAGTAGTTTCCCCTTTCCTAGKCTTCTGTGTATGTGATGTT 25582969 
25582968 GTTAATTTCTTTTATTGCATTATAAAATAAAAGGATTATGTATTTTTAACTAAGGTGAGA 25582909 
25582908 CATTGATAYATCCTTTTGCTACAAGCTRTAGCTAATGTGCTGAGCTTGTGCCTTGGTGAT 25582849 
25582848 TGATTGATTGATTGACTGATTGTTTTAACTGATTACTGTAGATCAACCTGATGATTTGTT 25582789 
25582788 TGTTTGAAATTGGCAGGAAAAATGCAGCTTTCAAATCATTGGGGGGAGAAAAAGGATGTC 25582729 
UBE3A (ENSG00000114062): UBE3Aex16b 
25584348 AAGAAAAACTTAAAGAGAGATTGTTGAAGGCCATCACGTATGCCAAAGGATTTGGCATGC 25584289 
25584288 TGTRAAACAAAACAAAACAAAATAAAACAAAAAAAAGGAAGGAAAAAAAAAGAAAAAATT 25584229 
25584228 TAAAAAAYTTTAAAAATATAACGAGGGATMAATTTTTGGTGGTGATAGTGTCCCAGTACA 25584169 
25584168 AAAAGGCTGTAAGATAGTCAACCACAGTAGTCACCTATGTCTGTGCCTCCCTTCTTTAYT 25584109 
25584108 GGGGACATGTGGGCTGGAACAGCRGATTTCAGCTACATATATGAACAAATCCTTTATTAT 25584049 
25584048 TATTATAATTATTTTTTTGCGTGAAAGTGTTACATATTCTTTCACTTGTATGTACAGAGA 25583989 
IGF2 (ENSG00000167244): IGF2 
2182259 CACCTGGCCTTCAGCCTGCCTCAGCCCTGCCTGTCWCCCAGATCACTGTYYYTCTGCCAT 2182200 
2182199 GGCCCTGTGGATGYRCCTCCTGCCYCTGCTGGCRCTGCTGGCCCTCTGGGGACCTGACCC 2182140 
2182139 RGCCRCAGCCTTTGTGAACCAASACCTGTGCGGCTCACACCYGGTGGAAGYTCTCTACCT 2182080 
2182079 AGTGTGCGGGGAACRAGGYTTCTTCTACACACCCAAGACCYGCCGGGAGGCAGAGGACCT 2182020 
2182019 GCAGG 
IGF2 (ENSG00000167244): IGF2ex11 
2154479 TGCTGACCAGCCCCTTCCCCTCCCAGGACAACTTCCCCAGATACCCCGTGGGCAAGTTCT 2154420 
2154419 TCCAATATGACACCTGGAAKCAGTCCACCCAGCGCCTGCGMAGGGGCCTGCCTGCCCTCC 2154360 
2154359 TGCGTGCCCGCCGGGGTCACGTGCTCGCCAAGGAGCTCRARGCGTTCAGGGAGGCCAAAC 2154300 
2154299 RTCACCRTCCCCTGATTGCTCTACCCACCCAAGACCCCGCCCACGGGGGYGCCCCCYMAG 2154240 
2154239 AGATGGCCAGCAATCGGAAKTGAGCAAAACTGCCGCRAGTCTGCAGCCYGGYGCCACCAT 2154180 
2154179 CCTGCAGCCTCCTCCTGACCACRGACGTTTCCATCAGGTTCCATCCCGAAAATCTCTCGG 2154120 
2154119 TTCCACGTCCCCCTGGGGCTTCTCCTGACCCAGTCCCCGTGCCCCGCCTCCCCGAAACAG 2154060 
H19 (ENSG00000130600): H19a 
2016760 TCAAAGCCTCCACGACTCTGTTTCCCCCGTCCCTTCTGAATTTWATTTGCACTAAGTCAT 2016701 
2016700 TTGCACTGGTTGGAGTTGTGGAGACSGCCTTGARTCTCDGTDCRAGTGTGCGTGAGTGTG 2016641 
2016640 AGCCACCTTGGCAAGTGCCTGYGCAGGGCCCGGCCGCCCTCCATCTGGGCCGGGTGACTG 2016581 
2016580 GGCGCCGGCTGTGTGCCCGAGGMCTCACCCTGCCCTCGCCTAGTYTGGAAGCTCCGACCG 2016521 
2016520 ACATCACGGAGCAGCCTTCAAGCATTCCATTACGCCCCATCTCGCTCTGTGCCCCTCCCC 2016461 
2016460 ACCAGGGCTTCAKCAGGAGCCCTGGACTCATCATCAATAAACACTGTTACAGCAATTTGT 2016401 
 
H19 (ENSG00000130600): H19b 
2017420 ACACCTTAGGCTGGTGGGGCTGCGGCAAGAAGCGGGTCTGTTTCTTTACTTCCTCCACGG 2017361 
2017360 AGTCGGCACACTATGGCTGCCCTCTGGGCTCCCAGAACCCACAACATGAAAGVTGAGGGG 2017301 
2017300 CTTCCTGCCACACTTGGGGTGGGGGGCACGCGAGAGGAGCTGAGTGGGACCTCACTCCTT 2017241 
2017240 CCCCATCSAMAGAAATGGKGCTACCCAGCTCAAGCCTGGGCCTTTGAATCCGGACACAAA 2017181 
2017180 ACCCTCTAGCTTGGAAATGAATATSCTGCACTTTACAACCACTGCACTACCTGACTCAGG 2017121 
2017120 AATCGGCTCTSGAAGGTGAVSACCAGCGCTCCTTCCGGAAGCCTCCAGGCCCCCGAGCAC 2017061 
2017060CCTGCCCCCATCCCACCCACGTGTCGCTATCTSYAGGTGAAGCKAGAGGAACCAGACCTC2017001 
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c) Sequences of primers used in mini-sequencing analysis to identify 
differential gene expression in embryos. 
 
Primer Chromosome Primer sequence 
MS_BRCAex11e_rs16941 
17 5'-CATTAGAGAAAATGTTTTTAAAAG-
3' 
MS_BRCAex12_rs1060915 17 5'-CCCTTCCATCATAAGTGACTC-3' 
MS_ACTBex7_rs852423 7 5'-CATTGTTTCTAGGAGAACC-3' 
MS_SNRPNe12_rs75184959 15 5'-ATGATCTGTAAGGCAGAGAT-3' 
MS_H19_rs11542721 11 5'-CACCTTGGCAAGTGCCTG-3' 
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d) Primer IDs, sequences, chromosomal locations, fluorescent labels, type of repeats and PCR product sizes that are used for 
aneuploidy analysis for differential gene expression study (Ensembl release dates 59). FAM stands for 6-carboxyfluorescein, 
YY for yakima yellow and DO for dragonfly orange.  
List of informative markers used in this study: 
Primer 
name 
Primer sequence 
Chromosome: Primer 
location on chromosome 
(bp) 
Fluorescent 
label 
Type of 
repeat 
Product 
range (bp) 
D7S2420_F CCTGTATGGAGGGCAAACTA 
7: 
106889627:106890251 
FAM 
Dinucleotide 240-292 D7S2420_
R AAATAATGACTGAGGCTCAAAACA  
D7S2459_F AAGAAGTGCATTGAGACTCC 
7: 
107331201:107331820 
FAM 
Dinucleotide 140 - 152 D7S2459_
R CCGCCTTAGTAAAACCC  
D7S486_F AAAGGCCAATGGTATATCCC 7: 
115894462:115895081 
FAM 
Dinucleotide 110-142 
D7S486_R GCCCAGGTGATTGATAGTGC 
 
D11S1338_
F GGAAAGAGTAGGAATAAGATGGTGTC 11: 
5987706:5988331 
FAM 
Dinucleotide 210-224 
D11S1338_
R TGCTACTTATTTGGAGTGTGAATTT  
D11S1997_
F CCAATTGACAGTGGATTTTTGA 11: 
6357947:6358568 
YY 
Trinucleotide 176-196 
D11S1997_
R CATAAAAGGGCCCGATACAA  
D11S4174_
F ACCAGGGCCTTTTTACAC 
11: 
84529968:84530594 
DO Dinucleotide 227 - 249 
 Appendix to Materials and Methods 
 
Section 2.2.2.11  255  
 
D11S4174_
R ATCATAGACTTCAGAGTCAGGTAGA  
D15SS992
_F ACAGATAAACGGCAGGGAGA 15: 
48,700,502:48,937,984 
FAM 
Dinucleotide 216-235 
D15S992_
R AGGAGGGCCACCTTGATAGT  
D15S123_F TTTTCATGCCACCAACAAAC 
15: 
48,700,502:48,937,984 
FAM 
Dinucleotide 182-198 D15S123_
R CTGAACCCAATGGACTCCTG  
D15S94_F TGTTGGCTTAGAAACTGACTGG 15: 
48,700,502:48,937,984 
FAM 
Dinucleotide 140-151 
D15S94_R GCTGCATTCCAGCCTAAAAG 
 
D17S579_F CAGATCACAGAGGTGGCTGA 
17: 
42806716:42807335 
FAM 
Dinucleotide 230-250 D17S579_
R GGCAGCAGTCCTGTAGACAA  
D17S1789_
F GGCTCAGGAGACTCAGAGGA 17: 
41,196,312:41,277,387 
FAM 
Dinucleotide 195-239 
D17S1789_
R GAGCCAAACTGCTTTGTTCC  
D17S1353_
F CTGAGGCACGAGAATTGCAC 17: 
7617123:7617742 
DO 
Dinucleotide 200-222 
D17S1353_
R TACTATTCAGCCCGAGGTGC  
D17S841_F TGGACTTTCTTACATGGCAG 
17: 
27542413:27543036 
DO 
Dinucleotide 253-273 D17S841_
R AGGTTAGTAGTCTATGTCACAGCG  
D19S112_F GCCAGCCATTCAGTCATTTGAAG 
19: 
46378681:46379303 
DO 
Dinucleotide 110-130 D19S112_
R CTGAAAGACACGTCACACTGGT  
APOC2_F GGCTACATAGCGAGACTCCATCTCC 19: FAM Dinucleotide 136-156 
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APOC2_R GGGAGAGGGCAAAGATCGATAAAGC 45449076:45449700 
 
       
List of primers that were tested but found to be uninformative for the couples: 
Primer 
name 
Primer sequence 
Chromosome: Primer location 
on chromosome (bp) 
Fluorescent 
label 
Type of 
repeat 
Product 
range (bp) 
D7S692_F 
CTGATGATTGCTATAGATATTCA
TC 7: 
108339409:108340033 
DO 
Dinucleotide 161-171 
D7S692_R 
TGTAAACACTTTTGTAGAAGAA
CCT 
 D11S4891_
F TTTATTCCAGCCCCACTGAC 11: 
5250626:5251245 
FAM 
Dinucleotide 160-170 
D11S4891_
R TACCCAGACTAGGGCCATTC 
 D11S2362_
F GGCTTTACCTTACCCCATTTC 11: 
4911823: 4912443 
DO 
Trinucleotide 140-157 
D11S2362_
R GGGGTTTCCCAGTCCTTTTA 
 D11S1303_
F TGTTGGATGAAGTAATACTGG 11: 
51382534: 51383154 
VIC 
Quadnucleotide 241-261 
D11S1303_
R CTGCACTCCCATATGAACTG 
 D11S1763_
F CCTTGGCCTCCCACTTACTT 11: 
42861098:42861717 
FAM 
Di nucleotide 240-270 
D11S1763_
R TCTTTAGGGGTGGTGGTGAG 
 D11S1871_
F TCTGGGAAAGCATGAAGTGA 11: 
5126600: 5127219 
FAM 
Dinucleotide 218-238 
D11S1871_
R GCAGAAGAAGTTGCCCTGAT 
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D11S1760_
F GGAAGAAAGAGACCCTGAGTG 11: 
5384045:5384665 
FAM 
Dinucleotide 210-225 
D11S1760_
R CTGCTGCATCATGACTTGAAA 
 D11S2362_
F GGCTTTACCTTACCCCATTTC 11: 
4911823:4912443 
DO 
Trinucleotide 140-150 
D11S2362_
R GGGGTTTCCCAGTCCTTTTA 
 D11S4174_
F CACCCCTTCAATACCCACTG 11: 
45257828:45258447 
DO 
Dinucleotide 210-230 
D11S4174_
R TTCCTGGCCAGCCTATCTAA 
 D15S978_F CTGGCCCCTTCTACTCACAC 
15: 
48,700,502:48,937,984 
FAM 
Dinucleotide 163-189 D15S978_
R GGAAAGTGCTGCTGACCTG 
 D15S1024_
F CTCCACACTAGCCCACCTCT 15: 
48,700,502: 48,937,984 
FAM 
Dinucleotide 202-212 
D15S1024_
R AGGCTATTGTGTGGCTCCAA 
 D15S1025_
F CCACGTTAACTGTTCGGTTC 15: 
69403189:69403810 
FAM 
Dinucleotide 88-114 
D15S1025_
R CCCAATGTTGCTTTAAAATTGT 
 D17S250_F GGAAGAATCAAATAGACAAT 
17: 
37151924:37152543 
VIC 
Dinucleotide 133-153 D17S250_
R 
GCTGGCCATATATATATTTAAAC
C 
 D17S1307_
F 
AATAGACTCCAAACCAGCCTAT
G 17: 
49297919:49298542 
YY 
Dinucleotide 138-150 
D17S1307_
R 
CCTCATCTACTCCTTCAAACAG
AC 
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D17S1323_
F TGTTCCCGATAGGAGATGGA 17: 
41237881:41238502 
DO 
Dinucleotide 142-162 
D17S1323_
R TTGAAGCAACTTTGCAATGAG 
 D17S1327_
F CTCCTCCCCTTACTCCTGCT 17: 
41375142:41375761 
YY 
Dinucleotide 100-116 
D17S1327_
R TGAAAGACAGACTCTGGGTGA 
 D17S261_F CTCCACCTAGGCACTGAAGC 
17: 
15359531:15360150 
FAM 
Dinucleotide 241-255 D17S261_
R ACAGCCCAAATCCAAGTCAG 
 D17S122_F CAGAACCACAAAATGTCTTGC 
17: 
15209045:15209665 
FAM 
Di nucleotide 150-165 D17S122_
R CAGACCAGGCTCTGCTCTACT 
 D17S1802_
F AAGACACATGGCCAACTTCC 17: 
40353097:40353716 
FAM 
Dinucleotide 179-199 
D17S1802_
R CGAAGGGAGTGCGAGTATGT 
 17S1789_F GGCTCAGGAGACTCAGAGGA 
17: 
41752716:41753336 
FAM 
Dinucleotide 255-270 D17S1789_
R GAGCCAAACTGCTTTGTTCC 
 D17S1356_
F GGGTGTGGCTTTCTTATCCA 17: 
14894452:14895073 
FAM 
Dinucleotide 258-175 
D17S1356_
R CCCCTTTTCATGCAGAGTTT 
 D17S839_F CCTTGAGAGAGACCCTGGAA 17: 
14484974:14485593 
FAM 
Dinucleotide 129-150 
D17S839_R CTGAGCAACAACAGCGAAAC 
 D17S1166_
F 
TAACAATTGTGGAACTGCAGCA
ATTATT 
17: 
29648716:29649343 YY 
Dinucleotide 189-214 
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D17S1166_
R 
CCCATACCTAGTTCTTAAAGTC
TGT 
 D17S1294_
F TGGCATGCAATTGTAGTCTC 17: 
28382106:28382730 
FAM 
Dinucleotide 244-252 
D17S1294_
R 
TTCTTTCCTTACTAAGTTGAGAA
CG 
 D17S2229_
F CCCATTCCATAGTCATCAGA 17: 
15059030:15059649 
FAM 
Dinucleotide 258-278 
D17S2229_
R 
GTGTCTTTGCCATTTTACCACA
AGAGG 
 D17S1793_
F AAGAATCCAGCCCAAGGTTT 17: 
40359098:40359717 
FAM 
Dinucleotide 243-260 
D17S1793_
R GATCGGCCAAAAGATGAAGT 
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e) Primer IDs, sequences and PCR product sizes that are used for 
methylation specific PCR.  
Primer name Primer sequence 
Expected 
product 
size (bp) 
ACTBpromoter_outer_F            GATTTGATTGATTATT 
TTATGAAGAT TTTT 210 
ACTBpromoter_outer_R            CTCATTACCAATAATAGATAACCTA 
ACTBpromoter_methylated_F       CGCGGTTATAGTTTTATTATTACGG
TCGAG 
96 
ACTBpromoter_methylated_R       ACCATCTCTTACTCGAAATCCAAAA
CGACG 
ACTBpromoter_unmethylated_
F     
TGTGGTTATA GTTTTATTAT 
TATGGTTGAG 
120 
ACTBpromoter_unmetylated_R ACCATCAAACAACTCATAACTCTTC
TCCAA 
H19promoter_outer_F GGTTTTTAGATAGGAAAGTGGT 
185 H19promoter_outer_R AATAAAATACTAAAAAACAAAAAAA
AATAC 
H19promoter_ unmethylated_F TTGTGAATGGGATTGGGGTGTTTA
GTGGTT 
124 
H19promoter_ unmethylated_R CACAAACCCCCTAATAAACACAATA
CC 
H19promoter_methylated_F GATCGGGGTGTTTAGCGGTTGTGG
GGATTT 
134 
H19promoter_ methylated_R CGCAAACCCCCTAATAAACGCGAT
ACC 
BRCA1promoter_outer_F TTTTTTTATTTTTTGATTGTATTTTG
ATTT 
184 
BRCA1promoter_R TTATCTAAAAAACCCCACAACCTAT
CCCCC 
BRCA1promoter_unmethylated
_F 
TTGGTTTTTGTGGTAATGGAAAAGT
GT 
86 
BRCA1promoter_unmethylated
_R 
CAAAAAATCTCAACAAACTCACACC
A 
BRCA1promoter_methylated_F TCGTGGTAACGGAAAAGCGCGGG
AATTA 
75 
BRCA1promoter_methylated_R AAATCTCAACGAACTCACGCCGCG
CAATCG 
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7.2.1.2 Developing a functional assay for MMR 
a) Chromosomal location of the synthetic oligonucleotides (A, G and T 
sequences) used for the formation of homo/heteroduplexes. The 
sequences were selected from MSH2 gene (human chromosomes 2, 
2p22-p21, Ensembl release 59) around SNP site rs1981929. The 
sequence of the oligonucleotides used to make the 
homo/heteroduplexes is highlighted in grey. Salmon-coloured regions 
represent the exons. The underlined, red “R” represents the SNP that 
the A and G alleles were substituted to create the A and G sequences, 
respectively. T allele was substituted to the same position of the SNP 
“R” within the complementary strand. 
MSH2 (ENSG00000095002, Ensembl release 59) 
47672468 GGGAAGCWTTGAGTGCTACATCATCTCCCTTTCTATAAAATAAATTGAGTACGAAACAAT 47672527 
47672528 TTGAATTAAAACACCTGAGTAAATAGTAACTTTGGAGACCTRCTGTACTATTTGTACCTT 47672587 
47672588 TTGGATCAAATGATGCTTGTTTATCTCAGTCAAAATTTTATGATTTGTATTCTGTAAAAT 47672647 
47672648 GAGATCTTTTTATTTGTTTGTTTTACTACTTTCTTTTAGGAAAACACCAGAAATTATTGT 47672707 
 
b) Annealing sites of the primers used for mini-sequencing to detect the 
SNP at rs1981929. The annealing sites for the primers are shown in 
aqua and green shades representing the “Forward A” binding to the A 
and G sequences and “Reverse T” binding to the T sequence, 
respectively. 
MSH2 (ENSG00000095002, Ensembl release 59) 
42961 GGGAAGCTTTGAGTGCTACATCATCTCCCTTTCTATAAAATAAATTGAGTACGAAACAAT 43020 
43021  TTGAATTAAAACACCTGAGTAAATAGTAACTTTGGAGACCTRCTGTACTATTTGTACCTT 43080  
43081  TTGGATCAAATGATGCTTGTTTATCTCAGTCAAAATTTTATGATTTGTATTCTGTAAAAT 43140  
43141  GAGATCTTTTTATTTGTTTGTTTTACTACTTTCTTTTAGGAAAACACCAGAAATTATTGT 43200 
43201  TGGCAGTTTTTGTGACTCCTCTTACTGATCTTCGTTCTGACTTCTCCAAGTTTCAGGAAA 43260 
43261 TGATAGAAACAACTTTAGATATGGATCAGGTATGCAATATACTTTTTAATTTAAGCAGTA 43320 
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7.3 Appendix to results 
7.3.1 Differential gene expression in preimplantation 
embryos and potential relation with differential 
methylation 
7.3.1.1 Sequencing panels obtained from genetic analyser ABI 
PrismTM 3100. 
Each peak represents the amplified alleles where red, green, black and 
blue represent T, A, G and C alleles, respectively. The informative SNPs 
are shown. 
Sequencing panels for ACTB 
Female partner of couple 29 
 
Male partner of couple 29 
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Female partner of couple 32 
 
Male partner of couple 32 
 
Female partner of couple 33 
 
Male partner of couple 33 
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Sequencing panels for SNRPN 
Female partner of couple 29 
 
Male partner of couple 29 
 
Female partner of couple 30 
 
Male partner of couple 30 
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Female partner of couple 33 
 
Male partner of couple 33 
 
Female partner of couple 38 
 
Male partner of couple 38 
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Sequencing panels for H19 
Female partner of couple 29 
 
Male partner of couple 29 
 
Female partner of couple 30 
 
Male partner of couple 30 
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Female partner of couple 33 
 
Male partner of couple 30 
 
Sequencing panels for BRCA1  
Female partner of couple 29 
 
Male partner of couple 29 
 
 
 
Appendix to Results 
 
Section 4.1                                                                                                                                                268  
 
Female partner of couple 29 
 
Male partner of couple 29 
 
Female partner of couple 30 
 
 
Male partner of couple 30 
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Female partner of couple 32 
 
Male partner of couple 32 
 
Female partner of couple 32 
 
Male partner of couple 32 
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Female partner of couple 33 
 
Male partner of couple 33 
 
Female partner of couple 38 
 
Male partner of couple 38 
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Female partner of couple 38 
 
Male partner of couple 38 
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7.3.1.2 Quality and concentration of RNA and DNA extracted 
from human preimplantation embryos 
RNA and DNA from human blastocysts were assessed using the Agilent 2100 
Bioanalyzer Pico chip electrophoresis and NanoDrop technology, respectively. 
Sample IDs, RIN value, RNA and DNA concentrations for a) cleavage, b) 
morula and c) blastocyst stage embryos are shown in this table. N/A (non-
applicable) indicates that this sample was not analysed for the particular 
subject. 
Sample 
ID
RIN
RNA 
concentration 
(pg/µl)
DNA 
concentration 
(ng/µl)
Sample 
ID
RIN
RNA 
concentration 
(pg/µl)
DNA 
concentration 
(ng/µl)
Sampl
e ID
RIN
RNA 
concentration 
(pg/µl)
DNA 
concentration 
(ng/µl)
3 1 5460 5.5 4 2 7232 17.9 1 6.9 12712 2.2
16 N/A 213 3.2 7 N/A 369 16.1 2 7.8 7382 12.3
17 N/A 221 4.5 8 5 6402 3.6 19 8.4 8511 3
20 2 116 7 9 N/A 393 29.8 52 N/A 48 21.6
23 N/A 422 N/A 10 7 7900 38.8 62 9.5 654 7.9
24 N/A N/A 3 11 5 19284 16.6 65 8.5 880 2.3
29 1 88 1.5 12 7 6400 2.4 66 7.4 646 11.4
32 N/A N/A 2.3 13 4 5813 1.3 67 9.1 272 3.6
35 6 60 22.8 14 N/A 444 4.1 68 6.7 329 0.1
36 1 55 16.7 15 N/A 237 3.1 69 8.1 852 4
37 N/A N/A 2.5 25 N/A N/A 4.5 72 7.3 471 5.4
38 N/A 355 50.6 26 2 162 1 74 7.6 184 18.1
39 1 66 11.7 28 N/A N/A 0.4 75 8.5 513 0.9
40 2 34 12.2 30 1 307 2.1 76 8.5 295 17.7
43 N/A 268 0.6 31 N/A N/A 4.1 77 4.6 223 10.1
44 1 29 N/A 33 1 257 3.9 78 9.3 291 12.4
44 8 184 N/A 34 1 589 6.1 84 2.6 65 10.7
45 1 61 1.7 41 4 94 N/A 85 2.6 245 35.4
46 N/A N/A 2.4 42 N/A 21449 N/A 86 N/A 453 13.5
48 N/A 684 N/A 47 5 2430 N/A 93 4.3 239 4.1
55 9 291 1 49 N/A 1011 0.6
57 N/A N/A 0.6 50 N/A N/A 1.9
60 N/A N/A 2.2 51 N/A 277 1.4
61 N/A N/A 3.4 53 3 1513 0.7
64 N/A 167 5.8 54 N/A N/A 0.2
83 N/A 451 N/A 56 N/A 464 0.2
88 2 3268 10.8 58 7 111 2.2
89 N/A N/A 2.9 59 6 161 6.9
90 3 4818 16.9 63 N/A N/A 13.7
71 N/A 200 3.1
73 7 33479 5.4
79 8 449 4.2
80 8 280 10.7
81 N/A 75 4.6
82 N/A 479 27
91 2 31.3 6
92 3 254 2.5
94 N/A 393 3.8
95 N/A 268 2.6
a) Cleavage stage embryos c) Blastocyst stage embryosb) Morula stage embryos
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7.3.1.3 Assay sensitivity by real time PCR 
Quantification for four genes analysed by real time PCR (HRM) Patient, embryo ID with 
Cq values are listed.  
       a) Cq values for ACTB       b) Cq values for SNRPN          c) Cq values for H19 
Patient 
ID
Embryo ID
Cq for 
ACTB
32
8 35
10 38
11 35
12 35
13 38
14 35
35 51 33
36
58 34
61 33
Patient 
ID
Embryo 
ID
Cq for SNRPN
29 1 34
30
2 36
3 33
4 35
33
19 32
20 34
24 35
26 36
28 33
37 62 32
38
66 32
67 32
68 33
69 33
70 31
71 35
41
88 34
89 34
90 38
42
92 37
93 34
Patient 
ID
Embryo ID Cq for H19
33
19 38
21 42
34
29 44
30 38
33 36
36 35
39 35
43 53
39
74 NR
77 42
78 45
79 38
80 41
82 NR
83 42
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         d) Cq values for BRCA1 
Patient 
ID
Embryo 
ID
Cq for BRCA1
BRCA
rs16941
BRCA
rs1060915
29 1 37 37
30
2 37 N/A
3 N/A 36
31 6 N/A 32
32
7 35 35
8 N/A 38
9 33 32
10 N/A 35
11 35 35
12 35 36
13 34 N/A
14 N/A 36
15 36 36
16 N/A 36
33
19 38 33
20 N/A NR
22 36 N/A
23 37 35
24 N/A 35
25 36 35
26 36 35
28 34 N/A
34
29 37 N/A
30 N/A 38
31 37 N/A
32 35 N/A
33 35 39
34 39 N/A
35 N/A 35
34 34 N/A
Patient 
ID
Embryo 
ID
Cq for BRCA
BRCA
rs16941
BRCA
rs1060915
34
37 N/A 35
38 N/A 36
39 N/A 37
41 35 36
44 33 N/A
45 36 37
46 33 34
35
47 N/A 32
48 N/A 33
49 N/A 35
51 N/A 34
53 N/A 36
38
65 37 N/A
66 32 32
67 33 32
68 36 N/A
69 35 33
70 N/A 37
71 34 35
72 36 34
39
74 N/A 34
76 N/A 32
77 33 35
78 32 33
79 31 31
80 32 34
83 32 32
40
84 N/A 37
85 N/A 36
86 36 36
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7.3.1.4 SNaPshot assay sensitivity for differential expression of parental genes 
7.3.1.4.1 Haplotype analysis: Allele sizes for different STR markers identified for the all the couples. 
a) Allele sizes for STR markers for chromosomes 7, 11 and 15 identified for the all the couples. 
D7S486 D7S2420 D7S692 D7S2459 D11S1338 D11D1970 D11S262 D11S4891 D11S1997 D11S2362 D11S1303 D11S4147 D11S1763 D11S1871 D15S94 D15S123 D15S992 D15S978 D15S1025 D15S978 D15S1024
Female 137 181/185 242/248 246/250 219/227 194 158 167 198/202 158 143 218/224 236 238 193/199 147/160 225 157/174 209 N/A N/A
Male 137 179/187 244/248 248/250 225/227 194/198 NR 167 193/202 158/161 131/141 224 236 237 197/201 158/160 213 157 203 N/A N/A
Female 225/227 194 158 N/A N/A N/A N/A N/A N/A N/A 198/201 149/160 223/229 155/168 209 N/A N/A
Male 219/225 NR 158 N/A N/A N/A N/A N/A N/A N/A NR 152/154 211/223 153/154 203/209 N/A N/A
Female
Male
Female 137/139 178/183 248 242/248
Male 137 183/189 242/248 240/246
Female 215/225 185/194 158/161 167 198/202 N/A N/A N/A N/A N/A 201 158 222/224 157 209 156/157 117
Male 225 194 155/158 167 193/223 N/A N/A N/A N/A N/A 201 152/158 212/222 155/157 209 155/157 117
Female 219/225 185/194 158 163/165 197 158 _ 220/228 236 240
Male 227 NR 158/167 163 167/206 158/167 131/139 209/220 235 236
Female 139/143 185/189 242/248 246/248
Male 130/137 183/187 244 242
Female 135/138 183/189 242 244/250 201 149/151 211/223 _ 209 N/A N/A
Male 137/143 185/191 242/248 248/250 201/203 153/160 214 159/172 203 N/A N/A
Female 135/138 183/189 242 244/250 191/201 152/160 222/223 155/157 201/209 155/157 110/118
Male 137/143 185/191 242/248 248/250 192/199 152/158 211/225 155/157 203/209 155/157 112/118
Female 201/203 154/160 219/221 157/172 201/209 157/172 110/117
Male 293/201 154 219/221 168/172 209/211 168/172 117/119
Female 219/225 185/194 158/161 163/165 193/202 158/167 143 218/224 N/A N/A
Male 219/225 NR 154/158 165/166 201 158/167 148 220/222 N/A N/A
Female 221/227 187/194 158/161 165/167 198 158/161 140 220/228 N/A N/A
Male 225/227 NR 153/161 166 198/202 155/161 143/148 218/224 N/A N/A
Female
Male
Female 199/201 149/160 220/224 159/168 203/209 N/A N/A
Male 201 152/163 226/227 151/155 209 N/A N/A
Negative
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/AN/A
N/A
N/A
N/A
N/A
N/A N/A
N/A
39
41
42
ClearClearClear
N/A
N/A
34
35
36
37
38
40
Family ID/ marker 
29
30
31
32
33
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b) Allele sizes for different STR markers of chromosome 17 identified for the all the couples. 
D17S250 D17S1307 D17S1323 D17S579 D17S1327 D17S261 D17S122 D17S1802 D17S1789 D17S1356 D17S839 D17S841 D17S1166 D17S1294 D17S2229 D17S1793 D17S1353
Female 152/157 _ 167/173 239/251 111/142 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male NR 208 175 249/251 140/142 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female NR 204/212 162/176 251 111/140 180 152/153 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male NR 204/208 173 239/249 140 180 150/152 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female 152/165 208 167/173 239/255 111/140 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male 140/157 208 167 249/253 111 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female 152/161 208 167 251/253 106/111 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male 150/152 200/208 162/173 243/256 111/136 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female 150/152 204/208 166/168 236/252 136/151 178/180 151/153 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male 152 204/208 170/172 249 111*149 180 153 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female 152/157 208 166/173 236/251 111/140 180/182 152 195 192/216 198 139 260/265 189/191 252 253/264 239 165/175
Male 152/161 208 162/166 251 112 180 145/155 195 194 198 136/139 260/267 189/191 252 253/262 239/240 179/183
Female 152 209 166/175 243/251 111/151 178 153/156 195/197 178/194 198 136/139 267 189/191 247 250/263 239 167/177
Male 167 201/209 _ 238/243 111/149 180 153 195 188/194 194/198 136 263/256 189/194 247/251 250/263 239/243 163/179
Female 157/163 208 166 247/253 112 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Male 150/163 208 166 251/253 109/132 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Female 150/152 208 166 243/249 111/134 N/A N/A 195 178/194 198/200 136/139 265/267 189/198 247 255 235/239 167/179
Male 157/169 204/208 _ 249/255 _ N/A N/A 195/197 194 198 136/139 263/265 193/198 247/255 _ 239 163/167
40
Clear
35
30
32
38
Family ID/ marker 
name
Negative
34
33
31
39
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7.3.1.4.2 Aneuploidy screening by aCGH 
aCGH profiles of all the embryos analysed.  
Embryo numbers are shown for each panel. The x-axis represents the 
chromosomes and the y-axis show the threshold. Any losses or gains are 
labelled. 
   
 
Embryo no. 8
Loss of 22
 
 
Embryo no. 11
Gain of 13
Loss of 22
 
Embryo no. 12
Gain of 14
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Embryo no. 14
Gain of 19
Loss of Y
  
 
Embryo no. 25
Loss of 1
 
  
 
Embryo no. 66
Loss of 21
 
 
Embryo no.69
Gain of 17
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Embryo no. 71
Loss of 3
 
Embryo no. 72
Gain of 17
Loss of 13
 
Embryo no. 74
Gain of 16
 
Embryo no. 75
Gain of 16
 
  
 
Embryo no.91
Loss of 1q
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